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Background: Chronic kidney disease (CKD) is a 
long-term condition and has been described as the 
gradual loss of kidney function over time. Early in the 
disease process, people with CKD often experience 
no symptoms. For a long time, CKD has been an 
underdiagnosed condition. Even in the absence of 
symptoms, CKD appears to add significantly to the 
burden of cardiovascular disease and death and, for an 
important minority, can progress to kidney failure.
Objective: To systematically review the evidence of 
the clinical effectiveness and cost-effectiveness of early 
referral strategies for management of people with 
markers of renal disease.
Data sources: Electronic searches of 12 major 
databases (such as MEDLINE, EMBASE, CINAHL, etc.) 
were conducted for the time period of 1990 to April 
2008 to identify studies comparing early referral to 
other care options for people with CKD. Additional 
searching was performed in the NHS Economic 
Evaluation Database to support the cost-effectiveness 
literature review.
Review methods: Two authors reviewed all titles, 
abstracts and full papers to select relevant literature. 
A Markov model was constructed to represent the 
natural history of CKD. The model allowed cohorts 
to be tracked according to estimated glomerular 
filtration rate (eGFR) status and the presence of other 
complications known to influence CKD progression 
and the incidence of cardiovascular events.
Results: From 36 relevant natural history studies, 
CKD was found to be, despite marked heterogeneity 
between studies, a marker of increased risk 
of mortality, renal progression and end-stage 
renal disease. Mortality was generally high and 
increased with stage of CKD. After adjustment for 
comorbidities, the relative risk of mortality among 
those with CKD identified from the general population 
increased with stage. For clinical populations, 
the relative risk was higher. All three outcomes 
increased as eGFR fell. Only seven studies, and no 
randomised controlled trials, were identified as 
relevant to assessing the clinical effectiveness of early 
referral strategies for CKD. In the five retrospective 
studies constructed from cohorts starting on renal 
replacement therapy (RRT), mortality was reduced in 
the early referral group (more than 12 months prior 
to RRT) even as late as 5 years after initiation of RRT. 
Only two studies included predialysis participants. One 
study, in people screened for diabetic nephropathy, 
reported a reduction in the decline in renal function 
associated with early referral to nephrology specialists 
(eGFR decline 3.4 ml/min/1.73 m2) when compared 
with a similar group that had no access to nephrology 
services until dialysis was required (eGFR decline 
12.0 ml/min/1.73 m2). The second study, among a 
group of veterans with two creatinine levels of at 
least 140 mg/dl, reported that a composite end point 
of death or progression was lower in the group 
receiving nephrology follow-up than in those receiving 
only primary care follow-up. The greatest effect was 
observed in those with stage 3 or worse disease after 
adjustment for comorbidities, age, race, smoking 
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and proteinuria {stage 3: hazard ratio (HR) 0.8 [95% 
confidence interval (CI) 0.61 to 0.9)]; stage 4: HR 
0.75 (95% CI 0.45 to 0.89)}. In the base-case analysis, 
all early referral strategies produced more quality-
adjusted life-years (QALYs) than referral upon transit 
to stage 5 CKD (eGFR 15 ml/min/1.73 m2). Referral 
for everyone with an eGFR below 60 ml/min/1.73 m2 
(stage 3a CKD) generated the most QALYs and, 
compared with referral for stage 4 CKD (eGFR < 30 ml/
min/1.73 m2), had an incremental cost-effectiveness 
ratio of approximately £3806 per QALY.
Limitations: Because of a lack of data on the natural 
history of CKD in individuals without diabetes, 
and a lack of evidence on the costs and effects of 
early referral, the Markov model relied on many 
assumptions. The findings were particularly sensitive to 
changes in eGFR decline rates and the relative effect of 
early referral on CKD progression and cardiovascular 
events; the latter parameter being derived from a 
single non-randomised study.
Conclusions: Despite substantial focus on the early 
identification and proactive management of CKD 
in the last few years, we have identified significant 
evidence gaps about how best to manage people with 
CKD. There was some evidence to suggest that the 
care of people with CKD could be improved and, 
because these people are at risk from both renal and 
cardiovascular outcomes, strategies to improve the 
management of people with CKD have the potential to 
offer an efficient use of health service resources. Given 
the number of people now being recognised as having 
markers of kidney impairment, there is an urgent need 
for further research to support service change.
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Background
Chronic kidney disease (CKD) is a long-term 
condition and has been described as the gradual 
loss of kidney function over time. Early in the 
disease process, people with CKD often experience 
no symptoms. For a long time, CKD has been an 
underdiagnosed condition. Even in the absence 
of symptoms, CKD appears to add significantly 
to the burden of cardiovascular disease and death 
and, for an important minority, can progress to 
kidney failure. In the last 10 years, the focus on 
mild to moderate, or ‘early’, CKD has grown, and 
an internationally adopted definition of CKD 
was introduced in 2002. Large population health 
surveys in the USA have estimated that 11% of the 
population have CKD.
Objectives
To systematically review the evidence of the clinical 
effectiveness and cost-effectiveness of early referral 
strategies for management of people with markers 
of renal disease. There were three phases of 
research:
1. Systematic review of the evidence of clinical 
effectiveness – to assess and synthesise the 
evidence for early referral strategies. In 
addition, we sought to explore the natural 
progression of patients identified as having 
CKD and the characteristics for an effective 
early referral programme.
2. Systematic review of the evidence of cost 
effectiveness – to assess and synthesise the 
evidence of cost-effectiveness of early referral 
strategies.
3. Economic analysis – informed by the findings 
of phase 1 and 2, to model the economic 
implications of different early referral 
strategies to assess the cost-effectiveness.
Methods
Systematic literature reviews of the clinical 
effectiveness of early referral and the natural 
history of CKD were undertaken. Electronic 
searches of MEDLINE, EMBASE, CINAHL, 
Science Citation Index, ISI Proceedings, British 
Nursing Index, Health Management Information 
Consortium, Social Science Citation Index, 
Cochrane Central Register of Controlled Trials, 
Cochrane Database of Systematic Reviews, National 
Research Register and the UK Clinical Research 
Network (updated to February 2009 for main 
search) were conducted for the time period of 
1990 to April 2008 to identify studies comparing 
early referral to other care options for people with 
CKD. Search terms did not restrict based on timing 
of referral; studies of early or late referral were 
identified. Additional searching was performed in 
NHS Economic Evaluation Database to support the 
cost-effectiveness literature review.
We considered evidence from any study design 
that compared a strategy for early referral with a 
relevant comparator group and any intervention 
that aimed to achieve the early referral of 
those with markers of renal disease to specialist 
nephrology care.
To identify the relevant literature on the natural 
history of CKD we searched MEDLINE (1950 to 
week 2 March 2008) and EMBASE (1996 to week 
4 March 2008). Searches were restricted to English 
and were from 1998 to 2008.
Two authors reviewed all titles, abstracts and full 
papers to select relevant literature. Data extraction, 
including quality assessment, was undertaken by 
two reviewers. Data were summarised in tabular 
form and reported narratively. A supplementary 
chapter on models of care for CKD was undertaken 
to support the development of the economics 
model and to supplement the limited evidence 
identified from the clinical effectiveness review.
A Markov model was constructed to represent the 
natural history of CKD. The model allowed cohorts 
to be tracked according to estimated glomerular 
filtration rate (eGFR) status and the presence 
of other complications known to influence CKD 
progression and the incidence of cardiovascular 
events. Within each cycle of the model, individuals 
could progress to more severe CKD states, 
experience fatal and non-fatal cardiovascular 
events, or die from other causes. The cost-
effectiveness of various early referral strategies was 
Executive summary
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assessed by superimposing additional costs and 
anticipated effects on top of the natural history 
model.
Results
From 36 relevant natural history studies, CKD 
was found to be, despite marked heterogeneity 
between studies, a marker of increased risk 
of mortality, renal progression and end-stage 
renal disease (ESRD). For many patients, other 
comorbidities associated with CKD contribute to 
this increased risk. Mortality was generally high 
(24–39% at 5 years, 20–52% at 10.0–12.6 years) 
and increased with stage of CKD. After adjustment 
for comorbidities, the relative risk of mortality 
among those with CKD identified from the general 
population ranged from 1.12 to 1.78 and increased 
with stage (from 1.2 in stage 3a to 1.8 in stage 
3b). For clinical populations, the relative risk was 
higher. ESRD was not a common outcome for 
people with mild to moderate CKD, particularly 
when identified through population screening 
(1.3–4.0% at 8 and 10 years for stage 3 CKD). 
All three outcomes increased as eGFR fell. There 
appeared to be a substantial subgroup (for stage 3: 
from 41% to as high as 96%) for whom an eGFR 
lower than 60 ml/min/1.73 m2 did not mark the 
start of declining kidney function after 2–4 years’ 
follow-up. There was little reported about the 
impact on quality of life.
Only seven studies, and no randomised controlled 
trials, were identified as relevant to assessing the 
clinical effectiveness of early referral strategies for 
CKD. In the five retrospective studies constructed 
from cohorts starting on renal replacement 
therapy (RRT), mortality was reduced in the 
early referral group (more than 12 months prior 
to RRT) even as late as 5 years after initiation 
of RRT. Only two studies included predialysis 
participants. One study, in people screened for 
diabetic nephropathy, reported a reduction in 
the decline in renal function associated with 
early referral to nephrology specialists (eGFR 
decline 3.4 ml/min/1.73 m2) when compared with 
a similar group that had no access to nephrology 
services until dialysis was required (eGFR decline 
12.0 ml/min/1.73 m2). The second study, among 
a group of veterans with two creatinine levels of 
at least 140 mg/dl, reported that a composite end 
point of death or progression was lower in the 
group receiving nephrology follow-up than in those 
receiving only primary care follow-up. The greatest 
effect was observed in those with stage 3 or worse 
disease after adjustment for comorbidities, age, 
race, smoking and proteinuria {stage 3: hazard 
ratio (HR) 0.8 [95% confidence interval (CI) 0.61 
to 0.9)]; stage 4: HR 0.75 (95% CI 0.45 to 0.89)}. 
Those cared for by specialists tended to have 
lower blood pressure and receive more aggressive 
antihypertensive therapy. Quality of life was not 
reported.
Cost-effectiveness modelling suggested that 
early referral strategies may have the potential 
to offer an efficient use of resources. In the 
base-case analysis, all early referral strategies 
produced more quality-adjusted life-years 
(QALYs) than referral upon transit to stage 5 
CKD (eGFR 15 ml/min/1.73 m2). Referral for 
everyone with an eGFR below 60 ml/min/1.73 m2 
(stage 3a CKD) generated the most QALYs 
and, compared with referral for stage 4 CKD 
(eGFR < 30 ml/min/1.73 m2), had an incremental 
cost-effectiveness ratio (ICER) of approximately 
£3806 per QALY. However, because of a lack of 
data on the natural history of CKD in individuals 
without diabetes, and a lack of evidence on the 
costs and effects of early referral, our model 
relied on many assumptions. The findings were 
particularly sensitive to changes in eGFR decline 
rates and the relative effect of early referral on 
CKD progression and cardiovascular events; the 
latter parameter being derived from a single 
non-randomised study. Moreover, the costs of 
implementing the modelled referral strategy 
will likely prove prohibitive. There is clear need 
for prospective cohort studies to assess CKD 
progression and the incidence of cardiovascular 
events in individuals identified in primary care as 
having an eGFR less than 60 ml/min/1.73 m2, with 
and without other complications/comorbidities 
such as microalbuminuria, proteinuria, diabetes 
and pre-existing cardiovascular disease. Once these 
data are available they will allow more accurate 
modelling of the cost-effectiveness of referral based 
on different eGFR cut-offs and other comorbidities. 
Future economic modelling should focus on 
assessing the cost-effectiveness of improving the 
management of individuals with early CKD in 
primary care.
Discussion
We have reported evidence of the potential 
for improvements in the care of people with 
CKD. While an early referral model, combining 
some form of shared care between primary 
and secondary care has the potential to be 
cost-effective, it is unlikely that such a model is 
affordable or feasible. Key areas of uncertainty were 
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identified around the natural history of people with 
CKD, in particular stage 1–3 CKD identified by the 
current ‘opportunistic screening’ approach, and 
whether subgroups can be identified where the risk 
of progression is low.
Priorities for further research include:
• Cohort studies of the natural history of stage 
1–3 CKD.
• Review of the clinical effectiveness and cost-
effectiveness of the main pharmacological 
interventions in people with stage 1–3 CKD.
• Randomised controlled trials of models of 
care for people with CKD. As a priority, shared 
care (with proactive involvement of primary 
care with delivery of more than simply a 
phlebotomy service) should be compared with 
standard specialist nephrology and primary 
care. Any trials should include prospective 
economic evaluations.
Conclusions
Despite substantial focus on the early identification 
and proactive management of CKD in the last 
few years, we have identified significant evidence 
gaps about how best to manage people with CKD. 
There was some evidence to suggest that the 
care of people with CKD could be improved and, 
because these people are at risk from both renal 
and cardiovascular outcomes, strategies to improve 
the management of people with CKD have the 
potential to offer an efficient use of health service 
resources. However, given the great uncertainty 
surrounding many parameter estimates, the 
effectiveness and cost-effectiveness of care 
strategies needs to be demonstrated in prospective 
randomised studies prior to implementation. Given 
the number of people now being recognised as 
having markers of kidney impairment, there is an 
urgent need for further research to support service 
change. The natural history of CKD in this new 
population identified as having kidney impairment 
needs to be better understood. For many, 
CKD occurs as part of a complex comorbidity 
cluster, with hypertension, diabetes mellitus and 
cardiovascular disease. In focusing on developing 
and evaluating approaches to provide care for 
people with CKD, it will be important to keep 
sight of opportunities to avoid developing silos of 
care and to balance with the need to identify those 
who have the most to gain from early specialist 
intervention.
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Introduction
Chronic kidney disease (CKD) is a long-term 
condition and has been described as the gradual, 
and usually permanent, loss of kidney function 
over time.1 Early in the disease process, people 
with CKD often experience no symptoms and 
CKD has, for a long time, been an underdiagnosed 
condition. Even in the absence of symptoms, 
CKD appears to add significantly to the burden of 
cardiovascular disease (CVD) and death and, for an 
important minority, can progress to severe kidney 
function impairment and kidney failure (end-stage 
renal disease; ESRD).2
In the last 10 years the focus on mild to moderate 
or ‘early’ CKD has grown. Its recognition as a 
major public health issue was highlighted by large 
population health surveys in the USA reporting 
an estimated 11% of the population as having 
evidence of renal impairment.3 A number of 
authors have written of the ‘exploding’ CKD 
burden and have called for screening, early 
intervention and prevention as key steps in 
managing the individual and societal impact of the 
rising rates of disease.
End-stage renal disease
End-stage renal disease, severe renal function 
impairment or established renal failure is 
associated with high morbidity and mortality, poor 
quality of life, and high health service and societal 
costs. As the kidneys fail, the body becomes unable 
to excrete waste products, excess fluids and salts, or 
to control acidity. Haemoglobin production, blood 
pressure (BP) control and bone metabolism are also 
affected.
Since the first successful dialysis treatment in 1960, 
the nephrology community has focused much 
attention on the management of ESRD.4 Data from 
122 countries (representing 92% of the total world 
population) on treatment for ESRD identified that 
1,783,000 people were receiving renal replacement 
therapy (RRT) by the end of 2004; 77% on dialysis 
and 23% with functioning renal transplants. Half 
of the dialysis patients, and more than 70% of 
transplant patients were from North America and 
Europe.5 With an annual growth of approximately 
6% compared with 2003, the number of people on 
RRT was rising globally.5
In the UK in 2007, the UK Renal Registry reported 
an acceptance rate for new RRT patients of 109 
patients per 1,000,000.6 The point prevalence of 
RRT at the end of 2007 was 45,484, an annual 
population prevalence of 0.075% and a 5% increase 
on the previous year. The acceptance rate has been 
relatively stable over recent years, thus the rising 
prevalence is being driven largely by improvements 
in survival on RRT (Figure 1). The 1-year survival 
on RRT for patients starting RRT in 2006 was 
94.8% [95% confidence interval (CI) 93.4 to 95.8] 
for all primary renal disease excluding diabetic 
nephropathy. Survival was reduced by age at onset 
of RRT.7
While survival on RRT has improved, more than 
30% of 18–64 year olds die within 5 years of 
developing ESRD, and patients’ quality of life is 
impaired.6,8,9
The number of people requiring RRT is expected 
to continue to increase as a result of population 
ageing, the increase in type 2 diabetes mellitus, 
improved technology facilitating access to RRT for 
patients with comorbidities and improved survival 
of people with ESRD. This has important resource 
implications for the NHS, which is estimated to 
spend 2% of the total annual NHS budget on 
delivering RRT, although this group comprises 
only 0.05% of the total population.10 In 2002, 
the National Institute for Health and Clinical 
Excellence (NICE) estimated that the average 
annual cost of haemodialysis in a satellite renal unit 
was £21,000 per patient.11
Definition of chronic kidney 
disease
Until recently, no agreed definition of CKD existed. 
Serum creatinine was commonly reported as a 
surrogate marker of filtration. The absolute upper 
limit of ‘normal’ serum creatinine value varied 
between laboratories and was vulnerable to patient 
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characteristics such as age, sex, race, size, muscle 
bulk, diet, etc.,12,13 and various cut-off thresholds to 
define CKD had been reported.14,15
The glomerular filtration rate (GFR) has become 
the most accepted test to assess filtration.12 
GFR defined as ‘the volume of plasma from 
which a given substance is completely cleared 
by glomerular filtration per unit time’, can 
be measured by assessing the clearance of 
exogenous or endogenous markers.16 Commonly 
used exogenous markers include radioisotopic 
and non-radioisotopic substances such as 
inulin (gold standard), I-iothalamate, Cr-
ethylenediaminetetraacetic acid (EDTA) and 
iohexol, but these are expensive and complex 
procedures for routine clinical use.12,16
Creatinine is the principal endogenous marker 
that is used to measure GFR. Creatinine clearance 
measurement, calculated from timed urine 
collection (24-hour urine) and serum creatinine, 
can result in overestimation of GFR due to tubular 
secretion of creatinine and problems of accurate 
urine collection.17,18 Estimating GFR based on 
serum creatinine and additionally correcting for 
variables such as age, gender, racial origin and 
body weight can be more reliable than 24-hour 
urinary creatinine clearance.16 Two validated 
equations are commonly used to estimate GFR 
based on serum creatinine: the Modification 
of Diet in Renal Disease (MDRD) formula and 
the Cockcroft–Gault (CG) equation to estimate 
creatinine clearance. MDRD has been adopted by 
laboratories reporting estimated GFR (eGFR) in 
the UK, but modifications to the equation are being 
developed with an aim to improving accuracy.19
Normal GFR in young adults is approximately 
120–130 ml/min/1.73 m2, but varies with sex, 
ethnicity and body size, and declines with 
increasing age. In February 2002, with the aim of 
providing a uniform definition of CKD, the Kidney 
Disease Outcomes Quality Initiative (KDOQI) 
of the US National Kidney Foundation (NKF) 
introduced the following definition of CKD and 
stages of CKD:
Kidney damage (with or without decreased 
GFR) or decreased kidney function 
(GFR < 60 ml/min/1.73 m2) for 3 or more 
months where kidney damage is defined as 
pathological abnormalities or markers of 
damage including abnormalities in blood or 
urine tests or in imaging studies.20
A threshold of GFR less than 60 ml/min/1.73 m2 
was selected because it is less than half the level of 
normal adult GFR.21 Additionally, this threshold 
(which is substantially above the level related to 
kidney failure) is detectable with current estimating 
equations for GFR based on serum creatinine, and 
there is evidence that GFR of 60 ml/min/1.73 m2 
and lower is associated with an increased risk 
of complications of CKD and other adverse 
outcomes.21
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TABLE 1 Kidney Disease Outcomes Quality Initiative: CKD Stages
CKD stages Definition
Stage 1 Kidney damage with normal or raised GFR (≥ 90 ml/min/1.73 m2)
Stage 2 Kidney damage with mildly impaired GFR (60–89 ml/min/1.73 m2)
Stage 3 Moderately impaired GFR (30–59 ml/min/1.73 m2)
Stage 4 Severely impaired GFR (15–29 ml/min/1.73 m2)
Stage 5 End-stage renal failure or GFR (< 15 ml/min/1.73 m2)
GFR, glomerular filtration rate.
To avoid the misclassification of acute renal failure 
as CKD, the KDOQI required that reduced GFR 
and/or kidney damage must be present for at 
least 3 months. Further, the KDOQI classified 
CKD into five stages based on level of kidney 
function (Table 1).20 The potential markers of 
kidney damage included proteinuria, haematuria, 
microalbuminuria in people with diabetes mellitus 
and abnormal imaging studies. Stage 3 CKD was 
regarded as the earliest stage of CKD for which 
GFR alone was a sufficient indicator of kidney 
disease.
Prior to 2002, the lack of common definition 
and terminology made the study of CKD 
difficult; prevalence estimates varied widely 
and the translation of research findings into 
clinical practice or policy was challenging. The 
KDOQI classification of CKD has been adopted 
internationally and has raised the profile of CKD, 
facilitating research and identifying people with 
evidence of kidney function impairment that had 
previously gone undetected.
The UK Renal Association proposed 
modifications to stage 3, dividing it into 
3A (eGFR 45–59 ml/min/ 1.73 m2) and 3B 
(30–44 ml/min/1.73 m2).22 Recent NICE guidelines 
on the management of CKD proposed further 
modification of the staging system to include an 
indication of the presence of proteinuria.23
Emerging ‘epidemic’: 
epidemiology of chronic 
kidney disease
With the introduction of the KDOQI definition 
for CKD, and analysis from large population-
based US health surveys (Nutrition Health and 
Nutrition Examination Survey II; NHANES 
II) estimating that 11% of the over 20-year-old 
population may have evidence of CKD, a number 
of commentators described CKD as a major public 
health issue.3,24–26 Analysis of repeated NHANES 
surveys suggested that the prevalence of CKD, as 
defined by the KDOQI (albeit reliant on a single 
measure of kidney function and therefore likely 
to over estimate the true prevalence of CKD), was 
increasing.27,28 This is a finding in keeping with an 
ageing population and the rise in obesity, diabetes 
and hypertension.29
Internationally, prevalence studies have been 
published from a wide range of countries across 
Europe, Asia, Central America and Australia. 
Methodologically they rely on two main 
approaches: population surveys or routine clinical 
laboratory data. In studies of stage 3–5 CKD, 
and therefore relying only on eGFR, estimates of 
prevalence have varied from 3.8%30 to 42.6%.31 The 
reason for such heterogeneity may be contributed 
to by methodological differences (definition of 
chronicity, denominator used, sampling strategy, 
approach to minimisation of assay bias) as well as 
differences in the study population (age, sex, race, 
comorbidities). In Europe, Hallan and colleagues32 
(2006) reported an adult population prevalence of 
4.7% for CKD based on a single eGFR estimate, 
and a similar prevalence has been reported in Italy, 
Switzerland, Spain and Iceland.33–36
In the UK, the only population-based survey 
estimate of CKD prevalence comes from a cohort 
of men aged 60–79 years and tested in 1998–2000. 
Wannamethee and colleagues37 estimated the 
prevalence of CKD to be 15.7%. In 2004–5, two 
studies, using routine laboratory data from the UK 
to estimate the prevalence of CKD based on eGFR, 
reported a prevalence of stage 3–5 CKD of 4.9%38 
and 4.3% respectively.39
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Management of chronic 
kidney disease: a UK 
perspective
The international adoption of the KDOQI 
definition for CKD initiated the epidemiological 
recognition that a far greater proportion of 
the population than previously recognised had 
evidence of kidney function impairment.
In England, the National Service Framework for 
Renal Services set out a vision for renal services. 
In 2004, the first part of the framework focused 
on dialysis and transplantation, providing 
recommendations for a pathway of care and 
emphasising the place of planned identification 
and referral of patients who are progressing 
towards ESRD.10 The second part delivered a 
framework for CKD as well as covering acute renal 
failure and end of life care.2 The framework set out 
the expectation that people considered to be at risk 
of developing or having undetected CKD should 
be identified, assessed and managed proactively 
with a focus on interventions to preserve kidney 
function, and minimise disease progression 
and complications. It also acknowledged the 
cardiovascular burden in patients with CKD. The 
framework targeted, in particular, those with 
diabetes mellitus and hypertension, and supported 
the proactive monitoring for CKD in such high risk 
patient groups.2
Chronic kidney disease guidelines first published 
by the UK Renal Association in 2005 sought to 
provide clarity on how people with CKD should 
be identified and optimally managed.40 The 
National Service Framework set out the need 
for development of protocols around measuring 
kidney function and the estimation of eGFR. The 
UK Renal Association guidelines recommended the 
adoption of the simplified MDRD equation.41
In 2006, the Quality and Outcomes Framework 
(QOF) incentive-based scheme supporting the 
General Medical Services contracts with primary 
care included a renal domain and set four renal 
criteria for primary care:
1. to establish a register of all patients with 
CKD (defined as an eGFR lower than 
60 ml/min/1.73 m2)
2. for those on the register to have had a recorded 
BP in the previous 15 months
3. for the BP to be below 140/85 mmHg
4. for treatment with renin–angiotensin system 
blocking medicines.
The need, nationally, for access to consistent 
eGFR reporting was therefore critical to support 
the development of registers without introducing 
geographical inequalities. The UK National 
External Quality Assessment Scheme was charged 
with harmonising laboratory methodology in order 
to minimise variability between laboratories, and, 
in 2006, the routine laboratory reporting of eGFR 
was rolled out across the UK.41
The introduction of eGFR reporting and in 
particular the decision to report values for eGFR 
only if lower than 60 ml/min/1.73 m2, treating all 
values higher than 60ml/min/1.73 m2 as ‘normal’, 
has made it very straightforward for clinicians to 
identify patients meeting the KDOQI definition of 
CKD.
Implications for health
Chronic kidney disease has the potential to affect a 
number of health areas:
• progressive renal function loss and ultimately 
ESRD and the need for RRT
• CKD-associated complications (anaemia, bone 
mineral metabolism disorders, hypertension)
• CVD
• survival
• quality of life
• anxiety.
These are considered in more depth in Chapter 3.
The treatment of CKD has focused the 
management of complications and preparation 
for ESRD and RRT. The introduction of medicines 
that inhibit the renin–angiotensin–aldosterone 
axis brought evidence of benefit in slowing the 
progression of kidney function decline and 
proteinuria. Recognition of the high cardiovascular 
morbidity and mortality among those with CKD of 
all stages suggests that there is also the potential to 
modify other risk factors for CVD.
Preventing progression and 
cardiovascular disease
In recent years there have been numerous trials of 
pharmacological interventions aimed at modifying 
the risk of renal disease progression and CVD. 
In 2008, NICE23 and the Scottish Intercollegiate 
Guidelines Network (SIGN)42 both published 
guidelines for the management of CKD. The 
management strategies for the prevention of 
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progression of renal disease and reduction of 
cardiovascular risk have hinged largely on three 
areas:
• BP control
• lipid profile modification using statins
• lifestyle risk factor modification.
Blood pressure control
NICE and SIGN guidelines note several 
systematic reviews and meta-analyses that 
support the important role of BP management 
in the prevention of progression of CKD. 
NICE recommended a target systolic BP below 
140 mmHg and diastolic below 90 mmHg. SIGN 
recommended a target of below 130 mmHg for 
systolic BP. The guidelines also presented evidence 
for the role of reduction of proteinuria in reducing 
the risk of renal disease progression.
The role of two groups of antihypertensive agents, 
angiotensin converting enzyme inhibitors (ACE 
Is) and angiotensin receptor blockers (ARBs), has 
received particular attention in the management of 
CKD.
Angiotensin converting enzyme inhibitors
In people with non-diabetic CKD, ACE Is have 
little benefit over placebo or other antihypertensive 
treatments in reducing all-cause mortality (ACM).43 
A statistically significant reduction in the risk of 
developing ESRD alone, or doubling of serum 
creatinine and ESRD [relative risk (RR) reduction 
of 40% and 30% respectively] was observed from a 
meta-analysis of 11 trials and after adjustment for 
difference in study baseline characteristics.43 The 
risk reduction was modified by, but independent 
of, change in BP and proteinuria. A benefit on 
renal outcomes from ACE Is was observed for those 
with proteinuria above 0.5 g/day. Below 0.5 g/day, a 
benefit could not be excluded but the findings were 
less robust.
Even in diabetics with CKD, ACE Is had no 
benefit on ACM44 unless patients were treated 
at maximum tolerable dose (RR 0.78, 95% 
CI 0.61 to 0.98),44 ACE Is reduced the risk of 
ESRD by 31% in diabetics when compared with 
placebo.44 ACE Is can prevent the progression 
of micro- to macroalbuminuria (reported RR 
reduction of 55–65% versus placebo) in diabetic 
renal patients.44,45 Regression from micro- to 
normoalbuminuria was also increased (RR 3.06, 
95% CI 1.76 to 5.35).44 When analysis was restricted 
to those with proteinuria, the findings were 
similar, with no evidence of benefit from ACE Is 
(as compared with placebo) on mortality, but a 
statistically significant effect on reduction of ESRD 
or doubling of serum creatinine (RR 0.60, 95% CI 
0.49 to 0.73).45
Angiotensin receptor blockers
Similar to ACE Is, ARBs have no significant impact 
on ACM in diabetics with CKD when compared 
with placebo or standard antihypertensive 
agents,44,46 or CVD morbidity and mortality.46 
However, there was evidence of a reduction in 
progression of CKD,44 with statistically significant 
risk reductions for ESRD (22%) and doubling of 
serum creatinine (21%). ARBs reduced progression 
from micro- to macroalbuminuria by more than 
50% as well as significantly increasing the numbers 
returning from micro- to normoalbuminuria. 
Regarding adverse effects, the only significant 
increase observed was in hyperkalaemia.
Strippoli and colleagues44 identified three studies 
that compared ACE Is with ARBs. They found no 
evidence of a difference in effect on mortality or 
renal outcomes.
A systematic review by Casas and colleagues47 
reported on effects of ACE Is or ARBs on renal 
outcomes, compared with placebo or other active 
interventions. Evidence of statistically significant 
risk reductions for ESRD was observed (RR 
0.87, 95% CI 0.75 to 0.99). Small reductions 
in creatinine concentration (mean difference 
–7.07 µmol/l, 95% CI –13.26 to –0.88) and urinary 
albumin excretion (mean difference –15.7 mg/day, 
95% CI –24.73 to –6.74) were reported, but 
significant heterogeneity among studies was noted. 
No significant difference was observed in change 
of GFR or on the composite end point of doubling 
of creatinine and ESRD. ACE Is/ARBs had no 
significant effects on GFR, ESRD or doubling of 
creatinine in diabetics. However, small reduction 
in urinary albumin excretion was observed in those 
with diabetic kidney disease (mean difference 
–12.21 mg/day, 95% CI –21.68 to –2.74). Casas 
and colleagues47 noted that larger studies were 
more likely to report smaller benefits, suggesting 
publication or other source of small study bias.
In people with CKD and diabetes with 
microalbuminuria, NICE and SIGN recommend 
treatment with ACE Is or ARBs regardless of 
BP. In non-diabetics with CKD, hypertension 
should be controlled using the range of available 
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antihypertensives. However, both guidelines 
recommend that in the presence of proteinuria and 
CKD, hypertension should be managed first line 
with ACE Is/ARBs.23,42
Anticholesteraemic agents
In a systematic review and meta-analysis of six 
trials, Strippoli and colleagues48 reported that 
statins had no significant benefits on mortality risk 
reduction in CKD when compared with placebo 
or other antilipaemic agents, although some 
benefit (19% reduction in ACM) in the predialysis 
group was observed. The same study reported a 
significant risk reduction in CVD morbidity (RR 
0.75, 95% CI 0.66 to 0.85) and mortality (RR 0.81, 
95% CI 0.73 to 0.90). The impact of statins on 
the rate of change in eGFR and proteinuria was 
variable between trials and between reviews.48–50
NICE and SIGN guidelines recommend that 
statin therapy should be considered in all patients 
with stage 1–3 CKD with a predicted 10-year 
cardiovascular risk of at least 20%.
Lifestyle intervention
Both guidelines recommend that healthy lifestyle 
advice should be offered to people with CKD, 
supporting an active lifestyle, a healthy diet, 
maintenance of a healthy weight and stopping 
smoking. However, evidence to support how best to 
deliver these interventions to people with CKD was 
lacking, as were trials of intervention to estimate 
the potential effect size.
NICE and SIGN noted the place of protein 
restriction in certain clinical circumstances and 
the need for this to be carefully assessed and 
supported. Systematic review of protein restriction 
diets has reported evidence of reducing risk of 
ESRD and/or ACM by 31–77% (from only one 
study with 82 participants) as compared with usual 
protein diet.51,52 Protein restricted diet in type 1 
and type 2 diabetes mellitus had little impact on 
the decline of GFR.52,53
The evidence base around treatments for CKD 
focuses on CKD as a single group and does not 
specifically identify the effectiveness of treatments 
for different stages of CKD. The benefits, and 
potential harms, to those with mild to moderate 
CKD have not been well reported.
When to refer to a 
specialist
Over the last two decades, commentators have 
noted the high proportion, 30–50% in some 
reports, of patients who are referred late to 
specialist nephrology care.54–56 Late referral has 
been variously defined as the first referral to 
specialist nephrology care occurring between less 
than 1 month and 6 months prior to the patient 
requiring the initiation of RRT. Retrospective 
studies have demonstrated an association between 
late referral and poor outcomes on RRT when 
compared with those referred earlier.57
In 2008, NICE and SIGN issued guidelines for the 
management of people with CKD.23,42 Like the UK 
Renal Association guidelines, guidance was given 
about the clinical features that may make referral 
to a specialist appropriate. The guidelines aimed to 
strike a balance between early referral and service 
capacity, and identified uncertainties around the 
potential benefits (and harms) of early referral.
NICE recommended the following groups to be 
considered for referral to a specialist:
• those with stage 4 and 5 CKD (with or without 
diabetes)
• those with higher levels of proteinuria 
[albumin–creatinine ratio (ACR) of at least 
70 mg/mmol] unless known to be due to 
diabetes and already appropriately treated 
proteinuria (ACR of at least 30 mg/mmol) 
together with haematuria and rapidly declining 
eGFR (more than 5 ml/min/1.73 m2 in 1 year, or 
more than 10 ml/min/1.73 m2 within 5 years)
• those with hypertension that remains poorly 
controlled despite the use of at least four 
antihypertensive drugs at therapeutic doses
• those with, or suspected of having, rare or 
genetic causes of CKD
• those with suspected renal artery stenosis
• those with CKD and renal outflow obstruction 
should normally be referred to urological 
services, unless urgent medical intervention is 
required.
SIGN guidelines noted the lack of evidence about 
when to refer individuals to a specialist, and 
provided an algorithm (Figure 2) to aid decision-
making which recognised that patients may 
seek medical attention for a number of different 
reasons.
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FIGURE 2 Algorithm to support decision-making for referral of patients with evidence of renal impairment. Reproduced with 
permission from SIGN guidelines 2008.41
Attention has turned to earlier referral for CKD 
and the opportunity to intervene not only to 
delay progression of renal disease and treat its 
complications at this early stage, but also to prevent 
CVD. Early referral to specialist nephrology care 
might provide a patient with access to an array of 
investigations, preventative treatments, education, 
dietary advice, etc., with an aim of:
• diagnosis of cause of renal disease – 
particularly to identify any causes that may be 
amenable to specific therapy
• appropriate use of renoprotective 
interventions – diet, cessation of smoking 
and pharmacotherapy to delay/prevent 
the progression of the renal disease 
(antihypertensive and specific antiproteinuric 
agents)
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• appropriate use of cardioprotective 
interventions – pharmacotherapy to prevent/
delay or minimise the impact of CVD (diet, 
exercise, smoking, lipid lowering therapy, 
smoking cessation and antiplatelet therapy)
• control of other metabolic and endocrine 
complications such as anaemia and renal bone 
disease
• preparation for a planned start to RRT – early 
intervention with all the above measures allows 
potential for a patient to reach RRT later and 
with fewer comorbidities, better nutrition and 
better psychological adjustment.
Aims and objectives
The aim of this report was to systematically 
review the evidence of the clinical effectiveness 
and cost-effectiveness of early referral strategies 
for management of people with markers of renal 
disease. There were three phases of research:
1. Systematic review of the evidence of clinical 
effectiveness – to assess and synthesise the 
evidence for early referral strategies. In 
addition, we sought to explore the natural 
progression of patients identified as having 
CKD and the characteristics for an effective 
early referral programme including:
 – Which patient groups were likely to benefit 
most?
 – What interventions were effective?
 – How were those interventions delivered 
most effectively?
 – At what stage in disease progression was 
the greatest benefit achieved?
 – What were the barriers to early referral?
2. Systematic review of the evidence of cost-
effectiveness – to assess and synthesise the 
evidence of cost-effectiveness of early referral 
strategies.
3. Economic analysis – informed by the findings 
of phases 1 and 2, to model the economic 
implications of different early referral 
strategies to assess the cost-effectiveness.
In Chapter 2 we set out the methods used for the 
literature reviews. The natural history of CKD is 
reported in Chapter 3. The impact of late referral 
is considered in Chapter 4. Chapter 5 reports the 
findings of the review of clinical effectiveness of 
early referral strategies, and Chapter 6 considers 
other models of care for people with CKD. Chapter 
7 reports the findings from the review of evidence 
of cost-effectiveness and describes the economic 
modelling to assess the potential cost-effectiveness 
of different early referral strategies. Finally, 
Chapter 8 provides a discussion, implications for 
the health service and research recommendations.
DOI: 10.3310/hta14210 Health Technology Assessment 2010; Vol. 14: No. 21
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
9
In this chapter we detail the methods used for the systematic review of the clinical effectiveness 
of early referral for CKD and for the review 
of the natural history of CKD. We also set out 
the methods for the supplementary chapter on 
models of care for CKD undertaken to support 
the development of the economics model and 
to supplement the limited evidence identified 
for clinical effectiveness. The methods for the 
economic modelling are described later, in  
Chapter 7.
Clinical effectiveness and 
cost-effectiveness literature 
reviews
Clinical effectiveness review 
method
Data sources and search strategy
Sensitive electronic searches were undertaken to 
identify studies comparing early referral to other 
care options for people with CKD. Initial searching 
was undertaken between January and April 2008, 
with the main search updated in February 2009. 
Electronic searches were restricted to reports 
published in the English language since 1990. We 
searched for meeting abstracts from January 2006 
only. In addition, reference lists of all included 
studies were scanned to identify additional 
potentially relevant studies. The search strategy is 
summarised in Appendix 1 and included clinical 
and cost effectiveness studies. Search terms did not 
restrict based on timing of referral; studies of early 
or late referral were identified.
The following databases were searched:
• Ovid MEDLINE, 1950 to 4 February 2009
• Ovid MEDLINE In-Process and Non-Indexed 
Citations
• EMBASE, 1988 to week 5 2008
• Science Citation Index, 4 February 2008
• ISI Proceedings, 4 February 2008
• British Nursing Index, 1994 to January 2008
• British Nursing Index Archive, 1985–96
• Health Management Information Consortium, 
January 2008
• Cumulative Index to Nursing & Allied Health 
Literature, 1982 to week 1 December 2007
• Social Science Citation Index, 4 February 2008
• Cochrane Central Register of Controlled Trials: 
Cochrane Library Issue 1 2008
• Cochrane Database of Systematic Reviews: 
Cochrane Library Issue 1 2008
• National Research Register Archive (up to 
October 2007), 19 March 2008
• The UK Clinical Research Network, 19 March 
2008
• The European Dialysis and Transplant Nurses 
Association/European Renal Care Association 
35th International Conference 2006 and 
36th International Conference 2007 Final 
Programmes.
Additional searching was performed in NHS 
Economic Evaluation Database to support the cost-
effectiveness literature review.
Study selection
Initial searching indicated that we would find 
very few randomised controlled trials (RCTs) of 
early referral strategies versus standard care. We 
therefore considered evidence from any study 
design that compared a strategy for early referral 
with a relevant comparator group. We included 
prospective and retrospective study designs. The 
research focused on adults with markers for early 
renal disease in either primary or secondary 
care. We included any intervention that aimed to 
achieve the early referral of people with markers 
of renal disease to specialist nephrology care. 
For retrospective studies, the definition of early 
referral was taken as referral at least 12 months 
before RRT. For prospective study designs, referral 
prior to reaching stage 5 CKD was required but 
other definitions of early referral were accepted 
(e.g. based on proteinuria thresholds in diabetic 
nephropathy). In the absence of a ‘gold standard’ 
for care, acceptable comparators included usual 
care, later referral (defined as less than 12 months 
prior to RRT for retrospective studies) or primary 
care. Outcomes of interest included:
• renal function
• onset of RRT
• quality of life
Chapter 2  
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• ACM
• CVD mortality
• hospitalisations
• emergency dialysis
• survival on dialysis.
Details of the care package were also sought.
Titles, abstracts and keywords were reviewed 
by two systematic reviewers, independently, to 
identify studies that met the inclusion criteria 
outlined above. Full papers were then considered 
for inclusion. Discrepancies were resolved by 
discussion, with involvement of a third reviewer if 
necessary.
The search identified that there was a substantial 
evidence base on the effect of late referral (defined 
as less than 12 months prior to RRT) and, where 
studies included mortality as an outcome, this has 
been included in Appendix 5. A supplementary 
search for literature about potential barriers to 
early referral was conducted using MEDLINE 
(1996 to week 2 April 2008) and EMBASE (1996 to 
week 15 2008).
Quality assessment of included studies
Two systematic reviewers independently assessed 
the methodological quality of the included studies. 
The quality of included studies was assessed using 
the criteria outlined in the Centre for Reviews and 
Dissemination Report 4.58 Checklists were adapted 
from those developed by NICE.59
Data extraction
Data extraction from the included studies was 
carried out independently by two systematic 
reviewers. Study characteristics, outcome results 
and aspects of study quality were collected using 
a standardised form (see Appendix 2). Any 
discrepancies were resolved by discussion and, 
where necessary, by involvement of a third reviewer 
(two occasions relating to terminology).
Data synthesis
Study characteristics and results were tabulated; 
analysis was qualitative. It was not possible to 
pool results for quantitative analysis because of 
the heterogeneity of study characteristics and the 
diversity in reporting of outcomes.
Economics review methods
The literature searches focused on identifying 
studies that assessed the cost-effectiveness of 
nephrology referral strategies for individuals 
with stage 3 CKD. In addition to the databases 
mentioned above, the reference lists of relevant 
studies were hand-searched. All abstracts were 
reviewed and the full article was obtained for any 
studies that were potentially relevant. Articles 
cited by other relevant studies were also retrieved 
for review. The review focused primarily on 
studies relating to individuals without diabetes, 
as more formal care pathways were already in 
place for individuals with diabetes and diabetic 
nephropathy.60
Study selection
Our inclusion criteria for formal appraisal were 
studies assessing the costs and consequences 
(long- or short-term) of early referral strategies 
for individuals with markers of renal disease. 
Early referral was defined as referral to a 
specialist prior to stage 4 CKD (i.e. eGFR higher 
than 30 ml/min/1.73 m2). We were not explicitly 
interested in extracting data from studies assessing 
the cost-effectiveness of population screening for 
proteinuria, but studies that looked at screening 
in non-diabetic populations were obtained to help 
inform the development of the economic model. 
Finally, studies assessing the cost-effectiveness of 
single interventions in individuals with CKD, such 
as the use of ACE Is to slow progression, were 
excluded from formal appraisal.
Quality assessment of included studies
Studies meeting our inclusion criteria were 
appraised using the British Medical Journal 
guidelines for reviewers of economic evaluations.61 
The quality of included decision models was also 
assessed against a published checklist for good 
practice in decision analytic modelling in health 
technology assessment.62
Data extraction
Plans were made to formally extract data from 
studies directly assessing the cost-effectiveness 
of nephrology referral for individuals with stage 
3 disease compared with referral at stage 4 or 5 
(current practice).
Other literature reviews
Separate systematic reviews were undertaken to 
support the following areas of the report: natural 
history of CKD and models of care for CKD.
Search strategies
Natural history
A systematic literature review was conducted to 
identify relevant literature on the natural history 
DOI: 10.3310/hta14210 Health Technology Assessment 2010; Vol. 14: No. 21
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of CKD. MEDLINE (1950 to March week 2 2008) 
and EMBASE (1996 to March week 4 2008) were 
searched. An internet search (Google scholar; 
http://scholar.google.co.uk/) was performed 
and potentially relevant studies were identified 
from clinical experts. Searches were restricted 
to the English language and were from 1998. 
Bibliographic searching of any included study was 
also undertaken (see Appendix 1 for the search 
strategy).
Systematic reviews, meta-analyses, observational 
cohorts and follow-up studies (prospective or 
retrospective) of adult populations with at least 
2 years’ of follow-up were considered. RCTs were 
excluded owing to the highly selected nature of 
their participants. Those studies where the main 
study populations were defined as having CKD 
were included. However, studies with broader 
participant inclusion criteria (diabetes, CVD 
or hypertension) were considered for inclusion 
when participants with CKD accounted for a 
substantial number of the total study population. 
Studies with less than 100 subjects were excluded. 
While a definition of CKD based on the KDOQI 
classification was considered to be optimal, 
the definition of CKD used by the authors was 
accepted.
Included studies were quality assessed. Systematic 
reviews and meta-analyses were evaluated based 
on a methodology checklist outlined by NICE.63 
Other study designs were evaluated based on 
a quality assessment tool adapted from various 
methodological criteria.39,64–67
Care model
Database searching was carried out in MEDLINE 
(1950 to present) and EMBASE (1996 to 
2008 week 25) combining keywords and medical 
subject heading (see Appendix 1). Internet and 
bibliographic searches of included studies were 
performed. No relevant studies were identified 
from the Cochrane review database and Health 
Technology Assessment (HTA) journal database of 
published reports. Any full papers or abstracts 
published in English (evaluation, audit, description 
of care) that reported a model of care for the 
management of CKD patients were included. Care 
models of management of RRT patients were 
excluded.
Data extraction
Data extraction was undertaken by one author and 
checked by a second author. A specifically designed 
and piloted data extraction form was used for 
each component. Information about study design, 
participants, definition and measure of CKD and 
relevant outcomes of the study were extracted. The 
data were extracted for all participants and for 
relevant clinical subpopulation including stages of 
CKD, diabetes mellitus, CVD, high blood pressure 
(HBP), sex, age group and race.
In the review of reports of care models, additional 
data were extracted about: setting (primary, 
secondary or other); model of care or intervention 
provided or proposed; description of participants 
or staff involved; and relevant outcomes/outcomes 
foreseen including, primarily, clinical outcomes and 
attitudes of patient or health-care provider towards 
service and, secondarily, improvements or changes 
in care/service and barriers to implementation of 
services.
Data synthesis
For all reviews, the study characteristics and 
results were tabulated and analysed qualitatively. A 
thematic approach was adopted for analysis of the 
barriers to early referral and care models.
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Introduction
Understanding the natural history of CKD is 
critical to understanding the effectiveness of 
interventions involving the ‘early’ referral of 
patients with CKD to specialists.
This review of the natural history of CKD focused 
on renal impairment defined by GFR. GFR was 
chosen because in the UK, since 2006, there has 
been universal reporting of eGFR from laboratories. 
In addition, general practitioners (GPs) in the UK 
have been asked to record all patients with an eGFR 
of less than 60 ml/min/1.73 m2 (stage 3 or higher) on 
a practice register. This cohort, therefore, makes up 
a critical and substantial component of the people 
increasingly labelled with CKD in the UK and for 
whom the appropriateness and timing of referral 
to a specialist is uncertain. The key outcomes of 
interest were ACM, cardiovascular mortality and 
morbidity, renal progression and ESRD, and  
quality of life.
Results
Description of included studies
The process of study identification and the number 
of relevant published papers are given in Figure 
3. Thirty-six studies were data extracted and 
appraised (42 published papers; five studies with 
more than one publication). Details of the excluded 
studies are given in Appendix 3.
A summary of the characteristics of the included 
studies is given in Table 2.
We did not identify any systematic reviews of the 
natural history of CKD that considered all of the 
outcomes of interest, but we did identify three 
systematic reviews that presented information 
about some aspects of natural history.
One review compared the risk of ACM and 
cardiovascular mortality in those with CKD as 
compared with non-CKD populations where studies 
included a range of study participants from healthy 
adults to those with comorbidities.68 We identified 
a second review comparing the risk of non-fatal 
myocardial infarction (MI) and cardiovascular 
mortality between those with evidence of CKD and 
no CKD in seven population studies of apparently 
healthy adults.69 These two reviews overlapped in 
one study (NHANES II 2002),70 and Tonelli and 
colleagues68 reported data from three primary 
cohort studies [ARIC (Atherosclerosis Risk in 
Communities) 2003,71 CHS (Cardiovascular Heart 
Study) 2003,72 FHS (Framingham Heart Study) 
199973] which were included by Di and colleagues69 
as a single study that pooled individual patient data 
from the original studies.74
These were good quality reviews (see Appendix 
4) and we therefore focused our further searches 
on studies quantifying the extent of progression 
and mortality in CKD populations. We limited our 
included studies to only those defining their study 
populations as having CKD, rather than further 
comparing risk to the general population. We did 
include comparative studies if they had not been 
included in the above reviews or where additional 
information of interest in our review was available 
in the original study. One study75 from Tonelli 
and colleagues68 and two studies74,76 from Di and 
colleagues69 were identified in our searches and 
included as primary studies because they presented 
additional information pertinent to this review.
Finally, Dale and colleagues77 reviewed studies of 
health utility in people with CKD and ESRD. Only 
one study78 included this review met our inclusion 
criteria and was thus data extracted separately.
All other studies included were prospective (21) or 
retrospective cohorts (13). Two included studies, 
defining their study population based on the 
presence of diabetes only, were retained because 
participants with CKD accounted for a substantial 
number of the total study population.79,80 Irie 
and colleagues81 reported on a subgroup of the 
participants included in the study by Imai and 
colleagues82 but reported on different outcomes 
and their work was, therefore, included as a 
separate study.
Chapter 3  
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FIGURE 3 Representation of the flow of studies through the natural history review process.
Definition of chronic kidney 
disease
Among the included studies, various definitions 
of renal impairment were reported. Definitions 
based on the KDOQI were the most widely used 
to describe CKD and classify stages, with an eGFR 
of less than 60 ml/min/1.73 m2 (stage 3 or worse) 
being the most commonly reported threshold 
(see Table 2). Others defined impaired renal 
function based on serum creatinine, creatinine 
clearance, microalbuminuria or some combination 
of measures. Several studies did not clearly 
define what they considered to be CKD, but 
they presented data for subgroups that met the 
inclusion criteria of our review and were therefore 
reported.
Where GFR was reported, most studies used the 
MDRD equation to estimate GFR; two studies 
used the CG equation.83,84 The re-expressed, ID-
MS (isotope dilution-mass spectrometry) traceable 
MDRD formula was used in two studies.32,85 
One compared the MDRD equation, the CG 
equation and the Mayo Clinic equations for 
estimating GFR.86 Three studies used the Cr-EDTA 
injection87–89 while another study used the iohexol 
clearance technique90 to measure kidney function. 
Five studies did not specify which measure was 
used to assess renal function.78,91–94 The systematic 
reviews included a variety of measures for assessing 
kidney function.68,69
We were able to define two categories of study 
based on the populations they included:
• Screened population – drawing from people 
in the community and using a population 
screening approach.
• Clinical population – drawing from clinical 
record databases, laboratories, primary care or 
clinical settings and the blood sample taken for 
a clinical indication.
Methodological quality of 
included studies
The quality of cohort or follow-up studies was 
assessed based on the following four criteria:
• sample selection
• follow-up
• determination of chronicity
• measure of renal impairment.
A summary of the quality assessment is presented 
in Table 3. Only 13 studies adequately defined 
CKD to be chronic. Assay calibration for the 
measurement of serum creatinine is a major 
Articles identified by searches
(3442) and from expert (9)
n = 3306
Articles for which abstract was
screened
n = 396
Articles for which full text was
obtained
n = 122
Articles excluded on the
basis of title and abstract
n = 274
Articles excluded on the
basis of title
n = 3055
Excluded articles
n = 86
Seven studies retained for data
extraction and inclusion for
natural history
n = 36
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determinant of the accuracy of GFR,112 and 
differences between clinical laboratories in 
calibration of serum creatinine or assays could be 
a source of error.113 Among the included studies, 
only 12 accounted for differences in assays over 
time or between labs. More than half of the studies 
had either complete follow-up or reported loss to 
follow-up of less than 10%. Most of the studies (27) 
fulfilled all or 85% of the criteria for study design 
and sample selection (see Appendix 4 for the 
quality assessment for systematic reviews).
Outcomes
The outcomes reported by included studies 
are summarised in Table 4. ACM was the most 
commonly reported outcome, with few studies 
reporting aspects of quality of life. Thirteen studies 
presented the outcomes by CKD stages as per the 
KDOQI.32,75,78–80,82,83,85,94,101,106,110,111
In the following section, we present a summary of 
the results of studies of general CKD populations 
not restricted to specific subgroups. We then 
present data for the following pre-specified 
subgroups: diabetes mellitus, hypertension (HBP), 
CVD, gender, race and age.
All-cause mortality: general 
chronic kidney disease 
population
ACM risk in those with CKD compared 
with no CKD
Eriksen and Ingebretsen96 reported a hazard 
ratio (HR) of 1.25 (95% CI 1.14 to 1.37) for 
each 10-ml/min/1.73 m2 decrease in eGFR. Five 
primary studies reported a small increased risk 
of mortality (risk ratios ranged from 1.12 to 1.78) 
for people with CKD as compared with those 
without CKD (Figure 4).74,76,81,85,92 These studies were 
based on general populations undergoing health 
screening76,81,85 or clinical record database review,92 
and all but one92 adjusted for comorbidities, age 
and sex. Herzog and colleagues92 adjusted for 
comorbidities only. A further two population health 
screening studies, comparing ACM in CKD cohorts 
with the population as standardised mortality rates 
(SMRs), noted higher risks of mortality with SMR 
2.2 (95% CI 2.1 to 2.4)96 and SMR 8.3 (95% CI 7.5 
to 9.2),98 but did not adjust for comorbidity (Figure 
4). Evans and colleagues98 included a cohort of 
participants with marked renal impairment with a 
serum creatinine level of at least 250 µmol/l. John 
and colleagues104 reported age and sex-adjusted 
SMRs for a CKD cohort compared with the general 
population, based on laboratory data (SMR 1.53, 
95% CI 1.44 to 1.62).
Tonelli and colleagues68 reported an unadjusted 
increased risk of death among those with CKD 
compared with no CKD in 93% of the 37 studies 
included in their meta-analysis (RR range 
0.94–5.00); however, significant heterogeneity was 
noted. From a series of meta-regression analyses, 
authors reported that a greater risk associated with 
CKD was observed in younger patients, women 
and studies in ‘general populations’. In nine 
studies classed as including a ‘general population’, 
the risk for mortality in the CKD group was 
threefold higher (RR 3.0, 95% CI 2.18 to 4.11), 
but again substantial heterogeneity was observed. 
Studies based on population health survey data 
(NHANES I114 and II,70 FHS73) reported lower HR/
RR of 1.38–2.26. One population-based heart risk 
factor study in North America (ARIC71) reported 
higher risk estimates (3.54); three studies included 
populations known to be at high risk of mortality 
and CKD (people over 65 years, aboriginal 
Australians, clinical records based cohort). Adjusted 
analysis for general population studies (possible 
for three studies) was also presented by Tonelli and 
colleagues68 and this reduced heterogeneity as well 
as reducing the risk estimate to close to 1 for all 
but one of the studies. Further details are given in 
Appendix 5.
Two studies reported adjusted risk of ACM by CKD 
stage (Table 5).75,85 Go and colleagues,75 studying 
a clinical population, reported an increasing risk 
with stage from HR 1.2 for stage 3a to 5.9 for stage 
5 (compared with no CKD). Astor and colleagues,85 
studying a general population, also reported an 
increase in risk with stage.
ACM rate in populations with CKD
Four studies reported ACM per 10,000 person-
years.74–76,85 All reported death rates among those 
with CKD that were greater than for those with 
no CKD (definitions varied) (Table 6). Death rate 
varied substantially between studies; Wiener and 
colleagues74 reported the highest rate of 3080 
deaths per 10,000 person-years, considerably 
more than any of the other studies. This study also 
reported a high death rate (980 per 10,000 person-
years) in the population with no CKD. There was 
evidence that death rate increased with the degree 
of proteinuria85 and stage,75 and was higher in men 
than in women.76
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TABLE 3 Quality assessment of included primary studies
Study ID
Hypothesis/
aim clearly 
described
Complete 
capture 
of study 
population
Clear 
inclusion and 
exclusion 
criteria
Clinical and 
demographic 
characteristics 
detailed
Information 
recorded 
prospectively 
(minimal recall 
bias)
Ascertainment of 
sample described
Assessment 
of outcome 
described
Number 
lost to 
follow-
up 
reported
Loss 
to 
follow-
up 
< 10%
Reason 
for 
loss to 
follow-
up 
given
Characteristics 
of patients loss 
to follow-up 
described
Design 
specific 
sources 
of bias 
mentioned
Appropriate 
methods 
to deal 
with bias/
confounding
Chronicity: 
adequately 
defineda
Accounted 
for 
differences 
in assays
Astor 200885 Yes Yes Yes Yes Yes Yes Yes Complete – – – Yes Yes Unclear Yes
Bruno 200779 Yes Yes Yes Yes Yes Yes Yes Yes Yes No No Yes Unclear No No
Cvengros 
200591
Yes Yes Yes Yes Yes Yes Yes Yes No No No Yes Yes No No
Djamali 200383 Yes Unclear Yes Yes Yes No No Yes No Yes No Yes No Yes No
Drey 200395 Yes Yes Yes Yes Yes Yes Yes Yes Yes No No Yes No No Yes
Eriksen 200696 Yes Yes Yes Yes Yes Yes Yes Complete – – – Yes Yes Yes Unclear
Evans 200598 Yes Yes Yes Yes Yes Yes Yes Complete – – – Yes Yes Yes No
Go 200475 Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No No Yes Yes
Gorodetskaya 
200578
Yes No Yes Yes Yes Yes Yes Yes No Yes No Yes No No No
Hallan 200632 Yes Yes Yes Yes Yes Yes Yes Complete – – – Yes Yes No Yes
Hemmelgarn 
2006101
Yes Yes Yes Yes Yes Yes Yes Complete – – – Yes Yes No Yes
Herzog 200492 Yes Yes Yes Yes Yes Yes Unclear Complete – – – Yes Yes No No
Hovind 200193 Yes Unclear Yes Yes Yes Yes Unclear No – – – Yes Yes Yes No
Hsu 2003103 Yes Yes Yes Yes Yes Yes Yes Complete – – – Yes Yes No Yes
Imai 200882 Yes Yes Yes Yes Yes Yes Yes Complete – – – Yes Yes No Yes
Irie 200681 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No Yes
John 2004104 Yes Yes Yes Yes Yes Yes Yes Complete – – – No No Yes Yes
Jones 2006105 Yes No Unclear Yes Yes Yes Yes Complete – – – Yes Yes Yes Yes
Keith 2004106 Yes Yes Yes Yes Yes Yes Yes Complete – – – Yes Yes Yes Unclear
Khatami 
2007108
Yes Unclear Yes Unclear Yes Yes Yes Complete – – – No No Unclear Yes
Kollerits 
200790
Yes Unclear Yes Yes Yes Unclear No Yes No Yes Yes Yes Yes Yes No
Leehey 2005109 Yes Unclear Yes Yes Yes Yes Yes Complete – – – Yes Yes Yes No
Levin 200184 Yes Unclear Yes Yes Yes Yes Unclear Yes Yes No No Yes No No No
Maaravi 200786 Yes Yes Yes Yes Yes Unclear Unclear Complete – – – Yes Yes Unclear Unclear
Meisienger 
200676
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No Unclear
Mulec 199887 Yes Unclear Yes Yes Yes Yes Unclear Complete – – – No No Unclear No
O’Hare 
2006110
Yes Yes Yes Yes Yes Yes Yes Unclear – – – Yes Yes No No
Orlando 
2007111
Yes Unclear Yes Yes Yes Yes Yes Yes Yes No No Yes Yes Yes No
Patel 200580 Yes Unclear Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes Unclear No
Rossing 200488 Yes Unclear Yes Yes Yes Yes Yes Unclear – – – Yes Yes Yes Unclear
Tarnow 200589 Yes Unclear Yes Yes Yes Yes Yes Yes Yes Yes No No No No Unclear
Tseng 200894 Yes Yes Yes Yes Yes Yes Yes Complete – – – Yes Yes Yes No
Wannamethee 
200637
Yes Yes Yes Yes Yes Yes Yes Yes Yes No No Yes Yes No No
Weiner 200474 Yes Yes Yes Yes Yes Yes Unclear Yes Yes No No Yes Yes No Yes
a CKD is defined to be chronic if decreased eGFR persisted for more than 3 months.
Quality assessment of two systematic reviews (Di 200768 and Tonelli 200667) is not presented here, but is given in Appendix 4.
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TABLE 3 Quality assessment of included primary studies
Study ID
Hypothesis/
aim clearly 
described
Complete 
capture 
of study 
population
Clear 
inclusion and 
exclusion 
criteria
Clinical and 
demographic 
characteristics 
detailed
Information 
recorded 
prospectively 
(minimal recall 
bias)
Ascertainment of 
sample described
Assessment 
of outcome 
described
Number 
lost to 
follow-
up 
reported
Loss 
to 
follow-
up 
< 10%
Reason 
for 
loss to 
follow-
up 
given
Characteristics 
of patients loss 
to follow-up 
described
Design 
specific 
sources 
of bias 
mentioned
Appropriate 
methods 
to deal 
with bias/
confounding
Chronicity: 
adequately 
defineda
Accounted 
for 
differences 
in assays
Astor 200885 Yes Yes Yes Yes Yes Yes Yes Complete – – – Yes Yes Unclear Yes
Bruno 200779 Yes Yes Yes Yes Yes Yes Yes Yes Yes No No Yes Unclear No No
Cvengros 
200591
Yes Yes Yes Yes Yes Yes Yes Yes No No No Yes Yes No No
Djamali 200383 Yes Unclear Yes Yes Yes No No Yes No Yes No Yes No Yes No
Drey 200395 Yes Yes Yes Yes Yes Yes Yes Yes Yes No No Yes No No Yes
Eriksen 200696 Yes Yes Yes Yes Yes Yes Yes Complete – – – Yes Yes Yes Unclear
Evans 200598 Yes Yes Yes Yes Yes Yes Yes Complete – – – Yes Yes Yes No
Go 200475 Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No No Yes Yes
Gorodetskaya 
200578
Yes No Yes Yes Yes Yes Yes Yes No Yes No Yes No No No
Hallan 200632 Yes Yes Yes Yes Yes Yes Yes Complete – – – Yes Yes No Yes
Hemmelgarn 
2006101
Yes Yes Yes Yes Yes Yes Yes Complete – – – Yes Yes No Yes
Herzog 200492 Yes Yes Yes Yes Yes Yes Unclear Complete – – – Yes Yes No No
Hovind 200193 Yes Unclear Yes Yes Yes Yes Unclear No – – – Yes Yes Yes No
Hsu 2003103 Yes Yes Yes Yes Yes Yes Yes Complete – – – Yes Yes No Yes
Imai 200882 Yes Yes Yes Yes Yes Yes Yes Complete – – – Yes Yes No Yes
Irie 200681 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No Yes
John 2004104 Yes Yes Yes Yes Yes Yes Yes Complete – – – No No Yes Yes
Jones 2006105 Yes No Unclear Yes Yes Yes Yes Complete – – – Yes Yes Yes Yes
Keith 2004106 Yes Yes Yes Yes Yes Yes Yes Complete – – – Yes Yes Yes Unclear
Khatami 
2007108
Yes Unclear Yes Unclear Yes Yes Yes Complete – – – No No Unclear Yes
Kollerits 
200790
Yes Unclear Yes Yes Yes Unclear No Yes No Yes Yes Yes Yes Yes No
Leehey 2005109 Yes Unclear Yes Yes Yes Yes Yes Complete – – – Yes Yes Yes No
Levin 200184 Yes Unclear Yes Yes Yes Yes Unclear Yes Yes No No Yes No No No
Maaravi 200786 Yes Yes Yes Yes Yes Unclear Unclear Complete – – – Yes Yes Unclear Unclear
Meisienger 
200676
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes No Unclear
Mulec 199887 Yes Unclear Yes Yes Yes Yes Unclear Complete – – – No No Unclear No
O’Hare 
2006110
Yes Yes Yes Yes Yes Yes Yes Unclear – – – Yes Yes No No
Orlando 
2007111
Yes Unclear Yes Yes Yes Yes Yes Yes Yes No No Yes Yes Yes No
Patel 200580 Yes Unclear Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes Unclear No
Rossing 200488 Yes Unclear Yes Yes Yes Yes Yes Unclear – – – Yes Yes Yes Unclear
Tarnow 200589 Yes Unclear Yes Yes Yes Yes Yes Yes Yes Yes No No No No Unclear
Tseng 200894 Yes Yes Yes Yes Yes Yes Yes Complete – – – Yes Yes Yes No
Wannamethee 
200637
Yes Yes Yes Yes Yes Yes Yes Yes Yes No No Yes Yes No No
Weiner 200474 Yes Yes Yes Yes Yes Yes Unclear Yes Yes No No Yes Yes No Yes
a CKD is defined to be chronic if decreased eGFR persisted for more than 3 months.
Quality assessment of two systematic reviews (Di 200768 and Tonelli 200667) is not presented here, but is given in Appendix 4.
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TABLE 4 Outcomes reported in included studies
Study ID ACM CVD M&M RRT ESRD CKDP QoL
Astor 200885 × ×
Bruno 200779 × ×
Cvengros 200591 ×
Di 200769 ×
Djamali 200383 × ×
Drey 200395 × × × ×
Eriksen 200696 × × ×
Evans 200598 × × × ×
Go 200475 × × ×
Gorodetskaya 200578 × × ×
Hallan 200632 × ×
Hemmelgarn 2006101 × × ×
Herzog 200492 ×
Hovind 200193 ×
Hsu 2003103 × ×
Imai 200882 ×
Irie 200681 × ×
John 2004104 × × ×
Jones 2006105 × × ×
Keith 2004106 × × ×
Khatami 2007108 ×
Kollerits 200790 × ×
Leehey 2005109 ×
Levin 200184 × × × ×
Maaravi 200786 ×
Meisienger 200676 × ×
Mulec 199887 ×
O’Hare 2006110 ×
Orlando 2007111 × ×
Patel 200580 × × ×
Rossing 200488 × × × ×
Tarnow 200589 × ×
Tonelli 200668 × ×
Tseng 200894 × ×
Wannamethee 200637 ×
Weiner 200474 × ×
ACM, all-cause mortality; CKDP, chronic kidney disease progression; CVD M&M, cardiovascular disease morbidity and 
mortality; ESRD, end-stage renal disease; RRT, renal replacement therapy; QoL, quality of life.
DOI: 10.3310/hta14210 Health Technology Assessment 2010; Vol. 14: No. 21
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FIGURE 4 Risk of all-cause mortality. Comparing those with CKD with those without CKD. aThree studies reported by Tonelli 200668 
as ‘general populations’ with adjusted analysis; Sihvonen 2004115 included only people with rheumatoid arthritis so recoded as ‘clinical 
population’ in this review. Clin, clinical; CVD, cardiovascular diseases; DM, diabetes mellitus; F, female; FHS, Framingham Heart 
Study; Gen, general; HBP, high blood pressure; HR, hazard ratio; M, male; NHANES I, National Health and Nutritional Survey I; Pop, 
population; RR, relative risk; SMR, standardised mortality rate. 
TABLE 5 Risk of all-cause mortality by CKD stage
Study ID Measures Values (variance) Reference group Adjusted analysis
Astor 200884 RR (95% CI) Stage 2: 1.05 (0.89 to 1.25)
Stage 3–5: 1.77 (1.47 to 2.13)
eGFR ≥ 90 ml/
min/1.73 m2
Age, sex, race/ethnicity, previous 
CVD, BP, use of antihypertensive 
medication, DM, smoking, BMI, 
physical activity, cholesterol and 
C-reactive protein
Go 200474 HR (95% CI) Stage 3a: 1.2 (1.1 to 1.2)
Stage 3b: 1.8 (1.7 to 1.9)
Stage 4: 3.2 (3.1 to 3.4)
Stage 5: 5.9 (5.4 to 6.5)
eGFR ≥ 60 ml/
min/1.73 m2
Age, sex, income, education, 
dialysis, prior CVD, DM, HBP, 
dyslipidaemia, cancer, serum 
albumin  
< 3.5g/dl, dementia, cirrhosis, 
chronic lung disease, proteinuria, 
prior hospitalisation
BP, blood pressure; BMI, body mass index; CI, confidence interval; CVD, cardiovascular disease; DM, diabetes mellitus; 
eGFR, estimated glomerular filtration rate; HBP, high blood pressure; HR, hazard ratio; RR, relative risk.
Natural history
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TABLE 6 Summarised result of all-cause mortality for general CKD population (eGFR < 60 ml/min/1.73 m2 unless stated)
Study ID Measures Values (variance) Follow-up
Comparators/
CKD other 
stages Comments
Deaths per person-years
Astor 200885 Events/10,000 person-
years (read from 
graph)
Stage 3–5 no A: 290
Stage 3–5 microA: 510
Stage 3–5 macroA: 880
13 years eGFR > 90 ml/
min/1.73 m2 no A: 
180
Go 200475 Events/10,000 person-
years
Stage 3a: 108
Stage 3b: 476
Stage 4: 1136
Stage 5: 1414
Median 
2.84 years
eGFR ≥ 60 ml/
min/1.73 m2: 76
Meisinger 
200676
Events/10,000 person-
years
M: 329.3
F: 154.8 
Median 
12.5 years
eGFR ≥ 60 ml/
min/1.73 m2: M: 
194.7; F: 90
Weiner 
200474
Events/10,000 person-
years
3080 Mean 8.3 
years
eGFR ≥ 60 ml/
min/1.73 m2: 980
Cumulative mortality within follow-up period
Djamali 
200383
Deaths in 12.6 yearsa 19.7% 12.6 years CKD defined as 
SCr > 115 µmol/l; 
presented as 
survival analysis in 
paper
Eriksen 
200696
Deaths in 5 years 
(95% CI)
32% (30 to 34) 10 years Presented as 
cumulative 
incidence of death 
in paper
Deaths in 10 years 
(95% CI)
52% (48 to 55)
Evans 200598 Deaths in 1 year 3% 5 years Presented as 
survival rate in 
paper
Deaths in 5 years 39%
Herzog 
200492
Deaths in 1 year CKD 
only
8.2% 1 year CKD defined 
based on ICD-9-
CM codes
Deaths in 1 year 
CKD + CHF + anaemia
22.9%
Seven primary studies presented cumulative 
mortality for a specified time period.81,83,86,92,96,98,105 
At 1 year, mortality varied from only 3%98 to 
15%.105 At 5 years, 31–39% died.96,98 For studies 
reporting 9.0–12.5 years’ follow-up, cumulative 
mortality ranged from 19.7% to 52.0%.81,83,86,96 
Five other studies presented the proportion of 
deaths in a given mean follow-up time and thus 
were not directly comparable.68,76,84,101,104 Drey 
and colleagues95 reported an exceptionally high 
proportion of deaths (69%) in mean 5.5 years. The 
results of these are summarised in Table 6.
Four primary studies reported the proportion 
of deaths for different stages of CKD.75,83,106,111 
The proportion of people dying was observed to 
increase with declining eGFR.
Cardiovascular disease 
morbidity and mortality: 
chronic kidney disease 
population
Studies did not report a consistent definition of 
CVD morbidity and mortality, and reporting was 
often lacking in detail so caution should be used 
when drawing comparisons across studies.
CVD risk in those with CKD compared 
with no CKD
As for ACM, most studies observed a higher risk 
of CVD deaths or events in those with CKD as 
compared with people without CKD. As shown in 
Figure 5, the adjusted risk estimates for general 
population studies were reasonably consistent 
DOI: 10.3310/hta14210 Health Technology Assessment 2010; Vol. 14: No. 21
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Study ID Measures Values (variance) Follow-up
Comparators/
CKD other 
stages Comments
Irie 200681 Deaths in 10 years 20.7% 10 years
Jones 2006105 Deaths in 1 year 15% 3 years
Deaths in 3 years 25%
Keith 2004106 Deaths in 5 years Stage 3: 24.3%
Stage 4: 45.7%
5 years eGFR 60–89 ml/
min/1.73 m2 no P: 
10.2%
Stage 2: 19.5%
Maaravi 
200786
Deaths in 12 years MDRD equation 36.4%
CG equation 35.4%
12 years Presented as 
survival rate in 
paper
Mortality (%)
Drey 200395 Deaths SCr > 1.7 mg/dl: 69%
SCr 1.7–3.3 mg/dl: 69%
SCr 3.4–5.7 mg/dl: 77%
SCr > 5.7 mg/dl: 59% 
Mean 5.5 
years
Median survival 35 
months
Go 200475 Stage 3a: 7.54%
Stage 3b: 22.7%
Stage 4: 62.2%
Median 2.8 
years
eGFR ≥ 60 ml/
min/1.73 m2: 2.79%
Hemmelgarn 
2006101
Deaths eGFR < 30 ml/
min/1.73 m2: 6%
Median 2 
years
John 2004104 Deaths 38.6% Median 2.6 
years
Median survival 
28.1 months
CKD: 
SCr ≥ 135 µmol/l
Levin 200184 Deaths 2.6% Median 1.9 
years (462 
patient 
years)
Selected by 
physicians to be 
expected to be 
alive at 12 months
CKD: CrCl  
10–75 ml/min
Meisinger 
200676
Deaths M: 30%; F: 17% Median 
12.5 years
eGFR ≥ 60 ml/
min/1.73 m2: M: 
22%; F: 10.7%
Orlando 
2007111
Deaths Stage 3: 49%
Stage 4: 52%
Stage 5: 27%
Mean 3.6 
years
Stage 1: 21%
Stage 2: 31%
Tonelli 
200668
Deaths 12.4% Median 4.5 
years
eGFR ≥ 60 ml/
min/1.73 m2: 3.1%
A, albuminuria; CG, Cockcroft–Gault; CHF, congestive heart failure; CKD, chronic kidney disease; CPT, physicians’ 
current procedural terminology; CrCl, creatinine clearance; eGFR, estimated glomerular filtration rate; F, female; ICD-
9-CM, International Classification of Diseases, Ninth Edition, Clinical Modification; macroA, macroalbuminuria; M, male; 
MDRD, Modification of Diet in Renal Disease; microA, microalbuminuria; P, proteinuria; SCr, serum creatinine.
TABLE 6 Summarised result of all-cause mortality for general CKD population (eGFR < 60 ml/min/1.73 m2 unless stated) (continued)
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FIGURE 5 Risk of cardiovascular morbidity and mortality. Comparing those with CKD with those without CKD. CVD, cardiovascular 
diseases; DM, diabetes mellitus; F, female; Gen, general; HBP, high blood pressure; HR, hazard ratio; M, male; Pop, population; RR, 
relative risk; SMR, standardised mortality rate.
(RR 1.14–1.81) with the exception of studies by 
Astor and colleagues85 (RR 2.12, 95% CI 1.65 to 
2.73), Weiner and colleagues74 (HR 1.09, 95% CI 
0.91 to 1.29) (pooled analysis of four population-
based health studies in the USA), and Tonelli and 
colleagues.68 Across the 14 studies included in a 
review by Tonelli and colleagues68 that reported 
on CVD mortality and morbidity, the unadjusted 
RRs ranged from 1.43 to 3.73. The risk for CVD 
mortality was 2.47 (95% CI 1.42 to 4.30) in the 
CKD group as compared with the non-CKD 
population for three general population studies, 
but substantial heterogeneity was observed.68 The 
authors described adjusted analysis for all 14 
studies being particularly sensitive to age, with a 
greater risk associated with CKD in younger people 
(no details in paper). Di and colleagues69 also 
reported an increased risk of CVD morbidity and 
mortality (RR 1.41, 95% CI 1.19 to 1.68) from the 
meta-analysis of seven general population studies, 
with statistically significant heterogeneity observed 
(p = 0.045).
Two studies, reporting the risk of CVD events 
associated with different stages of CKD, reported 
an increase with decreasing eGFR (Table 7).
CVD rate in populations with CKD
The rate of CVD deaths or events was reported 
in five studies and varied between studies by 
population, age, sex and CKD stage.32,74–76,85 Rates 
of CVD events and deaths more than doubled from 
stage 3a to stage 3b.
Cardiovascular disease morbidity and mortality was 
reported for follow-up periods that ranged from a 
median of 23 months84 to 12.5 years.76 Frequency 
of CVD death was low in the study by Levin and 
colleagues,84 where study participants were selected 
because they were thought to be clinically healthier. 
Proportions experiencing CVD death or a CVD 
event increased with CKD stage and were higher 
in men than in women.32,75 Summarised results of 
the CVD rates and proportions experiencing CVD 
morbidity and mortality are presented in Table 8.
Renal outcome: chronic kidney 
disease population
Nineteen studies reported renal outcomes and 
included ESRD, RRT and/or CKD progression. The 
results are summarised in Table 9.
DOI: 10.3310/hta14210 Health Technology Assessment 2010; Vol. 14: No. 21
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TABLE 7 Risk of CVD morbidity and mortality during different stages of CKD
Study ID Measures Values (variance) Reference group Adjusted analysis
Astor 200885 CVD deaths, 
RR (95% CI)
Stage 2: 1.37 (1.07 to 1.75)
Stage 3–5: 2.12 (1.65 to 2.73)
eGFR ≥ 90 ml/
min/1.73 m2
Age, sex, race/ethnicity, previous 
CVD, BP, use of antihypertensive 
medication, DM, smoking, BMI, 
physical activity, cholesterol and 
C-reactive protein
Go 200475 CVD events, 
HR (95% CI)
Stage 3a: 1.4 (1.4 to 1.5)
Stage 3b: 2.0 (1.9 to 2.1)
Stage 4: 2.8 (2.6 to 2.9)
Stage 5: 3.4 (3.1 to 3.8)
eGFR ≥ 60 ml/
min/1.73 m2
Age, sex, income, education, 
dialysis, prior CVD, DM, HBP, 
dyslipidaemia, cancer, serum 
albumin  
< 3.5g/dl; dementia, cirrhosis, 
chronic lung disease, proteinuria, 
prior hospitalisation
BP, blood pressure; BMI, body mass index; CVD, cardiovascular disease; DM, diabetes mellitus; eGFR, estimated 
glomerular filtration rate; HBP, high blood pressure; HR, hazard ratio; RR, relative risk.
TABLE 8 Summarised result of cardiovascular morbidity/mortality for general CKD population (eGFR < 60 ml/min/1.73 m2 unless 
stated)
Study ID Measures Values (variances) Follow-up
Comparators/
other CKD stages Comments
Deaths per person-years
Astor 
200885
CVD deaths 
rate/10,000 
person-years
(read from graph)
Stage 3–5 no A: 120
Stage 3–5 microA: 240
Stage 3–5 macroA: 410
13 years eGFR ≥ 60 ml/
min/1.73 m2: 50
Adjusted to the 
incidence rates of 
a 60-year-old non-
Hispanic white male
Go 200475 CVD events 
rate/10,000 
person-years
Stage 3a: 365
Stage 3b: 1129
Stage 4: 2180
Stage 5: 3660
Median 2.8 
years
eGFR ≥ 60 ml/
min/1.73 m2: 211
Rates standardised 
to age
Hallan 
200632
CVD deaths 
rate/10,000 
person-years
Stage 3a: 350
Stage 3b: 740
eGFR < 30 ml/
min/1.73 m2: 1010
Median 8 
years
eGFR ≥ 60 ml/
min/1.73 m2: 40
Meisinger 
200676
CVD deaths 
rate/10,000 
person-years
M: 189.8
F: 87.1
Median 12.5 
years
eGFR ≥ 60 ml/
min/1.73 m2: M: 82.7; 
F: 33
Meisinger 
200676
Incident rates 
of MI/10,000 
person-years
M: 146.5
F: 48.2
Median 12.5 
years
eGFR ≥ 60 ml/
min/1.73 m2: M: 84.1; 
F: 22.9
Weiner 
200474
Incident rates 
of MI or fatal 
CHD/10,000 
person-years
1390 Mean 8.3 
years
eGFR ≥ 60 ml/
min/1.73 m2: 650
Cumulative CVD mortality/morbidity
Irie 200681 Number of CVD 
deaths
M: 82/824 (10.0%)
F: 150/2073 (7.2%)
10 fixed 
years
Keith 
2004106
Number of CHD 3435/13,796 (24.9%) 5.5 fixed 
years
continued
Natural history
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Study ID Measures Values (variances) Follow-up
Comparators/
other CKD stages Comments
Events (%) during follow-up
Drey 200395 Number of CVD 
deaths
339/1071 (31.7%) Mean 5.5 
years
CKD: 
SCr ≥ 150.3 µmol/l
Evans 200598 Number of CVD 
deaths
146/920 (15.9%) Mean 4.4 
years
CKD: stage 4 and 5 
only
Go 200475 Number of CVD 
events
Stage 3a: 
34,690/153,426 (22.6%)
Stage 3b: 
18,580/34,275 (54.2%)
Stage 4: 8809/7085
Stage 5: 3824/1373
Median 2.8 
years
eGFR ≥ 60 ml/
min/1.73 m2: 
73,108/924,136 
(7.9%)
An individual could 
experience more 
than one event –
number of events 
presented
Hallan 
200632
Number of CVD 
deaths
Total: 691/3057 (22.6%)
Stage 3a: 456/2389 
(19.1%)
Stage 3b: 185/548 
(33.8%)
eGFR < 30 ml/
min/1.73 m2: 50/120 
(41.7%)
Median 8 
years
eGFR ≥ 60 ml/
min/1.73 m2: 
1913/62,099 (3.1%)
John 2004104 Number of CVD 
deaths or events
497/3240 (15.3%) Median 2.6 
years
CKD: M: 
SCr ≥ 180 µmol/l
F: SCr ≥ 135 µmol/l
Levin 200184 Number of CVD 
events
New or worsening 
symptoms: 48/244 
(19.7%)
Median 23 
months 
(462 patient 
years)
CKD: CrCl 10–
75 ml/min
Meisinger 
200676
Number of CVD 
events
M: 83/480 (17.3%)
F: 72/753 (9.6%)
Median 12.5 
years
eGFR ≥ 60 ml/
min/1.73 m2: M: 
317/3380 (9.4%); F: 
115/2921 (3.9%)
Meisinger 
200676
Number of 
incident MI
M: 46/441 (10.4%)
F: 31/737 (4.2%)
Median 12.5 
years
eGFR ≥ 60 ml/
min/1.73 m2: M: 
275/3221 (8.5%) F: 
71/2894 (2.5%)
Tonelli 
200668
Number of CVD 
events
182/750 (24.3%) Median 4.5 
years
Weiner 
200474
Number of MI or 
fatal CHD events
168/1664 (10.1%) Mean 8.3 
years
eGFR ≥ 60 ml/
min/1.73 m2: 
1111/20,970 (5.3%)
A, albuminuria; CHD, coronary heart disease; CKD, chronic kidney disease; CrCl, creatinine clearance; CVD, 
cardiovascular disease; eGFR, estimated glomerular filtration rate; F, female; M, male; MI, myocardial infarction; SCr, 
serum creatinine.
TABLE 8 Summarised result of cardiovascular morbidity/mortality for general CKD population (eGFR < 60 ml/min/1.73 m2 unless 
stated) (continued)
Eriksen and Ingebretsen96 reported a 2.5 times 
increase in the risk of developing ESRD for every 
10-ml/min/1.73 m2/year decline in renal function, 
and the incidence of developing ESRD for those 
with an eGFR of less than 60 ml/min/1.73 m2/year 
was five times greater than for the general 
population.96 Hallan and colleagues32 presented 
the adjusted risk of ESRD in different stages of 
CKD and noted a fourfold increase from stage 3a 
to stage 3b. From stage 4, the risk of ESRD was 
substantially increased (HR 68.5, 95% CI 30 to 156) 
and an incidence rate of 260 per 10,000 person-
years was reported.
The rate of CKD progression was measured 
in terms of mean rate of decline of creatinine 
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TABLE 9 Summarised result of renal outcomes for general CKD population (eGFR < 60 ml/min/1.73 m2 unless stated)
Study ID Measures
Values 
(variance) Follow-up
Definitions of 
renal outcomes Comments
ESRD
Risk and rates
Eriksen 
200696
HR (95% CI) of 
renal failure
2.5 (1.89 to 3.31) 10 years Renal failure defined 
as irreversible stage 
5 CKD or initiation 
of RRT
For each eGFR 
decrease of 10 ml/
min/1.73 m2; adjusted 
for age and sex
Eriksen 
200696
Incidence rate ratio 
(95% CI) of renal 
failure
5.3 (3.9 to 7.3) 10 years Renal failure defined 
as irreversible stage 
5 CKD or initiation 
of RRT
Standardised to 
Tromsø general 
population
Hallan 200632 HR (95% CI) of 
ESRD
Stage 3a: 1.0 
(reference)
Stage 3b: 4.2  
(1.5 to 11)
eGFR < 30: 68.5 
(30 to 156)
Median 8 
years
ESRD not defined Adjusted for sex, 
age, diabetes, 
and hypertension 
(smoking, BMI and 
CVD at baseline 
were not significant)
Hallan 200632 Incidence rate of 
ESRD/100 person-
years
Stage 3a: 0.04
Stage 3b: 0.2
eGFR < 30: 2.6
Median 8 
years
ESRD not defined
Cumulative ESRD and ESRD during follow-up duration
Eriksen 
200696
Renal failure 10 years Renal failure defined 
as irreversible stage 
5 CKD or initiation 
of RRT
5 years cumulative 
incidence (95% CI)
0.02 (0.01 to 
0.02)
10 years cumulative 
incidence (95% CI)
0.04 (0.03 to 
0.06)
Hallan 200632 Number reaching 
ESRD
Total: 38/3057 
(1.2%)
Stage 3a: 9/2389 
(0.4%)
Stage 3b: 7/548 
(1.3%)
eGFR < 30: 
22/120 (18.3%)
Median 8 
years
ESRD not defined eGFR ≥ 60 ml/
min/1.73 m2: 13/62066 
(0.02%)
Djamali 
200383
Kidney deaths 
(presented as 
kidney survival in 
the study)
Stage 3: 13.5 
years 12.9%
Stage 4: 11.2 
years 4.9%
Mean 4.6 
years
Kidney survival 
defined as time from 
first visit to time of 
last visit or incidence 
of ESRD or patient 
death with functional 
kidney
Stage 1: 12.7 years 
38.1%
Stage 2: 12.1 years 
26.8%
Adjusted for age and 
sex
RRT
Levin 200184 Number reaching 
RRT
Dialysis: 24/313 
(7.7%)
Transplant: 1/313 
(0.3%)
Median 1.9 
years (462 
patient years’ 
follow-up)
RRT was defined 
as need for 
either dialysis or 
transplantation
CKD: CrCl 10–75 ml/
min
Incidence of RRT at 
6 months
10/268 (3.7%)
Incidence of RRT at 
12 months
7/218 (3.2%)
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Study ID Measures
Values 
(variance) Follow-up
Definitions of 
renal outcomes Comments
continued
Incidence of RRT at 
24 months
18/94 (19.1%)
Kollerits 
200790
Number reaching 
RRT
29/177 (16.4%) Mean 3.9 
years
Drey 200395 Number reaching 
RRT
4% Mean 5.5 
years
RRT: either dialysis 
or transplantation
SCr ≥ 150.3 µmol/l
Hemmelgarn 
2006101
Number reaching 
dialysis
eGFR < 30: 81/87 
dialysis (93.1%)
Median 2 
years
eGFR < 90 ml/
min/1.73 m2
Keith 2004106 Number reaching 
RRT
Stage 3: 
transplant 0.2%; 
dialysis 1.1%
Stage 4: 
transplant 2.3%; 
dialysis 17.6%
5.5 years RRT defined 
as initiation of 
dialysis or renal 
transplantation
Stage 2 no protein: 
transplant 0.01%; 
dialysis 0.06%
Stage 2 + protein: 
transplant 0.2%; 
dialysis 0.9%
Evans 200598 Number reaching 
dialysis
739 (80.3%) Median 4.4 
years
Mean observation 
time in the RRT 
analysis was 2.0 (SD 
1.8) years
Number of 
transplantation
248 (34%)
Gorodetskaya 
200578
Number starting 
dialysis
Stage 4 +: 31/115 
(27.0%)
Mean 10 
(range 6–24) 
months
Jones 2006105 Number starting 
RRT
73 (10%) Median 2.9 
years
CKD progression
Rate of CKD progression
Djamali 
200383
Mean rate of CrCl 
decline (SD) ml/min/
year
Stage 3: 5.4 (7.4)
Stage 4: 5.7 (5.6)
Stage 5: 1.5 (8.5)
Mean 4.6 
years
Stage 1: 11 (12)
Stage 2: 8.4 (10)
CKD: 
SCr > 115 µmol/l
Hemmelgarn 
2006101
Mean rate of eGFR 
decline (95% CI) ml/
min/year
Stage 3–5
Male:
No DM: 3.5  
(2.7 to 4.3)
DM: 7.2  
(5.9 to 8.6)
Female:
No DM: 2.0  
(1.4 to 2.6)
DM: 5.1  
(3.8 to 6.3)
Median 2 
years
Gorodetskaya 
200578
Mean rate of decline 
in eGFR (IQR) ml/
min/1.73 m2/year
Stage 4 +: 1.3  
(2.4 to 0.4)
Mean 10 
(range 6–24) 
months
Imai 200882 Mean rate of decline 
in eGFR
Presented 
graphically only
Jones 2006105 Mean rate of decline 
in eGFR (IQR) ml/
min/1.73 m2/year
Pre referral 5.4  
(2 to 13)
Post referral 0.34 
(–3 to 3)
Median 2.9 
years
TABLE 9 Summarised result of renal outcomes for general CKD population (eGFR < 60 ml/min/1.73 m2 unless stated) (continued)
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Study ID Measures
Values 
(variance) Follow-up
Definitions of 
renal outcomes Comments
Proportion experiencing CKD progression during follow-up
Kollerits 
200790
Proportion 
progressed to renal 
end point
65/177 (36.7%) Mean 3.9 
years
Renal end point 
defined as RRT or 
doubling of baseline 
SCr
CKD estimated 
based on SCr
Doubling of baseline 
SCr without 
reaching ESRD
36/177 (20.3%)
John 2004104 Proportion as 
per various rate 
of eGFR (ml/
min/1.73 m2) decline 
per year
eGFR decline:
< 2: 79.3%
2–3.9: 8.7%
≥ 4: 12.4%
Median 2.6 
years
CKD:
M: SCr ≥ 180 µmol/l
F: SCr ≥ 135 µmol/l
Jones 2006105 Declining GFR 
(slopes more 
negative than 1 ml/
min/1.73 m2)
Post referral:
Decline: 314/726 
(43.3%)
No decline: 412 
(56.7%)
Pre referral:
Decline: 607 
(83.6%)
No decline: 119 
(16%)
Median 2.9 
years
Khatami 
2007108
Proportion 
progressing to 
stages 4 and 5
22/520 (4.2%) 4 years eGFR < 60 ml/
min/1.73 m2 at 
baseline
Proportion 
regressed to stage 2
‘Approx 20%’
Proportion stable ‘Approx 76%’
Orlando 
2007111
Proportion of 
progressors
Stage 3: 70 (17%)
Stage 4: 21 (24%)
Stage 5: 6 (23%)
Mean 3.6 
years
Progression defined 
as from one stage to 
other
Stage 1: 583 (48%)
Stage 2: 276(31%)
BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; CrCl, creatinine clearance; CVD, 
cardiovascular disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; ESRD, end stage renal disease; 
F, female; HR, hazard ratio; IQR, interquartile range; M, male; SCr, serum creatinine; SD, standard deviation; RR, relative 
risk ratio; RRT, renal replacement therapy.
TABLE 9 Summarised result of renal outcomes for general CKD population (eGFR < 60 ml/min/1.73 m2 unless stated) (continued)
clearance by Djamali and colleagues,83 and 
they reported a mean 6.6-ml/min/year decline. 
Normal GFR decline was defined, by the KDOQI, 
as a reduction in eGFR by approximately 
1 ml/min/1.73 m2/year from a normal level of 
125 ml/min/1.73 m2. Jones and colleagues105 
defined CKD progression as any slope more 
negative than a decline of 1 ml/min/1.73 m2/year. 
The study found that 84% of study participants 
had evidence of progression (slope decline of 
more than 1 ml/min/1.73 m2/year) with 52% 
of these experiencing fast progression (slope 
decline of at least 5 ml/min/1.73 m2/year). As they 
followed the cohort over time (and following 
referral to a specialist service) the mean rate 
of decline was noted to reduce. This may be 
the result of interventions, referral or stage of 
disease. John and colleagues104 also reported 
CKD progression according to rates of decline 
in GFR; 8.3% showed a decline of at least 
5 ml/min/1.73 m2/year, 12.4% had decline rates 
between 2.0 and 4.9 ml/min/1.73 m2/year, with the 
remaining 79.3% having little evidence of renal 
function decline. Gorodetskaya and colleagues78 
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reported an estimated mean rate of decline 
in eGFR as 1.3 ml/min/1.73 m2/year [standard 
deviation (SD) 0.4–2.4] for those with an initial 
eGFR lower than 30 ml/min/1.73 m2. Djamali and 
colleagues83 reported that the absolute rate of CKD 
progression was fastest during stages 1 and 2. By 
contrast Hemmelgarn and colleagues101 reported 
the absolute rate of progression increased as eGFR 
declined.
Eriksen and Ingebretsen96 presented cumulative 
incidence of ESRD, reporting 2% and 4% at 5 
and 10 years respectively. Another study reported 
incidence of RRT in 6 months (3.7%), 12 months 
(3.2%) and 24 months (19.1%).84 The other studies 
presented the number starting dialysis or receiving 
a renal transplant as a proportion in a given follow-
up time and, therefore, could not be compared 
directly. An exceptionally high proportion of RRT 
(80.3%) during 4.4 years’ follow-up was observed by 
Evans and colleagues.98
One study presented the progression 
and regression of CKD (eGFR lower than 
60 ml/min/1.73 m2) over 4 years of follow-up108 for 
a subset of 522 patients with a repeat creatinine. 
Around 4% progressed to stages 4 and 5, 20% 
improved to stage 2 or better, and most (76%) 
were stable during the 4 years of follow-up. 
Hemmelgarn and colleagues101 reported that 41% 
of study participants with stage 3 disease and 
approximately 25% (from graph) of those with 
eGFR lower than 30 ml/min/1.73 m2 had stable, 
or an increase in, eGFR during the 2-year study 
period. Orlando and colleagues111 reported that in 
stages 1 and 2, the highest proportion of people 
showed evidence of progression (48% and 31% 
respectively). In stage 3–5, 17–24% progressed. Of 
note, in each stage the proportion not progressing 
because of death increased (from 21% in stage 1 to 
52% in stage 4). Nonetheless, 22–38% of the study 
population neither progressed nor died.
Quality of life
Two papers describe aspects of quality of life in 
patients with CKD.78,91 One prospectively analysed 
the association between kidney function, health-
related quality of life and estimates of utility in 
205 people.78 This was based on the data obtained 
from three measures of quality of life, i.e. Kidney 
Disease Quality of Life short form-36 (KDQOL-
36TM), Health Utilities Index (HUI) and time 
trade-off (TTO). KDQOL-36 is a specific measure 
of health-related quality of life for CKD that 
includes effects and burden of kidney disease and 
physical and mental health score while HUI-3 is a 
generic instrument that measures the population 
preference or utility function such as vision, pain, 
hearing or cognitive function. TTO measures the 
health preferences of patients. Health-related 
quality of life according to the KDQOL-36TM and 
HUI-3 was found to decrease significantly across 
the stages of CKD, but only once eGFR had fallen 
below 30 ml/min/1.73 m2 (with the exception of 
the mental health score which was unchanged 
with stage). For example, HUI-3 (ranges from 1 
to –0.36 where 1 represents perfect health and 0 
death, negative scores represent states considered 
worse than death) reported estimates of 0.67 (SD 
0.31) for eGFR > 60 ml/min/1.73 m2, 0.67 (SD 0.31) 
at stage 3, 0.55 (SD 0.34) at stage 4 and 0.54 (SD 
0.36) at stage 5. For TTO there was a small but 
statistically insignificant decline in quality of life 
from stage 3 to stage 5.
The other study prospectively investigated the 
effect of the internal health-specific locus of 
control (HLOC) on changes in depression state in 
patients with progressive CKD.91 The study mostly 
described the psychological measure and predictors 
of chronic disease. Internal HLOC measures 
patients’ belief in personal control over their 
health outcomes. The study found that internal 
HLOC score change from baseline was a significant 
predictor for changes in depression from baseline 
to follow-up, with increased internal control on 
one’s health predicting lower depression. Further, 
Cvengros and colleagues91 identified that this 
association was restricted to those progressing to 
receive dialysis. The CKD patients who did not 
progress to end stage seemed to have no relation 
between changes in internal HLOC to follow-up 
depression.
Subgroup analysis
CKD with diabetes
The results from cohorts that included only people 
with diabetes mellitus are summarised in Appendix 
6. In studies with at least 6–10 years’ follow-up, 
mortality was reported as ranging from 19.7%79 
to 35.0%88 with cardiovascular deaths accounting 
for a substantial proportion of this. GFR declined 
at between 3.8 and 4.5 ml/min/1.73 m2/year 
and, after 6.5 years, 7% of the study population 
was reported to have ESRD.88 Three studies 
presented data that compared diabetics with non-
diabetics.101,105,111 Jones and colleagues105 observed 
that diabetic nephropathy was a predictor for 
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having ‘fast progressive’ disease (eGFR decline 
of > 5 ml/min/year). Hemmelgarn and colleagues101 
showed that CKD progression increased as the 
stages increased, with higher progression in late 
stages (CKD stages 3 and 4). Relative to the non-
diabetic population, Orlando and colleagues111 
found a higher risk of progression among those 
with diabetes in stage 1–2 (RR versus no diabetes 
mellitus 1.32, 95% CI 1.13 to 1.55), but no 
difference in progression in higher stages.
CKD with cardiovascular disease and 
hypertension (HBP)
While many studies included people with CVD 
and hypertension (HBP), few presented data on 
outcomes stratified by these subgroups. One study 
compared the risk of CKD progression for different 
CKD stages for those with CVD at baseline with 
those without CVD.111 Compared with no CVD 
at baseline, people with CVD in CKD stage 1–3 
were at a 35–52% increased risk of progression; 
in stage 4–5 there was no difference in the risk 
of progression.111 Others presented the number 
accepted onto RRT as a proportion in a given 
follow-up time (see Appendix 6). Tonelli and 
colleagues68 analysed ACM and CVD mortality 
for studies recruiting only patients with CVD or 
patients with HBP at baseline, comparing CKD 
with no CKD. For those with CVD and CKD at 
baseline, the RR of ACM compared with no CKD 
was 1.71 (95% CI 1.49 to 1.96), substantially 
lower than that reported in the studies in general 
populations summarised in the section All-cause 
mortality: general CKD population (RR 3.0), 
and possibly reflecting the nature of the ‘general 
population’ studies that included known high risk 
groups. The RR for CVD mortality was 1.8 (95% 
CI 1.45 to 2.24), again lower than the studies of 
general populations. For studies of populations 
with hypertension, Tonelli and colleagues68 
reported an ACM RR of 2.15 (95% CI 1.17 to 2.61) 
and a CVD mortality RR of 2.35 (95% CI 1.52 to 
3.64). See Appendix 6 for detailed results.
Gender, race and age in CKD
The age standardised risk of mortality was 
reported by Evans and colleagues98 to be higher 
in females with CKD (SMR 12.3, 95% CI 10.3 to 
14.5) than in males (SMR 7.2, 95% CI 6.3 to 8.1), 
as compared with the general population. Males 
had higher cumulative mortality and cumulative 
incidence of ESRD after 10 years than females.96 
Drey and colleagues95 found a similar proportion 
of deaths in males (69.34%) as in females (67.76%) 
during 5.5 years of mean follow-up. Meisinger and 
colleagues76 and Irie and colleagues81 reported a 
higher risk of CVD mortality in females than in 
males (see Table 44, Appendix 6), while risk of ACM 
was similar in both genders. The rate of decline 
in GFR was found to be higher in males than in 
females.82,101 See Appendix 6 for detailed results.
Chronic kidney disease seemed to have a greater 
impact on ACM risk (HR 1.83, 95% CI 1.33 
to 2.52) for African-Americans than for white 
people (1.31, 95% CI 1.16 to 1.49) (ACM in 
those with CKD versus no CKD).74 Similarly, risk 
of cardiovascular morbidity increased more in 
African-Americans with CKD (2.09, 95% CI 1.33 to 
2.52) than in white people with CKD (1.01, 95% CI 
0.84 to 1.21).74 Additionally, Hsu and colleagues103 
reported the 5-year incidence rate of ESRD cases 
was higher among African-Americans (5.4%) than 
among white people (1.1%).
The mortality and incidence rate ratios for 
ESRD were significantly higher in younger 
groups (less than 69 years old) than in older 
patients when comparing CKD with no CKD.96 
Hsu and colleagues103 also presented incident 
ESRD rates that were greater among younger 
patients (20–60 years old) than among older ones 
(61–74 years old). The mortality rate ranged 
from 0.4% per year for 18- to 44-year-old patients 
with an eGFR ≥ 60 ml/min/1.73 m2 to 36.0% per 
year for the most elderly patients (85–100 years 
old) with an eGFR ≤ 15 ml/min/1.73 m2.110 The 
RR of mortality increased with decreasing 
eGFR, but the relative impact was less as age 
increased.110 For example, risk of ACM for 
those with an eGFR of 40–49 ml/min/1.73 m2 
decreased from HR 1.90 (95% CI 1.35 to 2.67) 
in 18–44 year olds to HR 1.35 (95% CI 1.32 to 
1.39) in 65–74 year olds. Similarly, for those 
with eGFR of 30–39 ml/min/1.73 m2, the HR 
decreased from 3.58 (95% CI 2.54 to 5.05) in 
18–44 year olds to HR 1.81 (95% CI 1.75 to 
1.87) in 65–74 year olds.110 Imai and colleagues82 
reported that the mean rate of decline of GFR 
from an initial GFR of 30–39 ml/min/1.73 m2 was 
higher (3.28, SD 0.72 ml/min/year) in younger 
males (40–49 years old) than in those in older 
age groups, with mean rate of decline 0.91 
(SD 3.28) in 50–59 year olds, 0.98 (SD 0.18) in 
60–69 year olds and 1.24 (SD 0.25) in 70–79 year 
olds. No difference in progression rate across age 
groups in male participants with a starting GFR 
of 60–69 ml/min/1.73 m2 was observed, although 
the progression rate was much lower (0.31–0.36, 
SD 0.01–0.03 ml/min/year).82 Among female 
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participants, the mean rate of decline of GFR from 
an initial GFR of 60–69 ml/min/1.73 m2 was higher 
for ages 40–49 years (0.45, SD 0.01) ml/min/year 
than for 50–79 year olds (range 0.24–0.29, SD 
0.01–0.02 ml/min/year). See Appendix 6 for 
detailed results.
Discussion
We identified 36 studies describing the natural 
history of CKD.
Studies could be broadly defined into two 
categories based on the types of study participants:
• ‘Screened population’ studies where researchers 
drew participants from the general population 
through some type of health survey process. 
This group included a mix of population 
surveys using robust methods to minimise 
participant selection bias and others relying on 
volunteers responding to calls to participate in 
health screening.
• ‘Clinical population’ studies where studies 
were based on the identification of people 
with evidence of CKD from clinical settings 
including laboratory data, hospital clinics 
and general practice registers. In common, 
these participants had all had a blood test for 
a clinical indication that identified them as 
having CKD. While some may have had blood 
tests as part of a general health check, the 
majority would have had a medical condition 
or symptoms that led to testing.
The significance of these differences in study 
design is that the age and comorbid profiles of 
the two groups differed, with those in clinical 
populations tending to be older and to have a 
greater burden of comorbidity.
While the studies were generally large, with 
adequate follow-up and minimal losses to follow-up, 
there were a number of limitations. The definition 
of CKD was not standard across all studies, and 
less than half were able to define chronicity (i.e. 
had more than one abnormal test result at least 
3 months apart). This means that such studies will 
have overestimated the ‘CKD’ population and this 
may affect the associations observed between CKD 
and outcomes. In addition, the use of different 
definitions for clinical outcomes (and in some 
cases, the lack of clarity about the definition) made 
comparison between studies difficult. In particular, 
cardiovascular morbidity and mortality included a 
number of definitions and this is likely to account 
for at least some of the heterogeneity in results 
observed. Few studies reported their outcomes 
by race. While the studies covered a range of 
geographical areas, the heterogeneity in methods 
makes it difficult to determine if differences in 
outcomes were related to race. Finally, none of 
the studies described in any detail the health care 
available to their study populations. Differences in 
management between study populations may also 
be contributing to the heterogeneity in outcomes 
observed.
All-cause mortality rate was generally high in the 
studies included in this review; 24.3–39.0% at 
5 years and 19.7–52% at 10–12.6 years. ACM rate 
was higher in males than females and increased 
with stage of CKD. Populations defined by having 
an eGFR < 60 ml/min/1.73 m2 were consistently 
found to have a higher mortality than comparator 
groups where there was no evidence of CKD.
In studies comparing risk in those with CKD with 
those without CKD, there was evidence that an 
eGFR <60 ml/min/1.73 m2 was a predictor of ACM 
in some but not all of the studies. Adjustment 
for comorbidities, age and sex reduced the RR. 
We observed that in studies constructed from the 
general population, the risk of ACM associated 
with CKD, after adjustment, was small. Many 
of the cohort studies included people with a 
range of comorbidities and often reported a 
higher risk of ACM. CKD commonly occurs in 
association with comorbidities known to increase 
the risk of cardiovascular mortality (HBP, diabetes 
mellitus, CVD, increased age), and adjustment 
for comorbidities consistently reduced ACM 
risk ratios.76,79 We made a decision to exclude 
data from the control arms of RCTs. While such 
studies do provide a view of the natural history 
of the condition, the strict selection of patients to 
participate in RCTs means that their outcomes are 
very different. For example, Jafar and colleagues43 
reported a meta-analysis of RCTs for ACE Is in 
non-diabetic renal disease. From pooled RCT data, 
they reported a low ACM (1.2% in a mean follow-
up of 2.2 years) and a relatively high progression 
to ESRD (11.6%), reflecting the selection of trial 
participants and the difficulty in generalising such 
findings.
However, in studies constructed from populations 
with high levels of comorbidity (diabetes, 
hypertension, CVD), the risk of ACM associated 
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with CKD, compared with no CKD, was somewhat 
higher. The reverse was observed in the review 
by Tonelli and colleagues,68 but for only the 
unadjusted analysis. This is an oversimplification of 
the true impact of CKD on mortality. Analyses by 
stage demonstrated a substantially increased risk 
associated with increasing stage. Indeed, stage 3b 
carried a markedly increased risk as compared with 
3a.
Some of the variation in ACM between studies may 
have been as a result of methodological issues: 
definition of CKD, duration of follow-up and 
composition of the cohort. However, this does not 
appear to account for all the heterogeneity. For 
example, Eriksen and Ingebretsen96 and Djamali 
and colleagues83 both reported clinical cohorts 
defined based on more than one measure of 
eGFR < 60 ml/min/1.73 m2, one study was from the 
USA82 and one from Norway.96 Despite both studies 
considering people with mild to moderate CKD, 
Djamali and colleagues83 reported a substantially 
lower death rate over the 12.6 years of follow-up 
than that reported by Eriksen and Ingebretsen96 
(19.7% versus 52%).
With the exception of study by Weiner and 
colleagues,74 the risk of CVD morbidity and 
mortality was reported to be greater in those with 
CKD than those with no CKD, and again this risk 
increased as the CKD stage increased, even after 
adjustment for comorbidities. Reported rates of 
CVD morbidity and mortality varied between 
studies, reflecting definitions used for CVD and the 
other methodological issues outlined above.
Attention in the renal community has focused 
on early recognition of CKD with the aim of 
prevention of progression to ESRD. As for ACM, 
there was substantial heterogeneity in the reported 
proportion of patients progressing to ESRD and in 
the definitions used for renal progression. These 
differences related in part to methodological 
issues, but were substantially influenced by the 
study population characteristics and how the 
cohort was constructed. Clinical cohorts had higher 
progression rates even where patients were in 
‘early’ stages of CKD at baseline, reflecting some 
selection bias when compared with the general 
population.
We found that frequency of ESRD as an outcome 
was variable and appeared to relate to patient 
characteristics. In studies of people identified as 
having a low eGFR as a result of population health 
screening, the risk of ESRD was low, even after 
8 years of follow-up. Where patients were recruited 
from clinics into follow-up studies, the risk of ESRD 
was substantially greater, reflecting a selection 
bias that partly represents clinical practice. Those 
with lower eGFR, diabetes and HBP experienced 
a greater risk of progression to ESRD. While few 
studies reported the proportion of patients who 
did not show a change in renal function, where 
it was reported, stable or even improvements in 
eGFR were common place. Where progression in 
eGFR was observed, many participants had not 
progressed to ESRD during the course of follow-up 
(up to 8 years). For an individual with CKD, the 
most common outcome during study follow-up was 
death, not progression to ESRD.32,95,104
CKD stage was associated with an increase in 
mortality and renal progression, with a substantially 
greater risk observed for those in stage 3b than 
those in stage 3a. The rate of renal progression 
also appeared to be variable and influenced by age, 
stage and comorbidities.
The impact of CKD on quality of life was rarely 
reported in the natural history literature. Cross-
sectional analysis of the short form 36-item 
questionnaire results from a large population 
study in Australia116 which has noted significant 
impairment of quality of life for those with an 
eGFR < 60 ml/min/1.73 m2, even after adjustment 
for comorbidities. Mental health was affected the 
most in younger people and physical function in 
the older group.
In this chapter we focused on eGFR as a 
measure of renal function impairment, reflecting 
current clinical practice with the creation 
of CKD registers in primary care based on 
eGFR < 60 ml/min/1.73 m2. Proteinuria and, in 
diabetes, microalbuminuria have been widely 
accepted as independent markers of kidney 
damage. While all people with diabetes are 
screened for microalbuminuria, there is not yet 
a consensus on screening for microalbuminuria 
or proteinuria in adults without diabetes. Recent 
analysis of the Prevention of Renal and Vascular 
Endstage Disease cohort study in the Netherlands 
demonstrated the potential predictive value 
of testing for microalbuminuria in the general 
population. Microalbuminuria was associated with 
an increased risk of needing RRT over 9 years’ 
follow-up (20–100 mg/l, HR 3.0; 100–200 mg/l, 
HR 47).117 However, a large number of people with 
microalbuminuria (and often no other renal risk 
Natural history
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factors) were identified from which only a small 
number required RRT. As with low eGFR, people 
with evidence of microalbuminuria or proteinuria 
were at increased risk of CVD. Intervention with 
ACE Is or statins in groups with microalbuminuria 
or proteinuria and other CVD risk factors has 
shown benefit in reducing progression, but it is 
unknown whether such benefits can be attained for 
those without other CVD risk factors, and at what 
cost.118 Hallan and colleagues32 recently reported 
on the benefits of screening all people with reduced 
eGFR for microalbuminuria or proteinuria. This 
method improved the specificity of detecting 
people with significant kidney function impairment 
(1.4% of the population had both reduced eGFR 
and microalbuminuria or proteinuria as compared 
with 4.9% with reduced eGFR alone) without losing 
detection power for ESRD (identified 65.6% of 
people who developed ESRD versus 69.4% using 
eGFR alone).100
Conclusion
Chronic kidney disease is an important marker 
of increased risk of ACM and ESRD. For many, 
other comorbidities, associated with CKD, 
contribute to this increased risk. However, there 
appears to be a substantial subgroup for whom 
an eGFR < 60 ml/min/1.73 m2 does not mark 
the start of declining kidney function. In the 
UK, there has been a change in approach to 
indentifying CKD in the population, utilising 
GPs to establish clinical registers of all patients 
with an eGFR < 60 ml/min/1.73 m2 from blood 
tests undertaken for a clinical indication. This 
opportunistic screening has identified large 
numbers of people with evidence of kidney 
function impairment that had previously gone 
unrecognised. The outcomes in people with CKD 
identified through such an approach remain 
uncertain, but as described here, there was 
evidence that the risk of renal progression and 
mortality were influenced by the approach adopted 
to identify people with CKD.
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Introduction
Late referral to specialist nephrology care is an 
important problem and numerous potential 
barriers have been identified. Evidence-based 
guidelines have recognised the need for earlier 
referral and, in particular, to allow for preparation 
for transplant or dialysis. In Appendix 7, the 
literature about the impact of ‘very’ late referral 
has been summarised. In these studies, very late 
referral was compared, in most cases, with referral 
that was 1–6 months before the initiation of dialysis 
or RRT. Thus patients included in these studies 
were in an advanced stage of CKD and might all 
now be considered to have been referred late to 
specialists.
In this chapter we consider whether there is 
evidence that early referral for CKD is clinically 
effective.
Definition
A definition for ‘early referral’ was not specified 
in the original commissioning brief. There are 
two elements to ‘early referral’: timing and the 
intervention. ‘Early’ can be defined in three ways:
1. Time in relation to another event such as 
starting RRT.
2. Severity or stage of disease.
3. Duration from the onset of the condition.
While duration from onset might be considered 
to be the gold standard definition, it is almost 
impossible to determine onset in the absence of 
regular population screening for a condition. For 
the purposes of our review, we accepted definitions 
of early based on time from dialysis (> 12 months) 
or severity (stage 3–4 disease).
‘Referral’ was defined as an appointment with a 
specialist in nephrology care (medical, nursing or 
other allied health-care professional).
Results
Study characteristics
The number of published papers identified at 
each stage of the systematic review is shown in 
Figure 6. There were 3306 articles identified by 
searches. The full text of 63 articles were retrieved 
for scrutiny against the inclusion and exclusion 
criteria. A total of 56 full text articles were 
excluded. Excluded studies, together with the 
reason for exclusion are listed in Appendix 3.
No systematic reviews were identified in the search. 
Seven studies56,111,119–123 met the inclusion and 
exclusion criteria, and were included in the review; 
their characteristics are summarised in Table 10. 
We did not find any randomised or controlled 
trials. All seven included studies were cohort 
designs. The key feature of these cohorts was how 
they were constructed in relation to the timing 
of the ‘intervention’ of interest to us – predialysis 
care. Five of the cohorts recruited people who 
were starting on dialysis for the first time and 
reviewed their records to define the timing of their 
first referral to nephrology care.56,119,121–123 These 
cohorts, therefore, included only those people 
surviving and progressing to require dialysis and 
did not include people with CKD who died before 
reaching dialysis or who did not have a progressive 
deterioration in their renal function within the 
study period. We have called these ‘retrospective 
cohorts’ in terms of the timing of the cohort 
construction in relation to specialist referral. The 
remaining two cohorts identified people with 
CKD and followed them prospectively, comparing 
those who were referred to specialist care and 
those who were cared for only by a primary care 
physician.111,120 We have called these ‘prospective 
cohorts’.
Three studies originated in the USA,111,122,123 two in 
France,119,121 one in Mexico120 and one in the UK.56 
A total of 114,073 people were reported in the 
included studies, but study size varied considerably, 
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Articles identified by searches
n = 3306
Articles for which abstract was
screened
n = 946
Articles for which full text was
obtained
n = 63
Articles excluded on the
basis of title and abstract
n = 883
Articles excluded on the
basis of title
n = 2360
Excluded articles
n = 56
Seven studies retained for data
extraction and inclusion for
clinical effectiveness
FIGURE 6 Flowchart of identification of studies for inclusion in the systematic review of clinical effectiveness.
ranging from 117 to 109,321 people. One 
thousand six hundred and seventy participants had 
pre-ESRD at the time of inclusion in the cohort 
(i.e. participated in a ‘prospective cohort’ study).
One study was restricted to patients with diabetes 
mellitus and renal impairment.120 The other 
six studies did not restrict their cohorts by the 
underlying cause of renal impairment; nonetheless, 
diabetes mellitus was commonly reported among 
participants, ranging from 13.2% to 52.4%. Males 
exceeded females in all of the studies, ranging from 
51% to 100%.
Few of the studies reported information about 
the stage of CKD at key time points, i.e. first 
diagnosis or first referral to a specialist. Kessler 
and colleagues119 noted the time since first 
creatinine level > 177 µmol/l (2 mg/dl). Martínez-
Ramírez and colleagues120 diagnosed renal 
impairment based on micro- (30–300 mg/dl) and 
macroalbuminuria (> 300 mg/dl). They reported 
that 40% had CKD stage 1, 35% stage 2 and 25% 
stage 3 at the start of their study period with a 
mean eGFR of 78.6–83.8 ml/min/1.73 m2. Orlando 
and colleagues111 defined CKD as a creatinine 
level ≥ 1.4 mg/dl and noted at baseline that 89% of 
study participants had evidence of proteinuria.
Quality of included studies
Each included study was quality assessed and the 
results are summarised in Table 11. While all the 
retrospective studies suffered from differences 
in the groups at baseline, attempts were made to 
adjust for these differences in the analysis. There 
were five main problems with the included studies 
in determining effectiveness of early referral:
• None of the studies randomly allocated 
participants to the intervention groups. While 
attempts were made to adjust for differences 
in the analysis, unknown confounders could 
not be addressed. In particular, complex 
confounders such as confounding by indication 
could not be accounted for.
• There were significant differences in the 
baseline characteristics of the comparison 
groups in all studies, with the exception of 
the study reported by Martínez-Ramírez and 
colleagues.120
• None of the studies adequately described 
the ‘intervention’ in terms of the type of care 
delivered to enable comparisons between 
studies.
• Only two studies defined their cohorts 
prospectively in relation to the 
intervention.111,120 Studies designed around 
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cohorts of people starting dialysis miss all the 
people with CKD who have not yet progressed 
to end-stage disease or who die before they 
reach that point.
• Only the two prospective studies reported the 
criteria they used to define CKD.111,120 None of 
the studies defined the criteria for triggering 
referral to a specialist.
Does early referral improve 
outcomes?
Renal function: progression and onset of 
RRT
Five studies reported creatinine clearance or 
eGFR at the start of RRT but did not report 
renal function at the time of referral, at first 
diagnosis or during follow-up.56,119,121–123 Only two 
studies reported renal function over time as an 
outcome.111,120
Renal function at the onset of RRT was not 
substantially or consistently altered by referral 
to the specialist team at least 12 months prior to 
requiring RRT.56,119,121–123
Orlando and colleagues111 retrospectively 
compared those receiving care by primary care 
physicians alone with those receiving specialist 
nephrology input to assess progression (defined 
by change of stage or death). More progressed to 
a more advanced stage of CKD in the nephrology 
referral group at each stage of disease than the 
primary care only group, but fewer died. There 
was little difference in time spent in follow-up 
between groups in stages 1 and 2. For stage 3, 
316 more days were spent in follow-up in the 
nephrology group than the primary care only 
group. The difference in deaths was particularly 
marked for those with stage 3 or worse CKD. Cox 
HRs for the risk of progression, adjusting for 
age, race, medication use, comorbidities and risk 
factors showed no statistically significant difference 
between nephrology referral and primary care 
only for those with stage 1 or 2 disease. For those 
with stage 3 or worse, nephrology care reduced 
progression or death (after adjustment) with an 
HR of 0.8 (95% CI 0.61 to 0.90) for stage 3 disease 
and 0.75 (95% CI 0.45 to 0.89) for stage 4. Of the 
1553 participants, 26 progressed to ESRD during 
the 5-year follow-up with six (0.4%) in the primary 
care only group and 20 (1.29%) in the specialist 
care group. The higher progression in the referred 
group reflects, at least in part, that fewer people 
died during stages 3–5 and thus survived to require 
dialysis.111
Martínez-Ramírez and colleagues120 reported 
that during the 1-year prospective follow-up of 
diabetic patients with evidence of early or overt 
nephropathy, only one patient deteriorated 
to requiring RRT (in the unreferred group). 
Among the group where no referral to a 
specialist service was available, mean (SD) eGFR 
deteriorated from 78.6 (28.1) ml/min/1.73 m2 to 
66.6 (29.9) ml/min/1.73 m2, a statistically significant 
fall of 12.0 ml/min/1.73 m2 (p < 0.05). In the 
cohort referred early to specialist nephrology care, 
mean (SD) eGFR was 83.8 (26.1) ml/min/1.73 m2 
at baseline and was not statistically significantly 
altered after 12 months [80.4 (35.5) ml/min/1.73 m2]. 
A similar pattern was observed regardless of 
whether the patient had early or overt diabetic 
nephropathy (defined by the presence of 
microalbuminuria with eGFR > 60 ml/min/1.73 m2 
versus proteinuria or eGFR < 60 ml/min/1.73 m2).120
Table 12 summarises the data from these studies.
Mortality
All seven studies reported mortality as an 
outcome.56,111,119–123 Roderick and colleagues,56 
however, did not report it by the referral groups of 
interest here. Martínez-Ramírez and colleagues120 
reported three deaths during the 1-year follow-up, 
all in the group who were not referred to specialist 
care, and all cardiovascular deaths. Orlando and 
colleagues111 reported higher numbers of deaths 
among those cared for in primary care than among 
those referred to a specialist. This pattern held at 
all stages of CKD.
In all of the retrospective studies, starting their 
cohorts from the initiation of dialysis, better 
dialysis survival was associated with early referral. 
This improvement was observed from 90 days119 
to 5 years121 after initiation of dialysis. Jungers 
and colleagues121 reported survival was highest in 
the group referred more than 72 months prior 
to dialysis. The difference in survival could be 
observed from 3 months after starting dialysis 
and was marked by 5 years (77.3% in those 
referred > 72 months prior to dialysis versus 
57.8% in those referred less than 6 months prior 
to dialysis; p < 0.001). CVD accounted for more 
than 50% of the deaths. The earlier referral groups 
(> 36 months and > 72 months) experienced fewer 
CVD deaths than those referred later. Adjusting 
for age, sex and comorbidities (diabetes mellitus, 
HBP, CVD), the RR of death for those with referral 
> 72 months prior to dialysis, as compared with 
< 6 months, was 0.24 (95% CI 0.10 to 0.59) at 
1 year and 0.53 (95% CI 0.35 to 0.79) at 5 years. 
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TABLE 12 Summary of effect of early referral on renal progression
Study Referral pattern Change in kidney function
Martínez-
Ramírez 
2006120
GFR 
baseline 
[mean 
(SD) ml/
min/1.73 m2]
GFR final 
[mean 
(SD)]
Change 
from 
baseline 
(p-value)
Difference at final (p-
value)
Referral to specialist (SR) 83.8 (26.1) 80.4 (35.5) –3.4 (NS) 13.8 (p < 0.05)
No specialist referral (no SR) 78.6 (28.1) 66.6 (29.9) –12.0 
(p < 0.05)
SR (early nephropathy) 95.6 (20.9) 98.8 (36.4) 3.2 (NS) 13.1 (NS)
No SR (early nephropathy) 99.0 (21.6) 85.7 (27.3) –13.3 
(p < 0.05)
SR (overt nephropathy) 71.1 (25.4) 61.3 (22.2) –9.8 
(p < 0.05)
10.5 (NS)
No SR (overt nephropathy) 61.7 (24.6) 50.8 (21.3) –10.9 
(p < 0.05)
Orlando 
2007111
Number transitioning through each stage and outcomes
Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
Pre-
ACKD to 
ACKD
PCP-only 995 624 209 28 6 1090
CKD progression 445 (45%) 156 (25%) 14 (7%) 4 (14%) 1 (17%) 27 (2%)
Died 231 (23%) 217 (35%) 131 (63%) 20 (71%) 2 (33%) 509 (47%)
Composite end 
pointa
676 (68%) 376 (60%) 145 (69%) 24 (86%) 3 (50%) 536 (49%)
Median days spent 
in stage
1168 1247 895 558 655 1936
Nephrology 
group
222 263 207 58 20 440
CKD progression 138 (62%) 120 (46%) 56 (27%) 17 (29%) 5 (25%) 67 (15%)
Died 24 (11%) 53 (20%) 74 (36%) 25 (43%) 5 (25%) 147 (33%)
Composite end 
pointa
162 (73%) 173 (66%) 130 (63%) 42 (72%) 10 (50%) 214 (49%)
Median days spent 
in stage
1127 1100 1211 834 776 1991
aPCP-only vs 
nephrology 
p-value
0.41 0.32 < 0.001 0.03 NA < 0.001
bAdjusted HR 
(95% CI)
1.08 (0.91 
to 1.29)
1.20 (0.99 to 
1.45)
0.80 (0.61 
to 0.90)
0.75 (0.45 
to 0.89)
NA 0.91 (0.76 
to 0.99)
ACE I, angiotensin converting enzyme inhibitor; ACKD, advanced chronic kidney disease (stage 4 or 5); CI, confidence 
interval; GFR, glomerular filtration rate; HR, hazard ratio; NA, not applicable; NS, not significant; PCP, primary care 
physicians; SD, standard deviation; SR, specialist referral.
a Death or CKD progression.
b Adjusted for age, race, ACE I use, statin use, comorbidities, smoking and proteinuria.
Kessler and colleagues119 reported an association 
between timing of referral and survival in the first 
90 days after initiating dialysis, with an almost 
threefold increase in risk (HR 2.7, 95% CI 1.2 to 
6.3) once referral was less than 12 months prior 
to dialysis, and as great as five times higher (HR 
5.2, 95% CI 2.2 to 12.3) if referral was less than 
1 month prior to dialysis after adjustment for age, 
sex and systolic BP. For survival over 3 months, 
the only independently associated factor relating 
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to referral timing was for those referred between 
1 and 4 months prior to dialysis, where a HR of 
2.2 (95% CI 1.4 to 3.5) was observed compared 
with referral < 1 month. Khan and colleagues121 
reported lower 1-year mortality on dialysis in 
those referred during the 24 months prior to 
dialysis (25–35%) as compared with those with 
no pre-dialysis referrals (51%) [HR 1.5 (95% CI 
1.44 to 1.55) after adjustment for age, sex, race, 
erythropoietin injections, non-nephrology care 
and comorbidities]. There was evidence of a ‘dose-
response’ gradient, with those receiving the most 
nephrology visits having the lowest mortality. 
Kinchen and colleagues123 reported lower mortality 
on dialysis in those referred more than 12 months, 
as compared to those referred less than 4 months, 
prior to dialysis. The differential in survival was 
observed to at least 3 years. An HR of 1.6 (95% 
CI 1.11 to 2.24) for later referral, as compared to 
referral > 12 months prior to dialysis, was observed 
after adjustment for type of dialysis, demographic 
characteristics, socioeconomic status, years of 
smoking, exercise status and Index of Coexistent 
Disease score. Table 13 provides a more detailed 
summary of the mortality data reported.
Hospitalisations
Three studies reported hospitalisations as an 
outcome.56,111,121
Orlando and colleagues111 compared 
hospitalisations in the group referred to 
nephrology specialists with those with renal disease 
managed only in primary care. The number of 
hospitalisation days differed little between the 
two groups (mean 2.8 versus 2.5 days respectively; 
p = 0.03).
One study reported on the impact of early 
referral on hospitalisation in the first 6 months 
after dialysis was initiated.56 Roderick and 
colleagues56 observed that those in the group with 
referral < 1 month prior to dialysis had more 
hospitalisation episodes within the first 6 months of 
dialysis than all others (1–4 months, 4–12 months 
and > 12 months) (mean 2.6 versus 1.7, p = 0.001). 
The median length of stay was shorter in those 
referred more than 1 month prior to dialysis 
(10 versus 18 days in the < 1-month group). 
Lengthening referral time to greater than 1 month 
prior to dialysis did not have any substantial effect 
on this outcome.
Jungers and colleagues121 reported the impact of 
referral on the duration of initial hospitalisation 
at the time of starting dialysis. They found a 
statistically significantly lower duration of initial 
hospitalisation in those referred at least 6 months 
prior to dialysis [mean 23.8 (SD 17.1) days] versus 
those referred 6 to 35 months prior to dialysis 
[mean of 7.5 (SD 8.9) days; p < 0.001] and some 
evidence of a dose response with improvements out 
to referral > 72 months prior to dialysis.
Emergency dialysis
Kessler and colleagues119 reported statistically 
significantly higher emergency dialysis among 
those referred late than those referred more than 
12 months prior to dialysis (83.3% versus 29.1%; 
p < 0.001).
Quality of life
None of the included studies reported quality of 
life as an outcome.
Barriers to early referral
None of these studies reported barriers as an 
outcome. In discussion, Khan and colleagues122 
noted the challenge of identifying patients 
with CKD early enough so that early referral 
intervention could be undertaken. Kinchen and 
colleagues123 noted that the reasons for late referral 
were numerous and included a lack of symptoms, 
non-compliance, lack of access to care, and primary 
care physicians’ attitudes and knowledge. Orlando 
and colleagues111 acknowledges that specialist 
nephrology referral for all patients with CKD, even 
if restricted to all with stage 3 disease or worse, 
was beyond the capacity of existing nephrology 
services.
What elements of early 
referral design and delivery are 
important?
Because of the nature of the studies identified 
(largely retrospective with regards to the 
‘intervention’ of early referral), the characteristics 
of the intervention were poorly reported. In the 
study by Martínez-Ramírez and colleagues,120 the 
referred cohort received a total of three visits in 
12 months to see a single nephrologist along with 
standard care of monthly visits to a primary care 
physician who was instructed not to modify the 
prescriptions of the nephrologist.
A number of studies did, however, describe aspects 
of management and how they differed between 
early referral to a specialist as compared with 
remaining in generalist care.
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TABLE 13 Summary of effect of early referral on all-cause mortality
All-cause mortality
Predialysis nephrological care duration (months)
Jungers 
2001121
< 6 6–35 36–71 ≥ 72
n 86 67 40 54
3 months’ mortality 
(SD)
7.3% ± 1.7a 4.2% ± 1.2 1.8% ± 0.9 0.7% ± 0.6
1-year mortality (SD) 13.6% ± 2.2b 7.4% ± 1.6 7.2% ± 1.8 2.5% ± 0.9
5 years’ mortality 
(SD)
42.2% ± 4.2c 34.7% ± 3.9 22.9% ± 3.7 22.8% ± 3.6
Cardiovascular mortality
< 6 6–35 36–71 ≥ 72
At 5 years n (%) 53 (62%) 41 (61%) 21 (52%) 29 (52%)
Duration of specialist care pre-dialysis (months)
Kinchen 
2002123
< 4 months 4–12 months > 12 months
n 245 184 399
1-year mortality 13.3% 9.5% 4.3%
2 years’ mortality 27.6% 22.4% 14.6%
3 years’ mortality 37.0% 32.7% 26.3%
Martínez-
Ramírez 
2006120
Primary care Nephrology 
care
n 65 52
1-year mortality 3 (5%) 0
Khan 
2005122
Frequency of specialist care pre-dialysis
0 MNC in 24 
months before 
dialysis
0 MNC in 6 
months before 
dialysis
1–2 MNC in 6 
months before 
dialysis
≥ 3 MNC in 6 
months before 
dialysis
n 55,087 5820 24,943 23,471
1-year mortality 51% 35% 33% 25%
Orlando 
2007111
Primary care Nephrology care
Proportion
Median days 
spent in each 
stage Proportion
Median days 
spent in each 
stage 
Stage 1 231 (23%) 1168 24 (11%) 1127
Stage 2 217 (35%) 1247 53 (20%) 1100
Stage 3 131 (63%) 895 74 (36%) 1211
Stage 4 20 (71%) 558 25 (43%) 834
Stage 5 2 (33%) 655 5 (25%) 776
Jungers 
2001121
RR for death 
for PDNC ≥ 72 
months
RRd 95% CI
At 3 months 0.13 0.03 to 0.58 Adjusted for age, diabetes, 
hypertension, cardiovascular diseases 
and nephropathy. 
At 1 year 0.24 0.10 to 0.59
At 2 years 0.44 0.25 to 0.81
At 3 years 0.45 0.28 to 0.74
At 5 years 0.53 0.35 to 0.79
CI, confidence interval; MNC, months of nephrological care; PDNC, predialysis nephrology care; RR, relative risk; SD, 
standard deviation
a < 6 months vs 36–71 months: p < 0.01; vs ≥ 72 months: p < 0.001.
b < 6 months vs 36–71 months or ≥ 72 months: p < 0.001.
c < 6 months vs 36–71 months: p < 0.01; vs ≥ 72 months: p < 0.001.
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Blood pressure control
In the two prospective studies of early referral for 
CKD, improvements in BP control were observed. 
Martínez-Ramírez and colleagues120 reported 
statistically significant improvements in systolic 
BP in the referred cohort [140 (SD 30) mmHg to 
130 (SD 21) mmHg] while BP control deteriorated 
in the unreferred group [140 (SD 19) mmHg 
to 145 (SD 23) mmHg] (p < 0.05). Orlando and 
colleagues111 reported that a higher proportion of 
patients in the nephrology care group had good BP 
control (41% versus 36%; p = 0.06).
At the initiation of dialysis, Jungers and 
colleagues121 reported BP was lower in all the 
group referred more than 6 months prior to 
dialysis and lowest in the group referred more than 
72 months prior to dialysis [systolic BP mean 171 
(SD 23) mmHg in the < 6-month group versus 
148 (SD 17) mmHg in the 6- to 35-month group 
and 141 (SD 12) mmHg in the ≥ 72 months group; 
p < 0.001]. However, Kessler and colleagues119 
and Kinchen and colleagues123 did not observe 
statistically significant differences in BP control 
at the start of dialysis. Khan and colleagues122 
and Roderick and colleagues56 did not report BP 
control.
Other clinical markers
Four studies56,111,121,123 reported serum albumin 
was statistically significantly higher if referred 
early, but none presented information about 
the underlying diagnoses. Those with nephrotic 
syndrome may have presented earlier, but have 
relatively preserved renal function despite their 
apparently poor clinical markers, e.g. low albumin 
as a result of heavy proteinuria. Kinchen and 
colleagues123 described statistically significant 
differences in serum albumin < 36 g/l at the time 
of initiation of dialysis (60.5% versus 77.9%; 
p < 0.001), when comparing early and late referral. 
Orlando and colleagues111 reported albumin 
levels < 40 g/l in 59% versus 49% (p < 0.001) (early 
versus late respectively). Roderick and colleagues56 
noted albumin was lower in those referred less 
than 1 month prior to dialysis [mean 32 g/l (SD 
0.83)] than for those with referral > 12 months 
[mean 37 g/l (SD 0.56)] (p < 0.001). Khan and 
colleagues122 found no statistically significant 
difference in albumin. Kinchen and colleagues123 
also described statistically significant differences in 
haematocrit < 0.3% (56% versus 68.1%; p < 0.001). 
Khan and colleagues,122 Roderick and colleagues56 
and Orlando and colleagues111 did not observe 
substantial differences in haematocrit between early 
and late referral groups.
Treatments
Martínez-Ramírez and colleagues120 reported 
statistically significant improvements in systolic 
BP in the referred cohort. In terms of treatments, 
the use of ACE Is increased more in the referred 
group and there was substantially higher use of 
ARBs and statins. Non-steroidal anti-inflammatory 
drug use fell in the referred group, but increased 
in the unreferred group (Table 14). Orlando and 
colleagues,111 however, reported no statistically 
significant differences between the groups for lipid 
lowering agent or ACE I use.
Roderick and colleagues56 reported that vitamin 
D supplementation (late 20% versus early 40%), 
TABLE 14 Comparison of treatments in the referred and unreferred groups120
Comparisons of baseline and final treatments between cohorts, number (%)
Treatment
Referred Unreferred
Baseline Final Change Baseline Final Change
ACE I 25 (48) 44 (90)a,b 19 (42) 35 (53) 37 (70)b 2 (17)
ARBs 1 (2) 22 (45)a,b 21 (43) 0 (0) 2 (4) 2 (4)
Statins 2 (4) 21 (43)a,b 19 (39) 10 (16) 5 (9) –5 (–7)
Aspirin 11 (21) 12 (24) 1 (3) 8 (15) 4 (7) –4 (–8)
Other NSAID 6 (11) 0 (0)a,b –6 (–11) 3 (5) 17 (32)b 14 (27)
ACE I, angiotensin converting enzyme inhibitor; ARBs, angiotensin receptor blockers; NSAID, non-steroidal anti-
inflammatory drugs.
a p < 0.05 vs control cohort in the same evaluation.
b p < 0.05 vs baseline of the same cohort.
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phosphate binders (late 29% versus early 44%), 
sodium bicarbonate (late 10% versus early 28%), 
lipid lowering agents (late 6% versus early 11%) 
and erythropoietin (late 5% versus early 23%) were 
all prescribed more frequently in those referred 
more than 12 months before starting dialysis.
Kinchen and colleagues123 described statistically 
significant differences in the following factors 
when comparing early and late referral: exercise 
one or more times per week (26.3% versus 14.9% 
respectively; p < 0.001); and erythropoietin 
treatment (25.3% versus 12.7%; p < 0.001).
Which patient groups benefit 
the most from referral and at 
what stage of disease?
Kinchen and colleagues122 reported that late 
referral was associated with a greater hazard of 
death on dialysis in diabetic subgroups (HR 2.4, 
95% CI 1.28 to 4.47); in black ethnic subgroups 
(HR 6.9, 95% CI 1.07 to 44.71); and if the cause of 
the ESRD is attributed to diabetes or hypertension 
(HR 2.0, 95% CI 1.14 to 3.46) (Table 15). Martínez-
Ramírez and colleagues120 noted a more marked 
effect of nephrology referral on those with 
early diabetic nephropathy (microalbuminuria) 
compared with those with overt proteinuria (Table 
15).
Orlando and colleagues111 observed that the impact 
of nephrology care on the composite end point of 
renal progression and death was only observed for 
stages 3–5. In stages 1–2 there was no statistically 
significant difference between nephrology care and 
primary care alone and, if anything, survival/renal 
progression were better in the primary care alone 
group.
Discussion
In comparison to the considerable literature base 
about the effect of late referral (see Appendix 7), 
we identified only seven studies that considered the 
impact of early referral on outcomes in people with 
evidence of renal impairment.56,111,119–123 This was 
despite adopting a wide definition of ‘early’ and 
‘referral’.
Five of the studies were retrospective, based on 
cohorts established at the time of starting RRT 
and then looking back to identify the timing and 
format of care in the months and years prior to 
RRT.56,119,121–123 Two studies compared management 
solely by primary care physicians to referral to 
specialist nephrology services for patients with 
evidence of CKD.111,120
No clinical trials were identified. No studies 
randomised patients to specialist care versus 
primary care or current practice. Few studies 
reported the stage of CKD, or other markers 
of renal impairment, at the time of referral to 
specialist services.
As a result it is difficult to draw conclusions about 
the clinical effectiveness of early referral strategies 
or indeed, what aspects of the strategies are driving 
the effect on outcomes.
Referral strategies
The limitations of the studies are discussed below, 
but one of the major difficulties was reporting 
of what the referral strategy encompassed. The 
limited details have been summarised in Table 16. 
Most studies based referral on ‘clinical indication’ 
that was not further specified. One screened all 
patients with diabetes mellitus as a high-risk 
group for renal disease. Management appeared 
to focus on pharmacotherapy for management 
of complications of CKD or for modification of 
cardiovascular risk and renal progression. None of 
the studies considered whether cardiovascular risk 
reduction could be delivered through optimisation 
of the management of the other comorbidities. 
eGFR, proteinuria, albuminuria and serum 
creatinine were all described as screening tests.
Evidence of clinical effectiveness of early 
referral
Despite the difficulties around the definition 
of CKD and referral, we sought to report what 
evidence was available about the effect of early 
referral on clinical outcomes.
Progression
One of the key aims of referral to specialist 
nephrology services is to initiate interventions 
to stop or slow progression towards ESRD. Many 
studies have demonstrated the effectiveness of ACE 
Is and ARBs in reducing the progressive decline in 
eGFR in trials.42–46 BP control is also important.42 
The comparison of nephrology referral for all 
those with diabetic nephropathy versus those 
with no access to nephrologists in Mexico120 
demonstrated better preservation in function in 
those referred to a specialist. The comparator 
group, with no access to specialist services, 
experienced a mean decline in renal function of 
DOI: 10.3310/hta14210 Health Technology Assessment 2010; Vol. 14: No. 21
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
51TA
B
LE
 1
5 
Su
m
m
ar
y 
of
 im
pa
ct
 o
f e
ar
ly
 r
ef
er
ra
l f
or
 s
ub
gr
ou
ps
: r
en
al
 p
ro
gr
es
si
on
 a
nd
 m
or
ta
lit
y
M
ar
tí
n
ez
-
R
am
ír
ez
 2
0
0
61
2
0
P
ro
gr
es
si
o
n
G
F
R
 b
as
el
in
e 
 
[m
ea
n
 (
S
D
)]
G
F
R
 fi
n
al
  
[m
ea
n
 (
S
D
)]
C
h
an
ge
 f
ro
m
 b
as
el
in
e 
(p
-v
al
u
e)
D
if
fe
re
n
ce
 b
et
w
ee
n
 
gr
o
u
p
s 
(p
-v
al
u
e)
R
ef
er
ra
l t
o 
sp
ec
ia
lis
t
83
.8
 (
26
.1
)
80
.4
 (
35
.5
)
–3
.4
 (
N
S)
13
.8
 (
p 
<
 0
.0
5)
N
o 
re
fe
rr
al
 t
o 
sp
ec
ia
lis
t
78
.6
 (
28
.1
)
66
.6
 (
29
.9
)
–1
2.
0 
(p
 <
 0
.0
5)
ER
 (
ea
rl
y 
di
ab
et
ic
 n
ep
hr
o
pa
th
y)
95
.6
 (
20
.9
)
98
.8
 (
36
.4
)
3.
2 
(N
S)
13
.1
 (
N
S)
LR
 (
ea
rl
y 
di
ab
et
ic
 n
ep
hr
o
pa
th
y)
99
.0
 (
21
.6
)
85
.7
 (
27
.3
)
–1
3.
3 
(p
 <
 0
.0
5)
ER
 (
ov
er
t 
di
ab
et
ic
 n
ep
hr
o
pa
th
y)
71
.1
 (
25
.4
)
61
.3
 (
22
.2
)
–9
.8
 (
p 
<
 0
.0
5)
10
.5
 (
N
S)
LR
 (
ov
er
t 
di
ab
et
ic
 n
ep
hr
o
pa
th
y)
61
.7
 (
24
.6
)
50
.8
 (
21
.3
)
–1
0.
9 
(p
 <
 0
.0
5)
K
in
ch
en
 2
0
02
12
3
M
o
rt
al
it
y 
[H
R
 (
95
%
 C
I)
] 
fo
r 
d
if
fe
re
n
t 
d
u
ra
ti
o
n
s 
o
f 
sp
ec
ia
li
st
 c
ar
e 
p
re
-d
ia
ly
si
s
>
 1
2 
m
o
n
th
s
4
–1
2 
m
o
n
th
s
<
 4
 m
o
n
th
s
A
ll 
pa
ti
en
ts
1.
0 
(r
ef
er
en
ce
 
gr
ou
p)
 
1.
4 
(0
.9
2 
to
 1
.9
9)
1.
6 
(1
.1
1 
to
 2
.2
4)
A
dj
us
te
d 
fo
r 
ty
pe
 o
f d
ia
ly
si
s,
 
de
m
og
ra
ph
ic
 c
ha
ra
ct
er
is
ti
cs
, 
so
ci
oe
co
no
m
ic
 s
ta
tu
s,
 y
ea
rs
 
of
 s
m
ok
in
g,
 e
xe
rc
is
e 
st
at
us
 
an
d 
In
de
x 
of
 C
oe
xi
st
en
t 
D
is
ea
se
 s
co
re
. S
en
si
ti
vi
ty
 
an
al
ys
es
: r
ed
efi
ni
ti
on
 o
f l
at
e 
re
fe
rr
al
, t
im
e 
of
 e
va
lu
at
io
n 
m
is
si
ng
D
M
 –
 y
es
1.
0
1.
6 
(0
.8
4 
to
 2
.9
4)
2.
4 
(1
.2
8 
to
 4
.4
7)
D
M
 –
 n
o
1.
0
0.
6 
(0
.2
3 
to
 1
.6
1)
0.
9 
(0
.4
2 
to
 1
.9
7)
Et
hn
ic
it
y 
– 
w
hi
te
1.
0
1.
0 
(0
.6
0 
to
 1
.7
3)
1.
5 
(0
.9
2 
to
 2
.3
7)
Et
hn
ic
it
y 
– 
bl
ac
k
1.
0
1.
8 
(0
.2
6 
to
 1
2.
30
)
6.
9 
(1
.0
7 
to
 4
4.
71
)
A
tt
ri
bu
te
d 
ca
us
e 
of
 E
SR
D
 –
 h
yp
er
te
ns
io
n 
or
 D
M
1.
0
1.
1 
(0
.5
9 
to
 1
.9
3)
1.
99
 (1
.1
4 
to
 3
.4
6)
A
tt
ri
bu
te
d 
ca
us
e 
of
 E
SR
D
 –
 g
lo
m
er
ul
on
ep
hr
it
is
 
or
 o
th
er
1.
0
1.
0 
(0
.3
5 
to
 2
.6
3)
0.
6 
(0
.2
2 
to
 1
.5
1)
A
ge
 <
 6
5 
ye
ar
s
1.
0
1.
4 
(0
.6
8 
to
 2
.9
1)
1.
5 
(0
.8
2 
to
 2
.8
7)
A
ge
 ≥
 6
5 
ye
ar
s
1.
0
1.
0 
(0
.4
6 
to
 1
.9
9)
1.
7 
(0
.8
6 
to
 3
.2
2)
C
I, 
co
nfi
de
nc
e 
in
te
rv
al
; D
M
, d
ia
be
te
s 
m
el
lit
us
; E
R
, e
ar
ly
 r
ef
er
ra
l; 
ES
R
D
, e
nd
-s
ta
ge
 r
en
al
 d
is
ea
se
; H
R
, h
az
ar
d 
ra
ti
o;
 L
R
, l
at
e 
re
fe
rr
al
; N
S,
 n
ot
 s
ig
ni
fic
an
t;
 S
D
, s
ta
nd
ar
d 
de
vi
at
io
n.
Clinical effectiveness
52
TABLE 16 Summary of the characteristics of the early referral strategies: population selection, testing methods, sampling and management
Population selection
Screening High risk groups Opportunistic Clinical indication
Testing
Albuminuria Martínez-Ramírez 2006120 Martínez-Ramírez 2006120
Creatinine Orlando 2007111
eGFR
Not described Jungers 2001;121 Kessler 
2003;119 Khan 2005;122 Kinchen 
2002;123 Roderick 200256
eGFR, estimated glomerular filtration rate.
Testing
Albuminuria Creatinine eGFR Not described
Sampling
Single sample
Two samples,  
3 months apart
Orlando 2007111
Repeat sampling 
and exclusion of 
reversible causes
Martínez-Ramírez 2006120
Not described Jungers 2001;121 Kessler 2003;119 
Khan 2005;122 Kinchen 2002;123 
Roderick 200256
Cut-off level to 
define referral
Martínez-Ramírez 2006120
Albumin > 30 mg/dl
Orlando 2007111
Creatinine > 140 mg/dl
Not described Jungers 2001;121 Kessler 2003;119 
Khan 2005;122 Kinchen 2002;123 
Roderick 200256
eGFR, estimated glomerular filtration rate.
Management
Management of 
reversible causes 
of impaired renal 
function
Medicine interventions
Lifestyle 
modification
Preparation 
for RRT Not described
Management 
of 
complications 
of CKD
Cardio-
protection
Population selection
Screening Martínez-
Ramírez 2006120
Martínez-
Ramírez 
2006120
High risk groups Martínez-
Ramírez 2006120
Martínez-
Ramírez 
2006120
Orlando 2007111
Opportunistic
Clinical indication Roderick 200256 Roderick 
200256
Roderick 
200256
Jungers 2001;121 
Kessler 2003;119 
Khan 2005;122 
Kinchen 2002123
CKD, chronic kidney disease; RRT, renal replacement therapy.
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12 ml/min/1.73 m2, which is approximately three 
times higher than we found described in the 
natural history review.88 This pattern was observed 
regardless of degree of baseline microalbuminuria. 
There was a high proportion of stage 1 and 2 CKD 
patients in this study and, as described by Djamali 
and colleagues,83 the absolute rate of decline may 
be at its fastest during these stages. Orlando and 
colleagues111 reported a higher risk (RR 1.32, 95% 
CI 1.13 to 1.55) of progression in stage 1–2, but not 
stage 3–5 for people with diabetes than those with 
no diabetes. The high rate of decline in function 
in the primary care only group may, therefore, be 
generalisable to a wider clinical setting.
Similarly, Orlando and colleagues111 reported 
better outcomes for a composite end point of death 
or progression in those referred to specialists with 
stage 3 disease or worse. However, looking at renal 
progression alone, the crude data suggest more 
people in specialist care experienced progression. 
This may be as a result of differences in case-
mix, survival and referral bias (where the sick 
or low risks are not referred by GPs) rather than 
due to differences in care. Predialysis survival 
was noted to be better in the group referred to 
specialists.111 This finding may reflect a selection 
bias where people considered to have other serious 
comorbidities were less likely to be referred. 
However, a composite end point of death and renal 
progression was found to be significantly reduced 
by referral to a specialist for people with stage 3–5 
CKD, even after adjustment for comorbidities and 
age.
Mortality
If patients progress to ESRD and survive to dialysis 
then there was evidence that post-dialysis survival 
was improved by early referral, even for referral 
more than 72 months prior to dialysis. Improved 
survival was sustained beyond that relating to 
initial establishment on RRT. This suggests that 
the survival advantage was not simply explained by 
technical preparation for dialysis and nutritional 
status. The differential effect of early referral to a 
specialist (> 72 months) on survival post dialysis 
lasted for at least 5 years.
The clinical difference at initiation of dialysis may 
reflect differences in care that are markers for 
overall care, or may in part reflect an improvement 
in clinical status of the patient at the time he 
or she starts dialysis that is causally linked to 
survival. Some hypothesise that they are markers 
for improved cardiovascular risk modification 
that then manifest in improved survival long after 
the early dialysis phase.121 However, in the types 
of studies presented, the differences in clinical 
markers may also reflect selection bias, where 
clinical staffs are selecting the healthiest and fittest 
to refer for dialysis.123,124
Kessler and colleagues119 noted those referred late 
had low contact with primary care compared with 
those referred early. If CKD was diagnosed only 
within 1 month of requiring dialysis, then 43.4% of 
patients received no regular primary care input.
There was little evidence that hospitalisations were 
affected in the pre- or post-dialysis phase by early 
specialist referral beyond 1 month prior to starting 
dialysis.
Other measures of effectiveness
Given the chronic nature of this condition and the 
important potential to effect quality of life it was 
perhaps surprising that no studies reported aspects 
of quality of life.
The nature of what early referral meant in terms 
of clinical care was essentially not described. The 
limited detail available has been summarised 
above. Looking at the impact of different care 
on aspects of management (of risk factors) and 
prescribing identified inconsistencies between 
studies. However, BP control and/or ACE I/ARB 
prescribing were the most consistently identified 
differences between referral and standard non-
specialist care. The use of CVD risk modifiers 
such as statins was also reported to be higher in 
specialist care by some authors.111,120
Which groups likely to benefit 
most
There was very limited information about 
subgroups that may have the most to benefit. 
Referral less than 12 months prior to starting 
dialysis was associated with poorer outcomes in 
certain groups: African-Americans, those with 
diabetes and those with hypertension;123 a finding 
consistent with other studies of late referral (see 
Appendix 7). The authors did not report whether 
certain groups benefited more from early referral. 
Orlando and colleagues111 reported that the 
benefit of referral to a specialist was not observed 
until stage 3 or worse. In contrast, in patients 
with diabetes, the greatest gains were reported 
when referral was made at the earliest stage 
(microalbuminuria).120 It is important to note that 
studies defined their cohorts based on meeting 
criteria for chronic CKD. In clinical practice, 
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when a patient first presents with a reduced 
eGFR or evidence of renal damage, it is often not 
immediately possible to determine the chronicity 
or otherwise of their condition. A proportion of 
patients presenting with apparently ‘early’ features 
of CKD will in fact have an acute renal problem 
that requires rapid referral to a nephrologist or, in 
some cases, urologist.23,41
Limitations of the evidence base
The major limitations of the evidence base have 
been alluded to already. The lack of studies and in 
particular RCTs made assessment of effectiveness 
of strategies for early referral difficult. The 
Cochrane Renal Group noted, in 2002, that there 
was a paucity of RCT data for interventions in renal 
disease, lower than all other internal medicine 
specialties. Furthermore, patients with renal disease 
are under-represented in many large intervention 
trials. For example, an analysis of 86 intervention 
trials for CVD between 1998 and 2005 noted that 
80% excluded ESRD and 75% excluded patients 
with known CKD.125 Indeed much of the evidence 
base around the management of patients with 
renal disease has relied on observational studies, 
extrapolation of RCT findings from other clinical 
groups and expert opinion.
Our review included all study designs, and has 
found evidence that there are some differences 
in the outcomes experienced after referral to a 
specialist compared with remaining in primary 
care. Some of those differences may be explained 
by the complex decision-making process around 
selecting which patients to refer. Adjustment for 
confounding in the analysis corrects for some of 
the differences in case-mix but not all. There are, 
however, differences in the care received by people 
in specialist care when compared with primary 
care. Differences in the medicines prescribed and 
markers of their general clinical condition support 
the hypothesis that care differs.
The evidence base reviewed here was not helpful 
in unpacking which components of a model of 
care are important. Orlando and colleagues111 
provided the only estimate of the RR of ACM 
and progression comparing referral to a 
nephrologist with primary care alone. This study 
relied on routine health-care data and the two 
groups were significantly different at baseline. 
Observed differences were adjusted for in the 
analysis, but this adjustment could not account for 
unmeasured differences between the two groups. 
The generalisability of this study was also limited; 
the data were based on a veterans’ health-care 
organisation (participants were all male) and the 
study took place in the USA, where non-specialist 
health care is very different from the primary care 
provision in the UK.
Conclusions
The studies identified provide some evidence 
to support the role of ‘early’ referral for CKD, 
identifying benefits in terms of BP control and 
renal progression among those referred earlier to 
specialist services. Very early referral benefits may 
be greater for certain clinical groups (those with 
diabetes) while others may show little gain until 
at least stage 3 disease. The evidence reviewed 
in this chapter does support the need for further 
good quality RCTs of methods of care delivery and 
timing of intervention. While referral to a specialist 
might be one approach to achieving optimal care, 
other care models exist. Given the large proportion 
of the population with stage 1–3 CKD and, from 
the review of natural history, the low progression to 
ESRD but significant cardiovascular morbidity and 
mortality once population screening is adopted, 
there may be appropriate and alternative ways of 
delivering care to such patients. The next chapter 
considers the other models of care delivery for 
CKD and the evidence of effectiveness.
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Introduction
Two decades of rapid expansion in services for 
people with kidney disease have focused largely on 
delivery of care for people with severe impairment 
of kidney function and those requiring RRT. In 
2002, the UK Renal Association126 supported 
the early detection and referral of people with 
evidence of CKD to enable early treatment with 
the aim of halting disease progression in those with 
CKD and preventing kidney function impairment 
in those who were at high risk of developing CKD. 
The need for involvement of primary care in early 
identification was highlighted along with the need 
for access to expert nephrology assessment in order 
to reduce complications, including ESRD.126
The shift in focus to active early recognition and 
management of chronic conditions has been a 
growing focus for health services in recent years. 
Along with growing demand and changing 
population demographics, important drivers 
for change included the recognition that people 
with chronic diseases frequently did not receive 
advice about modifying risk factors and did not 
feel included in the treatment decision-making 
process.127 Various chronic care models have been 
proposed but the essence is consistent, with a 
focus on self-care and including recognition of 
the importance of community services, informal 
support networks, multidisciplinary support and 
primary care in delivering care alongside specialist 
services. Chronic care models have now been 
adopted within the World Health Organization in 
recognition of the global nature of the challenge 
to support and manage people with chronic 
illnesses.128
In the management of diabetes mellitus, the 
chronic care model has been widely adopted and 
well studied. Care often includes a combination of 
self-management using various interventions along 
with management in partnership with primary and 
secondary care; a model with demonstrable clinical 
effectiveness and cost-effectiveness. Improvements 
in health outcomes including glycosylated 
haemoglobin, fasting blood glucose levels and 
diabetes knowledge were observed when patients 
were provided with group-based diabetes education 
programmes.129 There was evidence to support 
disease management (an organised, practical, 
integrated and population-based approach of 
management to health-care services that focused 
on particular disease and aspects of delivery 
services) and case management (an intervention to 
manage patients at high risk of poor outcomes and 
includes identification of an individual, assessment, 
development of a care plan, implementation and 
monitoring of outcomes).130 Similarly, multifaceted, 
professional intervention and enhancing the role of 
nurses in diabetes care have shown improvements 
in patients’ health outcomes and process of care.131
A similar kind of care including educational 
interventions, involvement of multiskilled 
professionals and enhancing the role of 
professionals may prove advantageous in CKD 
management. Here we report evidence about the 
types of care models that have been adopted for 
the management of CKD patients. The methods 
used to identify these studies were outlined in 
Chapter 2.
Result
Initially, 40 studies were identified, of which 
three were excluded as they described only the 
components of care that should be considered132,133 
or evaluated the care received before and after a 
clinical trial [RENAAL: The Reduction in Endpoint 
Study in NIDDM (non-insulin dependent diabetes 
mellitus) with the Angiotensin II Antagonist 
Losartan Study].134 They did not describe or 
evaluate a model of care. Thus a total of 37 studies 
were included and categorised into four groups:
• surveys/audits (n = 4) surveys/audits of current 
care provision135–138
• evaluation studies (n = 13) evaluating single 
services or comparing different services139–151
• descriptive studies (n = 7) describing single 
services, groups of services, individual 
specialties within services or an intervention for 
care152–158
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• aspirational studies (n = 14) reporting 
proposals for how the services/model of care 
for CKD management could be in future.159–172
The findings from these papers are presented 
below. Firstly, using the survey data, we provide an 
overview of the types of models of care delivery 
in the UK. We then present details of the types 
of models of care described in the literature, 
picking out commonality in the facets of the care 
programmes. The evidence of effectiveness for 
the models of care is summarised and, finally, 
the substantial literature describing aspirations 
for renal services is considered with regards to 
potential key components of care models.
Overview of existing models of 
care delivery
Chronic kidney disease management in the UK 
has been reported in the two surveys.135,136 A 
questionnaire by Ahmad and colleagues135 surveyed 
all 72 renal units in the UK and focused on the 
management of CKD patients with stages 4 and 
5. Similarly, Jones and colleagues136 surveyed all 
71 renal units and 11 district general hospital 
nephrology units, asking about systems of care for 
stable uncomplicated CKD patients that did not 
rely on direct contact with nephrologists. Five basic 
types of management pattern for CKD patients 
were reported: multidisciplinary renal teams, low 
clearance clinics, predialysis education,135 nurse-led 
clinics and shared care scheme (SCS)136 (Table 17).
Multidisciplinary renal teams were reported by 
97% of the renal units and comprised different 
skilled professionals who, along with nephrologists, 
managed CKD patients. Regular meetings brought 
the team together.135 Dieticians and dialysis 
education providers were common, attending 
CKD clinics in more than 95% of the renal 
units.135 Additionally, 70% of units ran satellite 
clinics for CKD patients in a general district 
hospital from where patients could access the full 
team services.135 Only two units reported to have 
shared primary and secondary care schemes.136 A 
further six centres were developing SCSs; three 
were developing nurse-led services where nurse 
specialists would manage stable patients and/or the 
initial assessment of new referrals.136 Low clearance 
clinics were run by 71% of units to manage patients 
approaching RRT, while 10 units were planning to 
set up such clinics. Most of the low clearance clinics 
were run by specialist renal nurses who had various 
roles including communicating with the staff 
involved in CKD management, patient education, 
counselling, transplant assessments, prescribing 
under medical supervision and reviewing 
patients.135 Pre-dialysis education was noted in 16% 
of the units136 where dialysis nurses, transplant co-
ordinators, dieticians and pharmacists provided 
dialysis education to CKD patients.135
A survey of the organisation of care provided to 
CKD stage 3–5 patients by nephrology clinics 
in Italy139 highlighted important and frequent 
deviations from guidelines in the centres’ policies 
for caring for CKD patients including: the 
definition of low eGFR, management of anaemia 
and bone mineral metabolism, and preparation 
for dialysis. A report of a local CKD network 
established in the UK (membership included: 
local GPs, consultant nephrologists, consultant 
nurses, commissioners, a patient representative 
and representatives from the primary care trusts) 
described a network approach with supporting 
referral guidelines and an education programme 
that had been introduced to support increasing 
local demand on nephrology services.140
Models of care observed (from 
evaluative/descriptive studies)
From the 19 evaluation and descriptive papers, 
three broad models of care were identified: 
multidisciplinary care (MDC), structured care by an 
individual specialty, and educational interventions. 
Among the MDCs, two were SCSs. Structured 
care by an individual specialty included studies 
reporting on a single clinical specialty (e.g. nurses, 
pharmacists) operating a service in isolation or as 
part of a multidisciplinary group (Table 18). The 
models of care are described in more detail below. 
Some of the papers described more than one 
model of care.153,154,157,158
Multidisciplinary care
Multidisciplinary care was the most commonly 
described approach to the management of CKD 
populations. Table 19 details the services and 
settings. MDC models were described in primary 
care150 and hospital-based clinics.142,143,145,146,151,152,154 
The MDC disease management programmes 
based in primary care involved community-based 
teams of nurses, dieticians, social workers and 
GPs with a wide scope including a named nurse 
available to each patient.150 Hospital care-based 
MDC nephrology clinics comprised nurses, nurse-
educators, social workers, dieticians, nephrologists 
and academics. Joint diabetics and renal clinics 
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TABLE 17 Types of management pattern for CKD patients
Type of care
Number of units 
providing care Detail of care
Multidisciplinary 
renal team 
services (MSRT)135
70/72 units (97%) Multidisciplinary teams consisted of 
dietician, dialysis education provider, 
anaemia co-ordinator, pharmacist, social 
worker, access co-ordinator, counsellor, 
diabetic nurse, occupational therapist, 
psychologist, physiotherapist and blood 
pressure nurse
Regular multidisciplinary teams meetings 
held as a part of this service 
Regular MSRT 
meeting
47/70 units 
(67%)
Monthly 
meeting
36%
Weekly meeting 49%
Shared care (SC) 
scheme136
2/76 units (3%) Stable uncomplicated CKD patients 
referred to SC where they are under 
the care of a GP but supervised 
by nephrologists based on clinical 
information and regular review. Patients 
attended the clinic every 6–12 months 
(as per the letter and blood form sent 
to them) and GP gathered clinical 
information (BP, urinanalysis, etc.) 
according to the SC form. Most of the 
time the practice nurse completed these 
forms. The patients examination result 
was reviewed by nephrologists and 
referred to hospital clinic or retained in 
SC as needed
Developing SC 6/76 (8%) units
Planning nurse 
management
2/76(3%) units
Developing 
initial 
assessment by 
nurse for new 
referrals
1/76 units (1%)
Low clearance 
clinics135
50/70 units (71%) These clinics were run for managing 
patients approaching RRT. Services 
carried out by renal nurse included 
delivery of CKD education, counselling, 
transplant education, prescribing and 
altering prescription under medical 
supervision, and communication with 
other personnel involved in the CKD 
patient care. Nephrologists and renal 
nurse reviewed patient on alternate basis
Renal nurse involvement in 84% of 
units
Predialysis 
education135
13/76 units (17%) The education was about types of 
dialysis, dietary restrictions, fluid balance, 
CKD-related anaemia, and renal bone 
disease, which were all well covered. 
Less commonly included were aspects of 
cardiovascular risk factors, sexual health 
and psychological support. Education 
materials were available in audio and 
Braille or translated in other languages. 
Specific dialysis education provider, 
dialysis nurses, transplant co-ordinators, 
dieticians and pharmacists were involved
CKD, chronic kidney disease; RRT, renal replacement therapy.
included MDC teams with specialists from clinical 
specialties.152 Some described a case management 
approach with a named team for individual 
patients.145
Shared care scheme
The Southampton Integrated Monitoring of 
Nephrology (SIMON) programme was the 
only structured SCS reported in detail in the 
literature that formally spanned secondary and 
primary care.147 It included an intensive hospital 
nephrology clinic and shared primary and 
nephrology care scheme. All patients were initially 
seen at the hospital nephrology clinic and while 
patients with stable CKD were monitored regularly 
through the shared primary and nephrology care 
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TABLE 18 Models of care reported in the included studies
Study ID Description of care MDC SCIS EI
Bending 2007152 Joint diabetes and renal clinic at Eastbourne, UK 
Compton 2002153 The Healthy Start Program at Ochsner Clinic in New Orleans,  
LA, USA

A renal disease management programme within a managed care 
setting – Boston, MA, USA
CKD programme at Western New England Renal and Transplant 
Associates

The division of Nephrology at Virginia Commonwealth University/
Medical College of Virginia, VA, USA

Cortes-Sanabria 
2008141
Primary care led by family physician with educative intervention 
[IMSS Primary Health-Care Units (Unidad de Medicina Familiar)] in 
Guadalajara City, Mexico

Curtis 2005142 Multidisciplinary clinic of hospitals in Canada and Italy 
Ghossein 2002154 Comprehensive renal care clinic called Healthy Living at 
Northwestern Memorial Hospital in Chicago, IL, USA
 
Hardy 2007143 Redesigned service for the management of diabetic nephropathy 
and diabetics with microalbuminuria at Whiston Diabetes Centre, 
Mersyside, UK (SCS)

Harnett 2008144 Primary care service and virtual care service 
Harris 1998145 Multidisciplinary case management clinic (general practice medicine 
of Regenstrief Health Center, IN, USA, affiliated with multispecialty 
outpatient facility)

Hemmelgarn 
2007146
Multidisciplinary clinic of Canada (Southern Alberta Renal program) 
Hostetter 2003155 National Kidney Disease Education Program, MD, USA 
Jones 2006147 SIMON programme of Southampton, UK, that includes intensive 
hospital nephrology clinic (HC) and shared primary and nephrology 
care scheme (SCS)

Joy 2005156 Physicians–pharmacist collaborative practice model 
Kelly 2008148 Pharmacist-led structured care (a protocol driven clinic) 
Leung 2005149 Pharmacist and diabetes specialist-led structured care at hospital 
Minutolo 2005137 Physician-led primary care service and nephrologist-led secondary 
care service

Minutolo 2006138 Physician-led primary care service and specialist (nephrologists or 
diabetologists)-led secondary care service

Richards 2008150 Disease management programme of West Lincolnshire Primary 
Care Trust, UK

Thanamayooran 
2005151
Multidisciplinary nephrology clinic of Halifax, Canada (tertiary care 
hospital)

Thomas 2004157 Patient-centred management and education at South-west Thames, 
UK (Primary care)
 
Thomas 2005158 A patient-centred education programme at local family doctor 
surgeries (primary care)
 
EI, educational interventions; IMSS, Mexican Institute of Social Security; MDC, multidisciplinary care; SCIS, structured 
care by individual specialty; SCS, shared care scheme; SIMON, Southampton Integrated Monitoring of Nephrology.
DOI: 10.3310/hta14210 Health Technology Assessment 2010; Vol. 14: No. 21
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
59TA
B
LE
 1
9 
D
es
cr
ip
tio
n 
of
 m
ul
tid
is
ci
pl
in
ar
y 
ca
re
 (M
D
C
) 
fo
r 
C
K
D
 s
et
tin
gs
 a
nd
 s
er
vi
ce
s
R
ef
er
en
ce
S
tu
d
y 
ty
p
e
T
yp
e 
o
f 
C
K
D
 
p
at
ie
n
ts
M
u
lt
id
is
ci
p
lin
ar
y 
cl
in
ic
F
ac
et
s 
o
f 
M
D
C
 p
ro
gr
am
m
e
S
ta
ff
 d
el
iv
er
in
g 
th
e 
p
ro
gr
am
m
e
C
o
m
p
ar
at
o
r 
gr
o
u
p
B
en
di
ng
 2
00
71
52
D
es
cr
ip
ti
ve
Es
ta
bl
is
he
d 
di
ab
et
es
 k
id
ne
y 
di
se
as
e
Jo
in
t 
di
ab
et
es
 
an
d 
re
na
l c
lin
ic
 a
t 
Ea
st
bo
ur
ne
, U
K
R
ef
er
ra
l t
hr
ou
gh
 d
ia
be
te
s 
sp
ec
ia
lis
t 
se
rv
ic
e 
fo
r 
in
it
ia
l d
ia
gn
os
is
 a
nd
 t
he
n 
fo
r 
fo
llo
w
-u
p 
de
pe
nd
in
g 
up
on
 t
he
 le
ve
l o
f S
C
r 
in
 o
rd
er
 t
o 
pr
ov
id
e 
re
na
l s
up
po
rt
 t
he
ra
py
. T
he
 s
er
vi
ce
 
in
cl
ud
es
 a
 p
ri
or
 r
ou
ti
ne
 s
tr
uc
tu
re
d 
sc
re
en
in
g 
fo
r 
m
ic
ro
al
bu
m
in
ur
ia
 a
nd
 c
lin
ic
al
 p
ro
te
in
ur
ia
 a
nd
 
ea
rl
y 
in
te
rv
en
ti
on
 (
A
C
E 
I/A
R
B
) 
to
 c
on
tr
ol
 B
P 
an
d 
gl
yc
ae
m
ia
 in
 a
ll 
pa
ti
en
ts
 t
o 
ha
lt
 t
he
 d
ev
el
o
pm
en
t 
of
 in
ci
pi
en
t 
di
ab
et
ic
 n
ep
hr
o
pa
th
y
N
A
C
om
pt
on
 
20
02
15
3
D
es
cr
ip
ti
ve
 
re
vi
ew
 p
ap
er
C
K
D
 a
t 
ea
rl
y 
st
ag
es
T
he
 H
ea
lt
hy
 S
ta
rt
 
pr
og
ra
m
 a
t 
O
ch
sn
er
 
C
lin
ic
 in
 N
ew
 
O
rl
ea
ns
M
ul
ti
di
sc
ip
lin
ar
y 
pr
og
ra
m
m
e,
 a
im
ed
 t
o 
in
te
rv
en
e 
in
 C
K
D
 a
t 
ea
rl
y 
st
ag
e,
 t
hu
s 
sl
ow
in
g 
pr
og
re
ss
io
n 
of
 
th
e 
di
se
as
e 
an
d 
im
pr
ov
in
g 
pa
ti
en
t 
ou
tc
om
es
N
R
N
A
C
om
pt
on
 
20
02
15
3
D
es
cr
ip
ti
ve
 
re
vi
ew
 p
ap
er
C
K
D
 p
at
ie
nt
s,
 
st
ag
e 
no
t 
sp
ec
ifi
ed
A
 r
en
al
 d
is
ea
se
 
m
an
ag
em
en
t 
pr
og
ra
m
m
e 
w
it
hi
n 
a 
m
an
ag
ed
 c
ar
e 
se
tt
in
g,
 B
os
to
n,
 M
A
, 
U
SA
M
ul
ti
di
sc
ip
lin
ar
y 
pr
og
ra
m
m
e 
pr
om
ot
in
g 
ea
rl
y 
re
fe
rr
al
 w
he
re
 in
te
rv
en
ti
on
s 
to
 s
lo
w
 t
he
 
pr
og
re
ss
io
n 
of
 t
he
 d
is
ea
se
 c
ou
ld
 h
av
e 
im
pa
ct
 o
n 
th
e 
m
or
bi
di
ty
 a
nd
 m
or
ta
lit
y 
as
so
ci
at
ed
 w
it
h 
C
K
D
. 
Ed
uc
at
io
na
l o
pp
or
tu
ni
ti
es
 p
ro
vi
de
d 
to
 p
at
ie
nt
s 
an
d 
fa
m
ily
 m
em
be
rs
Pr
im
ar
y 
ca
re
 p
hy
si
ci
an
s,
 
ne
ph
ro
lo
gi
st
s,
 
ne
ph
ro
lo
gy
 n
ur
se
s,
 
nu
tr
it
io
ni
st
s
N
A
C
ur
ti
s 
20
05
14
2
C
oh
or
t 
st
ud
y,
 
th
os
e 
ex
po
se
d 
to
 
M
D
C
 v
s 
st
an
da
rd
 
ne
ph
ro
lo
gy
 c
ar
e
In
ci
de
nt
 d
ia
ly
si
s 
pa
ti
en
ts
M
ul
ti
di
sc
ip
lin
ar
y 
cl
in
ic
 o
f h
os
pi
ta
ls
 in
 
C
an
ad
a 
an
d 
It
al
y
M
D
C
 in
cl
ud
ed
 e
du
ca
ti
on
al
 p
ro
gr
am
m
es
 a
s 
w
el
l a
s 
re
gu
la
r, 
pr
ot
oc
ol
is
ed
 c
lin
ic
 a
nd
 la
bo
ra
to
ry
 fo
llo
w
-
up
 o
f p
at
ie
nt
s 
w
it
h 
C
K
D
. T
he
 fr
eq
ue
nc
y 
of
 b
ot
h 
vi
si
ts
 a
nd
 la
bo
ra
to
ry
 t
es
ts
 w
as
 p
re
de
te
rm
in
ed
, 
ba
se
d 
on
 t
he
 le
ve
l o
f k
id
ne
y 
fu
nc
ti
on
 w
it
h 
re
m
in
de
r 
sy
st
em
 t
o 
fa
ci
lit
at
e 
fo
llo
w
-u
p.
 R
eg
ul
ar
ly
 
sc
he
du
le
d 
bl
oo
d 
w
or
k 
an
d 
cl
in
ic
al
 e
xa
m
in
at
io
n 
an
d 
pr
e-
sp
ec
ifi
ed
 e
du
ca
ti
on
al
 t
o
pi
cs
 w
er
e 
re
vi
ew
ed
 w
it
h 
ea
ch
 p
at
ie
nt
C
an
ad
a 
– 
nu
rs
e,
 
ed
uc
at
or
, p
hy
si
ci
an
, 
so
ci
al
 w
or
ke
r, 
nu
tr
it
io
ni
st
, a
nd
 
ph
ar
m
ac
is
t
It
al
y 
– 
pr
og
ra
m
m
e 
de
di
ca
te
d 
ne
ph
ro
lo
gi
st
s 
an
d 
m
ul
ti
di
sc
ip
lin
ar
y 
nu
rs
es
 w
ho
 t
oo
k 
re
sp
on
si
bi
lit
y 
fo
r 
im
pl
em
en
ti
ng
 
re
co
m
m
en
de
d 
di
ag
no
st
ic
 
an
d 
in
te
rv
en
ti
on
 
st
ra
te
gi
es
St
an
da
rd
 n
ep
hr
ol
og
y 
ca
re
N
ep
hr
ol
og
is
ts
 w
it
h 
ac
ce
ss
 t
o 
fa
ci
lit
ie
s 
an
d 
st
af
f o
f m
ul
ti
di
sc
ip
lin
ar
y 
cl
in
ic
 fo
r 
th
ei
r 
pa
ti
en
ts
. 
C
ar
e 
w
as
 s
ta
nd
ar
di
se
d 
an
d 
m
an
ag
ed
 a
cc
or
di
ng
 
to
 s
ta
nd
ar
d 
un
it
 
pr
ac
ti
ce
s
co
nt
in
ue
d
Models of care
60
DOI: 10.3310/hta14210 Health Technology Assessment 2010; Vol. 14: No. 21
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
61
R
ef
er
en
ce
S
tu
d
y 
ty
p
e
T
yp
e 
o
f 
C
K
D
 
p
at
ie
n
ts
M
u
lt
id
is
ci
p
lin
ar
y 
cl
in
ic
F
ac
et
s 
o
f 
M
D
C
 p
ro
gr
am
m
e
S
ta
ff
 d
el
iv
er
in
g 
th
e 
p
ro
gr
am
m
e
C
o
m
p
ar
at
o
r 
gr
o
u
p
G
ho
ss
ei
n 
20
02
15
4
Ev
al
ua
ti
on
 o
f 
co
m
pr
eh
en
si
ve
 
re
na
l c
ar
e
C
K
D
 s
ta
ge
 3
–5
C
om
pr
eh
en
si
ve
 
re
na
l c
ar
e 
cl
in
ic
 
ca
lle
d 
‘H
ea
lt
hy
 
Li
vi
ng
’ a
t 
N
or
th
w
es
te
rn
 
M
em
or
ia
l H
os
pi
ta
l, 
C
hi
ca
go
, I
L,
 U
SA
M
ai
n 
as
pe
ct
s 
of
 p
ro
gr
am
m
e 
w
er
e 
tr
ea
ti
ng
 
th
e 
co
m
pl
ic
at
io
ns
 o
f C
K
D
 (
an
ae
m
ia
, r
en
al
 
os
te
od
ys
tr
o
ph
y)
, p
ro
vi
di
ng
 n
ut
ri
ti
on
al
 s
up
po
rt
, 
id
en
ti
fy
in
g 
an
d 
m
an
ag
in
g 
co
m
or
bi
di
ti
es
, p
re
pa
ri
ng
 
fo
r 
tr
an
sp
la
nt
at
io
n 
an
d 
di
al
ys
is
. T
he
 m
ai
n 
ai
m
 
of
 t
he
 s
er
vi
ce
 w
as
 t
o 
sl
ow
 o
r 
st
ab
ili
se
 t
he
 
pr
og
re
ss
io
n 
of
 C
K
D
. T
he
 r
ef
er
ri
ng
 p
ri
m
ar
y 
ca
re
 p
hy
si
ci
an
s 
w
er
e 
gi
ve
n 
ed
uc
at
io
na
l s
es
si
on
s 
in
cl
ud
in
g 
le
ct
ur
es
 a
nd
 d
is
cu
ss
io
ns
 (
on
e-
to
-
on
e 
or
 s
m
al
l g
ro
up
). 
C
lin
ic
al
 p
ar
am
et
er
s 
an
d 
m
ed
ic
at
io
n 
of
 t
he
 p
at
ie
nt
s 
w
er
e 
m
on
it
or
ed
 a
nd
 
w
er
e 
sc
re
en
ed
 t
o 
ch
ec
k 
fo
r 
co
m
or
bi
d 
co
nd
it
io
ns
. 
Ed
uc
at
io
n 
on
 d
ia
ly
si
s 
pr
ov
id
ed
 t
o 
pa
ti
en
ts
N
ep
hr
ol
og
is
ts
, p
hy
si
ci
an
 
as
si
st
an
t,
 n
ur
se
s,
 
nu
tr
it
io
ni
st
, h
av
in
g 
an
 a
cc
es
s 
to
 r
en
al
 
so
ci
al
 w
or
ke
rs
, p
at
ie
nt
 
ed
uc
at
or
, r
en
al
 d
ie
ti
ci
an
, 
se
pa
ra
te
 t
ra
ns
pl
an
t 
te
am
N
A
H
ar
dy
 2
00
71
43
Ev
al
ua
ti
on
 o
f 
re
de
si
gn
ed
 
se
rv
ic
e
Ty
pe
 2
 d
ia
be
ti
c 
pa
ti
en
ts
 w
it
h 
m
ic
ro
al
bu
m
in
ur
ia
 
an
d 
di
ab
et
ic
 
ne
ph
ro
pa
th
y
R
ed
es
ig
ne
d 
se
rv
ic
e 
fo
r 
th
e 
m
an
ag
em
en
t 
of
 d
ia
be
ti
c 
ne
ph
ro
pa
th
y 
an
d 
di
ab
et
ic
s 
w
it
h 
m
ic
ro
al
bu
m
in
ur
ia
 
at
 a
 s
in
gl
e 
di
ab
et
es
 
cl
in
ic
U
nc
om
pl
ic
at
ed
 p
at
ie
nt
s 
w
er
e 
di
sc
ha
rg
ed
 t
o 
pr
im
ar
y 
ca
re
, w
hi
le
 c
om
pl
ic
at
ed
 p
ro
bl
em
s 
w
er
e 
fo
llo
w
ed
 in
 d
ed
ic
at
ed
 h
os
pi
ta
l-
ba
se
d 
cl
in
ic
s.
 A
 
sp
ec
ia
lis
t 
ne
ph
ro
pa
th
y 
cl
in
ic
 w
as
 e
st
ab
lis
he
d 
to
 
fo
cu
s 
on
 m
ul
ti
fa
ct
or
ia
l i
nt
er
ve
nt
io
ns
. P
at
ie
nt
s 
w
it
h 
di
ab
et
ic
 k
id
ne
y 
di
se
as
e 
re
fe
rr
ed
 fr
om
 
pr
im
ar
y 
ca
re
 (
or
 w
it
hi
n 
ho
sp
it
al
) 
w
er
e 
se
nt
 t
o 
‘n
ew
 p
at
ie
nt
 c
lin
ic
’ f
or
 a
ss
es
sm
en
t,
 c
on
su
lt
at
io
n,
 
ed
uc
at
io
n 
an
d 
op
ti
m
is
at
io
n 
of
 t
re
at
m
en
t 
w
it
h 
su
bs
eq
ue
nt
 v
is
it
s 
at
 o
ne
 o
f t
he
 o
th
er
 d
ed
ic
at
ed
 
‘n
ep
hr
o
pa
th
y’
 c
lin
ic
s.
 6
–
8 
pa
ti
en
ts
 v
is
it
ed
 
ea
ch
 c
lin
ic
 fo
r 
ap
pr
ox
im
at
el
y 
35
 m
in
ut
es
 p
er
 
pa
ti
en
t.
 F
ol
lo
w
in
g 
ea
ch
 o
f t
he
se
 n
ep
hr
o
pa
th
y 
cl
in
ic
s,
 a
ll 
pa
ti
en
ts
 w
er
e 
di
sc
us
se
d 
in
 d
et
ai
l i
n 
a 
m
ul
ti
di
sc
ip
lin
ar
y 
te
am
 m
ee
ti
ng
D
ia
be
to
lo
gi
st
s,
 d
ia
be
te
s 
nu
rs
e,
 c
on
su
lt
an
t 
an
d 
a 
se
ni
or
 c
lin
ic
al
 
fe
llo
w
 h
av
in
g 
ac
ce
ss
 t
o 
ne
ph
ro
lo
gi
st
s.
 T
hr
ee
 
ne
ph
ro
pa
th
y 
cl
in
ic
s:
 o
ne
 
le
d 
by
 c
on
su
lt
an
t,
 t
w
o 
le
d 
by
 d
ia
be
te
s 
nu
rs
e 
sp
ec
ia
lis
t
B
ef
or
e 
re
de
si
gn
in
g 
of
 
th
e 
se
rv
ic
e,
 p
at
ie
nt
s 
w
it
h 
di
ab
et
ic
 k
id
ne
y 
di
se
as
e 
w
er
e 
ca
re
d 
fo
r 
w
it
hi
n 
a 
‘g
en
er
al
’ 
di
ab
et
ic
 o
ut
pa
ti
en
t 
cl
in
ic
 in
 s
ec
on
da
ry
 
ca
re
 w
hi
ch
 in
cl
ud
ed
 
ne
w
 r
ef
er
ra
ls
, f
ol
lo
w
-
up
s 
an
d 
pa
ti
en
ts
 
w
it
h 
a 
w
id
e 
ra
ng
e 
of
 
co
m
pl
ic
at
io
ns
T
A
B
LE
 1
9 
D
es
cr
ip
tio
n 
of
 m
ul
tid
is
ci
pl
in
ar
y 
ca
re
 (M
D
C
) 
fo
r 
C
K
D
 s
et
tin
gs
 a
nd
 s
er
vi
ce
s 
(c
on
tin
ue
d)
Models of care
60
DOI: 10.3310/hta14210 Health Technology Assessment 2010; Vol. 14: No. 21
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
61
R
ef
er
en
ce
S
tu
d
y 
ty
p
e
T
yp
e 
o
f 
C
K
D
 
p
at
ie
n
ts
M
u
lt
id
is
ci
p
lin
ar
y 
cl
in
ic
F
ac
et
s 
o
f 
M
D
C
 p
ro
gr
am
m
e
S
ta
ff
 d
el
iv
er
in
g 
th
e 
p
ro
gr
am
m
e
C
o
m
p
ar
at
o
r 
gr
o
u
p
H
ar
ri
s 
19
98
14
5
R
an
do
m
is
ed
 
co
nt
ro
lle
d 
cl
in
ic
al
 t
ri
al
 o
f 
an
 in
te
ns
iv
e 
m
ul
ti
di
sc
ip
lin
ar
y 
ca
se
 m
an
ag
em
en
t 
pr
og
ra
m
m
e
C
hr
on
ic
 r
en
al
 
in
su
ffi
ci
en
cy
 
(S
C
r >
 1
.4
 m
g/
dl
)
M
ul
ti
di
sc
ip
lin
ar
y 
ca
se
 m
an
ag
em
en
t 
cl
in
ic
 (
ge
ne
ra
l 
pr
ac
ti
ce
 m
ed
ic
in
e 
of
 
R
eg
en
st
ri
ef
 H
ea
lt
h 
C
en
te
r, 
af
fil
ia
te
d 
w
it
h 
m
ul
ti
sp
ec
ia
lt
y 
ou
tp
at
ie
nt
 fa
ci
lit
y)
T
he
 fr
eq
ue
nc
y 
of
 t
hi
s 
ca
se
 m
an
ag
em
en
t 
cl
in
ic
 
w
as
 e
ve
ry
 6
 m
on
th
s,
 4
 m
on
th
s 
or
 3
 m
on
th
s 
de
pe
nd
in
g 
on
 S
C
r 
le
ve
l. 
In
te
rv
en
ti
on
 p
at
ie
nt
 
re
ce
iv
ed
 a
 c
om
pr
eh
en
si
ve
 p
ro
gr
am
m
e 
th
at
 
in
cl
ud
ed
 m
ed
ic
at
io
n 
re
vi
ew
, c
om
pl
ia
nc
e 
as
se
ss
m
en
t,
 e
du
ca
ti
on
, s
ur
ve
ill
an
ce
 o
f p
at
ie
nt
s,
 
di
et
ar
y 
co
un
se
lli
ng
, s
oc
ia
l s
er
vi
ce
 in
te
rv
ie
w
 a
nd
 
co
m
m
un
ic
at
io
n 
w
it
h 
pr
im
ar
y 
ca
re
 p
ro
vi
de
r 
w
he
re
 
ap
pr
o
pr
ia
te
. T
he
 u
se
 o
f A
C
E 
I w
as
 in
cr
ea
se
d,
 
B
P 
co
nt
ro
l i
m
pr
ov
ed
; u
se
 o
f n
ep
hr
ot
ox
ic
 d
ru
gs
 
an
d 
pr
ot
ei
n 
in
ta
ke
 d
ec
re
as
ed
, b
ar
ri
er
s 
to
 c
ar
e 
de
cr
ea
se
d
N
ep
hr
ol
og
is
ts
, 
ne
ph
ro
lo
gy
 fe
llo
w
, a
 
re
na
l n
ur
se
, a
 r
en
al
 
di
et
ic
ia
n 
an
d 
a 
so
ci
al
 
w
or
ke
r
U
su
al
 c
ar
e
Pa
ti
en
ts
 g
ot
 u
su
al
 
pr
im
ar
y 
ca
re
 fr
om
 
ph
ys
ic
ia
ns
 w
it
h 
ac
ce
ss
 
to
 n
ep
hr
ol
og
is
ts
 
if 
re
fe
rr
ed
 t
o 
th
e 
st
an
da
rd
 r
en
al
 s
er
vi
ce
H
em
m
el
ga
rn
 
20
07
14
6
R
et
ro
sp
ec
ti
ve
 
co
ho
rt
 s
tu
dy
, 
co
m
pa
re
d 
M
D
C
 
w
it
h 
no
n-
M
D
C
C
K
D
 s
ta
ge
 3
 a
nd
 
gr
ea
te
r
M
ul
ti
di
sc
ip
lin
ar
y 
cl
in
ic
 in
 C
an
ad
a 
(h
os
pi
ta
l b
as
ed
)
Pr
og
ra
m
m
e 
in
cl
ud
ed
 p
at
ie
nt
 e
du
ca
ti
on
, 
la
bo
ra
to
ry
 a
nd
 c
lin
ic
al
 e
xa
m
in
at
io
ns
 (
ev
er
y 
1–
3 
m
on
th
s 
an
d 
ev
er
y 
3–
6 
m
on
th
s 
re
sp
ec
ti
ve
ly
). 
Ed
uc
at
io
n 
se
ss
io
n 
in
cl
ud
ed
 d
is
cu
ss
io
n 
ab
ou
t 
C
K
D
, 
flu
id
 a
nd
 d
ie
ta
ry
 r
es
tr
ic
ti
on
s,
 m
on
it
or
in
g 
B
P,
 
m
ed
ic
in
e 
m
an
ag
em
en
t,
 a
nd
 li
fe
st
yl
e 
m
od
ifi
ca
ti
on
 
to
 r
ed
uc
e 
C
V
D
 r
is
k 
an
d 
de
la
y 
C
K
D
 p
ro
gr
es
si
on
. 
Pa
ti
en
ts
 w
er
e 
pr
ov
id
ed
 w
it
h 
a 
bo
ok
le
t 
pr
od
uc
ed
 
by
 t
he
 K
id
ne
y 
Fo
un
da
ti
on
Pr
im
ar
y 
ne
ph
ro
lo
gi
st
s 
(r
ef
er
re
d 
th
ei
r 
pa
ti
en
ts
 
to
 M
D
C
), 
sp
ec
ia
lis
ed
 
cl
in
ic
 n
ur
se
, r
eg
is
te
re
d 
di
et
ic
ia
n 
an
d 
so
ci
al
 
w
or
ke
r
N
on
-M
D
C
D
es
cr
ip
ti
on
 n
ot
 
re
po
rt
ed
Jo
ne
s 
20
06
14
7
R
et
ro
sp
ec
ti
ve
 
re
vi
ew
 o
f S
IM
O
N
 
pr
og
ra
m
m
e
C
K
D
 s
ta
ge
 3
–5
SI
M
O
N
 p
ro
gr
am
m
e 
of
 S
ou
th
am
pt
on
, 
U
K
, t
ha
t 
in
cl
ud
es
 
in
te
ns
iv
e 
ho
sp
it
al
 
ne
ph
ro
lo
gy
 c
lin
ic
 
(H
C
) 
an
d 
sh
ar
ed
 
pr
im
ar
y 
an
d 
ne
ph
ro
lo
gy
 c
ar
e 
sc
he
m
e
In
it
ia
lly
 a
ll 
pa
ti
en
ts
 w
er
e 
re
vi
ew
ed
 in
 h
os
pi
ta
l 
re
na
l c
lin
ic
. T
ho
se
 r
eq
ui
ri
ng
 c
on
ti
nu
ed
 c
ar
e 
w
er
e 
re
ta
in
ed
 in
 H
C
. S
ta
bl
e 
an
d 
un
co
m
pl
ic
at
ed
 p
at
ie
nt
s 
w
er
e 
en
ro
lle
d 
in
 s
ha
re
d 
pr
im
ar
y 
an
d 
ne
ph
ro
lo
gy
 
ca
re
 s
ch
em
e 
by
 n
ep
hr
ol
og
is
ts
, a
nd
 m
on
it
or
ed
 b
y 
us
in
g 
cl
in
ic
al
 a
nd
 la
bo
ra
to
ry
 r
ev
ie
w
s 
re
co
rd
ed
 in
 
pr
im
ar
y 
ca
re
 w
it
ho
ut
 a
tt
en
di
ng
 r
en
al
 u
ni
t.
 B
lo
od
 
an
d 
ur
in
e 
te
st
s 
an
d 
cl
in
ic
al
 e
xa
m
in
at
io
n 
(B
P,
 
w
ei
gh
t,
 m
ed
ic
at
io
ns
, e
tc
.) 
ca
rr
ie
d 
ou
t 
ev
er
y 
6
–1
2 
m
on
th
s 
if 
ne
ce
ss
ar
y.
 D
at
a 
re
co
rd
ed
 in
 S
IM
O
N
 
da
ta
ba
se
 w
hi
ch
 w
as
 r
ev
ie
w
ed
 b
y 
ne
ph
ro
lo
gi
st
s 
el
ec
tr
on
ic
al
ly
. N
ep
hr
ol
og
is
ts
 a
nd
 p
ri
m
ar
y 
ca
re
 
ph
ys
ic
ia
ns
 c
om
m
un
ic
at
ed
 b
et
w
ee
n 
ea
ch
 o
th
er
 
re
ga
rd
in
g 
pa
ti
en
ts
 r
ec
al
l t
o 
th
e 
H
C
 o
r 
an
y 
ch
an
ge
s 
in
 m
ed
ic
at
io
n.
 S
IM
O
N
 p
ro
gr
am
m
e 
us
ed
 a
 
co
m
pu
te
ri
se
d 
gr
ap
hi
ng
 s
ys
te
m
 t
ha
t 
al
lo
w
ed
 v
is
ua
l 
an
al
ys
is
 o
f c
ha
ng
es
 in
 G
FR
 a
nd
 o
th
er
 b
lo
od
 t
es
t
N
ep
hr
ol
og
is
ts
, p
ri
m
ar
y 
ca
re
 p
hy
si
ci
an
s,
 n
ur
se
s
N
A
co
nt
in
ue
d
Models of care
62
R
ef
er
en
ce
S
tu
d
y 
ty
p
e
T
yp
e 
o
f 
C
K
D
 
p
at
ie
n
ts
M
u
lt
id
is
ci
p
lin
ar
y 
cl
in
ic
F
ac
et
s 
o
f 
M
D
C
 p
ro
gr
am
m
e
S
ta
ff
 d
el
iv
er
in
g 
th
e 
p
ro
gr
am
m
e
C
o
m
p
ar
at
o
r 
gr
o
u
p
R
ic
ha
rd
s 
20
08
15
0
Ev
al
ua
ti
on
 
of
 d
is
ea
se
 
m
an
ag
em
en
t 
pr
og
ra
m
m
e
C
K
D
 s
ta
ge
s 
4 
an
d 
5,
 a
nd
 t
ho
se
 
at
 b
or
de
rl
in
e 
of
 
C
K
D
 3
/4
D
is
ea
se
 
m
an
ag
em
en
t 
pr
og
ra
m
 o
f W
es
t 
Li
nc
ol
ns
hi
re
 P
ri
m
ar
y 
C
ar
e 
Tr
us
t,
 U
K
Pa
ti
en
t 
ed
uc
at
io
n 
(e
nc
ou
ra
ge
d 
to
 e
ng
ag
e 
in
 t
he
ir
 
ow
n 
ca
re
 a
nd
 t
o 
ra
is
e 
aw
ar
en
es
s 
of
 c
ar
di
ov
as
cu
la
r 
ri
sk
 fa
ct
or
s)
, m
ed
ic
in
e 
m
an
ag
em
en
t,
 d
ie
te
ti
c 
ad
vi
ce
 a
nd
 o
pt
im
is
at
io
n 
of
 c
lin
ic
al
 m
an
ag
em
en
t 
to
 
ac
hi
ev
e 
cl
in
ic
al
 t
ar
ge
ts
. T
he
 p
ro
gr
am
m
e 
ha
d 
sa
m
e 
th
e 
fu
nd
am
en
ta
ls
 a
s 
th
e 
m
ul
ti
di
sc
ip
lin
ar
y 
re
na
l 
cl
in
ic
 b
ut
 h
ad
 w
id
er
 s
co
pe
 a
nd
 w
as
 p
ro
ac
ti
ve
. 
T
he
re
 w
as
 a
 n
am
ed
 n
ur
se
 fo
r 
ea
ch
 p
at
ie
nt
 w
ho
 
co
ul
d 
be
 a
cc
es
se
d 
di
re
ct
ly
 b
y 
te
le
ph
on
e 
or
 fa
ce
-
to
-f
ac
e 
w
it
ho
ut
 n
ee
di
ng
 a
n 
ap
po
in
tm
en
t.
 P
at
ie
nt
s 
re
ce
iv
ed
 p
ro
ac
ti
ve
 in
te
rv
en
ti
on
 fr
om
 t
he
 c
lin
ic
al
 
te
am
 a
t 
a 
fr
eq
ue
nc
y 
di
ct
at
ed
 b
y 
th
e 
pa
ti
en
t’s
 r
is
k 
as
se
ss
m
en
t 
an
d/
or
 b
y 
th
e 
pa
ti
en
ts
 t
he
m
se
lv
es
D
el
iv
er
ed
 b
y 
a 
co
m
m
un
it
y-
ba
se
d 
te
am
 
of
 n
ur
se
s,
 d
ie
ti
ci
an
 a
nd
 
so
ci
al
 w
or
ke
r
N
A
T
ha
na
m
ay
oo
ra
n 
20
05
15
1
R
ev
ie
w
 o
f a
 
pr
os
pe
ct
iv
e 
co
ho
rt
C
K
D
 p
at
ie
nt
s 
w
it
h 
C
rC
l  
<
 6
0 
m
l/m
in
M
ul
ti
di
sc
ip
lin
ar
y 
ne
ph
ro
lo
gy
 c
lin
ic
 
of
 H
al
ifa
x,
 C
an
ad
a 
(t
er
ti
ar
y 
ca
re
 
ho
sp
it
al
)
Pa
ti
en
ts
 w
er
e 
se
en
 a
nn
ua
lly
, e
ve
ry
 6
 m
on
th
s 
or
 e
ve
ry
 3
 m
on
th
s 
ac
co
rd
in
g 
to
 t
he
 le
ve
l o
f 
G
FR
. T
he
 s
er
vi
ce
 w
as
 fr
ee
 o
f c
ha
rg
e 
to
 t
he
 
pa
ti
en
t 
in
cl
ud
in
g 
m
ed
ic
al
, s
ur
gi
ca
l a
nd
 a
nc
ill
ar
y 
co
st
. A
lt
ho
ug
h 
th
er
e 
w
as
 n
o 
pr
ot
oc
ol
 fo
r 
ca
re
, 
co
ns
en
su
s 
w
as
 s
et
 fo
r 
so
m
e 
of
 t
he
 c
lin
ic
al
 
pa
ra
m
et
er
s 
lik
e 
B
P 
co
nt
ro
l, 
us
in
g 
A
C
E 
Is
 a
nd
 
A
R
B
s,
 m
et
ab
ol
ic
 c
on
tr
ol
 o
f c
al
ci
um
, p
ho
sp
ha
te
, 
pa
ra
th
yr
oi
d 
ho
rm
on
e 
an
d 
co
nt
ro
l o
f a
na
em
ia
A
 la
rg
e 
pe
ri
to
ne
al
 d
ia
ly
si
s 
an
d 
ha
em
od
ia
ly
si
s 
pr
og
ra
m
m
e 
w
as
 m
ai
nt
ai
ne
d 
at
 t
hi
s 
ce
nt
re
N
ur
se
s,
 n
ur
se
-
ed
uc
at
or
s,
 s
oc
ia
l 
w
or
ke
rs
, d
ie
ti
ci
an
s 
an
d 
fu
ll 
ti
m
e 
ac
ad
em
ic
 
ne
ph
ro
lo
gi
st
s
N
A
A
C
E 
I, 
an
gi
ot
en
si
n 
co
nv
er
ti
ng
 e
nz
ym
e 
in
hi
bi
to
r, 
A
R
B
, a
ng
io
te
ns
in
 r
ec
ep
to
r 
bl
oc
ke
r;
 B
P,
 b
lo
od
 p
re
ss
ur
e;
 C
K
D
, c
hr
on
ic
 k
id
ne
y 
di
se
as
e;
 C
rC
l, 
cr
ea
ti
ni
ne
 c
le
ar
an
ce
; C
V
D
, c
ar
di
ov
as
cu
la
r 
di
se
as
e;
 G
FR
, g
lo
m
er
ul
ar
 fi
lt
ra
ti
on
 r
at
e;
 N
A
, n
ot
 a
pp
lic
ab
le
, N
R
, n
ot
 r
ep
or
te
d;
 S
C
r, 
se
ru
m
 c
re
at
in
in
e;
 S
IM
O
N
, S
ou
th
am
pt
on
 In
te
gr
at
ed
 M
on
it
or
in
g 
of
 N
ep
hr
ol
og
y.
T
A
B
LE
 1
9 
D
es
cr
ip
tio
n 
of
 m
ul
tid
is
ci
pl
in
ar
y 
ca
re
 (M
D
C
) 
fo
r 
C
K
D
 s
et
tin
gs
 a
nd
 s
er
vi
ce
s 
(c
on
tin
ue
d)
DOI: 10.3310/hta14210 Health Technology Assessment 2010; Vol. 14: No. 21
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
63
scheme, complicated patients and those requiring 
continued care were retained in the hospital 
nephrology clinic.
The other described MDC involved referral from 
primary care to hospital care, or between two 
specialist clinics, in the usual way.143,145,146,151,152,154
Structured care by an individual 
specialty
Apart from nephrologists, CKD management 
has been influenced by the involvement of 
other health-care professionals. Pharmacy 
programmes included structured clinics solely 
led by pharmacists using protocols to manage the 
medication of patients with microalbuminuria and 
nephropathy.148 Pharmacists also operated within 
structured disease management programmes 
implemented by pharmacists and diabetes 
specialists managing diabetic nephropathy 
patients together.149 Joy and colleagues156 
described the support of pharmacists as part of 
a multidisciplinary team for the management of 
CKD patients. Some care programmes were run by 
renal specialist nurses, or renal specialists working 
closely with general nurses.157,158 Two studies 
compared the care given in primary care with 
that of specialists (nephrology and diabetology) 
in Italy.137,138 Care by GPs was also compared with 
virtual clinic management (Table 20).144
Educational intervention
Educational interventions for care in CKD were 
described by some of the studies. Generally, 
two types of educational programme were 
observed: education of general staff and patient 
education.141,142,146,150,153–158 The education 
programmes varied in content and delivery style 
and are detailed further in Table 21.
Description of the key facets of 
the care programmes
Various facets of programmes for CKD 
management have been reported within the 
three types of care model identified. See Table 22 
for a summary of the different elements of the 
programmes.
Patients surveillance
Patient surveillance, including regular clinical 
and laboratory examinations (e.g. BP, weight, 
haemoglobin, calcium, phosphate, other metabolic 
parameters) along with medical review, was the 
most commonly reported element of care within 
all models of care. Patient clinic visits or follow-
up varied from monthly to annually depending 
on the level of kidney function and clinical 
need.142,146,147,151,152 Appointments lasted for 
30–35 minutes143,148 and some included discussion 
of a patient in a multidisciplinary team meeting. 
Harnett and colleagues144 reported so-called 
‘virtual methods’ to conduct this surveillance with a 
patient attending a practice nurse for examinations 
and the results being logged for a remote specialist 
team to review them in the context of that patient’s 
clinical record.147 None of the studies described in 
any detail how patients were selected for inclusion 
in the CKD care model. Most appeared to rely on 
measures of eGFR (or creatinine thresholds), but 
there was rarely a description of why patients were 
originally tested (i.e. clinical need versus screening) 
or whether other factors were used to influence 
selection for further management.
Patient education
Patient education included reviewing pre-specified 
educational topics with patients,142 discussion 
about CKD, dietary restriction, monitoring BP, 
medicine management, lifestyle modification,146,150 
education on dialysis154 and discussion about 
clinical parameters.153 Some CKD management 
programmes developed a guideline, self-care 
manual or performance-based programme for 
patient education with education classes held 
prior to clinics.153 A patient-centred education and 
management approach was reported where renal 
nurses were working along with other specialists 
and primary care teams.157,158
Health-care professional education
Only three papers reported education provided 
to health-care professionals.141,154,156 In two 
studies, primary family physicians were provided 
with educational sessions.141,154 The educational 
intervention to physicians included lectures 
based on interactive theory–practice models and 
discussions (one-to-one or small group discussion 
of real cases led by investigators). Lectures 
included a theory course covering various aspects 
such as basic anatomy and physiology of kidney, 
epidemiology and clinical measures and advanced 
topics such as associated comorbidities, prevention 
and management.
Medicine management
With the aim of optimisation of treatment, most 
of the CKD programmes considered medicine 
management; in particular the use of ACE Is and 
ARBs.145,149 Pharmacist-led structured care models 
included medicine management and optimisation 
of treatment which were based on prescribing 
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recommendations and clinical standards.148 
Medicine management included a full drug history 
and ascertaining patients’ knowledge of their 
medicine treatments.148
Managing/preventing complications
Some of the MDC clinics focused on the 
management and prevention of complications 
associated with CKD.146,149,150,152,154 Education 
on lifestyle and cardiovascular risk factors was 
provided to reduce CVD risk and to delay CKD 
progression.146,149,150 To prevent the development 
of diabetic nephropathy, some care focused on 
screening for microalbuminuria and clinical 
proteinuria.152 Ghossein and colleagues154 
mentioned that a comprehensive renal care 
programme included screening for, and treating, 
the complications of CKD such as anaemia 
and renal osteodystrophy. Additionally, some 
MDCs endeavoured to run structured screening 
programmes (screening for comorbid conditions, 
microalbuminuria or proteinuria, or to identify 
those to prepare for dialysis and transplant).152,154 
The separation of ‘new referral’ assessment from 
follow-up was reported to enable more focused 
clinics and to identify patients where no follow-up 
was required.143
Nutritional advice
Nutritional advice was provided as a part of 
education programmes146,153 or as a separate 
element of more comprehensive care 
models.145,150,154
Social care
A few models of care included a component related 
to social care services.142,145,146,151 Social care workers 
were involved to decrease barriers to care by 
interviewing patients and by direct intervention if 
needed.145 Others stated that social workers were 
also involved in providing education to patients.146
Assessment of effectiveness
Clinical markers
Patients under the care of a MDC were consistently 
reported to have improved clinical surrogates such 
as BP, glycosylated haemoglobin and cholesterol 
when compared with before the start of treatment 
in the MDC (Table 23). Patients under the care of 
the SIMON programme had a significant reduction 
in mean BP after referral.147 Likewise BP was 
improved when patients attended multidisciplinary 
nephrology clinics and redesigned services.143,151 
It was observed that in the redesigned service for 
diabetic nephropathy patients, the mean fall in 
BP was –11/7 mmHg (148/80 mmHg at baseline 
to 137/73 mmHg at follow-up, p < 0.001) and 33% 
achieved a BP target of 125/75 mmHg.143 Moreover, 
patients’ glycosylated haemoglobin and low 
density lipoprotein cholesterol improved and there 
was minimal progression of microalbuminuria 
to diabetic nephropathy, and the proportion 
of patients with proteinuria fell. Similarly, in a 
multidisciplinary nephrology clinic, mean BP fell 
from 151 ± 27/80 ± 13 mmHg at the initial visit to 
135 ± 18/75 ± 11 mmHg at follow-up of 4 years.151
Structured care programmes run by 
pharmacists resulted in clinically and 
statistically significant improvements in mean 
BP (from 150.5 ± 19.3/79.7 ± 10.2 mmHg to 
132.6 ± 15.2/67.8 ± 10.5 mmHg, p < 0.001). 
Similar trends of significant results were observed 
for cholesterol and glycosylated haemoglobin in 
CKD patients.148 Likewise, CKD management by 
collaborative approach between pharmacists and 
diabetes specialists proved to be beneficial with 
improvements in clinical surrogates (BP and low 
density lipoprotein cholesterol) and risk reduction 
of end points compared with those receiving 
usual care.149 Those using educative intervention 
among family physicians have shown clinical 
improvements in BP and kidney function.141
Where comparator groups of patients were 
available, the findings were less consistent.
Curtis and colleagues142 reported patients exposed 
to MDC had clinical benefits including higher 
levels of haemoglobin, albumin and calcium 
at dialysis start than those receiving standard 
care. Minutolo and colleagues137 reported that 
hypertensive patients with CKD under nephrology 
care seemed to have improved BP (21.5% patients 
reached BP target of 130/80 mmHg, 95% CI 
15.6 to 27.4, p < 0.0001) compared with primary 
care (5.8%, 95% CI 2.9 to 8.6). Patients were 2.6 
times less likely to have reached their target BP 
in primary care versus nephrology care (after 
adjustment for age, diabetes and eGFR). However, 
in patients with diabetic renal disease, there was 
little difference in the proportions achieving 
target BP (10–14%), with similarly low levels in 
nephrology, diabetology and primary care.137
Harris and colleagues,145 reporting the only RCT, 
showed no difference in weight, BP or creatinine 
clearance when they compared people managed in 
an intensive MDC management programme with 
those receiving standard care.
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Prescription changes
Statistically significantly higher prescriptions of 
renin–angiotensin aldosterone system (RAAS) 
inhibitor agents were noted.143,147 Prescription rates 
were found to be significantly higher in specialist 
care than in primary care, and the choice of 
medicines differed.137,138 Nephrologists were more 
likely to use dual blockade of RAAS using ACE Is 
and ARBs and were more likely to prescribe loop 
diuretics than either primary care physicians or 
diabeteologists.138 These differences existed after 
accounting for clear differences in case-mix. Use 
of antihypertensives (including RAAS inhibitor 
agents) and cholesterol reducing drugs (statins) 
appeared to increase with the involvement of 
pharmacists and diabetes specialists in CKD 
care.148,149 Prescription of ACE I, in those without 
contradictions, increased from 66% to 100%, while 
that of ARBs (single or in combination) increased 
by 29%.148 Prescriptions for antihypertensive 
agents by physicians who underwent an educative 
intervention were higher than those by physicians 
without educative intervention.141 Harris and 
colleagues,145 however, reported little difference in 
prescribing behaviour between those cared for in 
intensive multidisciplinary case management and 
those receiving standard care.
Long-term outcomes
Long-term outcomes have been reported only for 
MDC models. See Table 24 for outcomes reflecting 
mortality and CKD progression.
Survival or mortality
Hemmelgarn and colleagues146 and Curtis and 
colleagues142 compared MDC with standard care, 
reporting a significant survival advantage for those 
CKD patients attending MDC clinics. A significant 
reduction in the risk of death (adjusted) (HR 
0.50, 95% CI 0.35 to 0.71) was observed in MDC 
patients compared with non-MDC patients by 
Hemmelgarn and colleagues,146 but no difference 
in hospitalisation rates were reported. Similarly, 
Leung and colleagues149 reported on adjusted risk 
reduction for mortality and ESRD (HR 0.40, 95% 
CI 0.23 to 0.68) for MDC compared with usual 
care.
Curtis and colleagues142 noted that incident dialysis 
patients who had received MDC had better survival 
on dialysis than those in standard care. In addition, 
the redesigned nephropathy clinic reported lower 
rates of mortality than two major renal studies: 
RENAAL (Reduction in End points in NIDDM with 
the Angiotensin II Antagonist Losartan) trial and 
IDNT (Irbesartan in Diabetic Nephropathy Trial) 
trial (2.2/100 person-years versus 6.8/100 person-
years and 5.8/100 person-years respectively).143 
However, an RCT of MDC management found 
no significant survival advantage of CKD patients 
within MDC compared with usual care, despite 
heavy costs for various aspects of the MDC 
intervention group.145
CKD progression
Most authors reported that MDC had a positive 
impact on slowing CKD progression (see Table 24). 
In an MDC clinic with an SCS, the median decline 
in GFR slowed significantly from –5.2 (–12.8 to 
–1.9) ml/min/1.73 m2/year before referral to –0.5 
(–3.3 to 2.5) ml/min/1.73 m2/year after referral 
(p < 0.001).147 Others reported that in patients 
with CKD stage 3, GFR decreased at a slower rate 
and those with CKD stages 4 and 5 had stable 
eGFR throughout the 15-month follow-up while 
receiving care within a comprehensive renal clinic 
involving a multidisciplinary team.154 The diabetes 
clinic taking care of diabetic nephropathy patients 
reported lower event rates such as doubling of 
serum creatinine (1.4/100 person-years) and 
ESRD (1.1/100 person-years) after the service 
was redesigned compared with previous trials on 
management of diabetic nephropathy: REENAL 
trial and IDNT trial.143 Leung and colleagues,149 
reported that the rate of renal decline slowed 
in patients with diabetic nephropathy where 
pharmacist and diabetes specialist worked together.
Attitudes of patients/health-care 
providers
The service delivered by joint diabetes and renal 
clinics for the patients with established diabetic 
kidney disease at Eastbourne, UK, has been 
appreciated by patients and was considered to be a 
level of care expected by GPs.152 Joint clinics have 
also been supported by NICE.173
The perception of Canadian nephrologists towards 
MDC-based CKD clinics has been presented in 
one survey.159 More than 90% of nephrologists 
reported that MDC-based CKD clinics were easily 
accessible to them. Regarding decision-making 
on referral to MDC clinics, most (more than 80%) 
of the nephrologists found calculated creatinine 
clearance the most useful method rather than 
depending on estimated months before ESRD. 
Fifty-seven per cent of nephrologists reported that 
they referred patients with a creatinine clearance 
of 20–29 ml/min, while around 30% reported 
earlier referral with creatinine clearance between 
30 and 59 ml/min as the best time for referral. 
Others referred at lower creatinine clearance 
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(10–19 ml/min). The survey also presented 
information about perceptions of the availability 
of multidisciplinary staff. More than 90% of 
nephrologists reported that they had excellent 
access to nurses, dieticians and social workers. 
Around 64% believed that pharmacists were 
comparatively less commonly available. According 
to nephrologists’ opinion, nurses provided 
more information about dialysis to patients than 
about palliative care, prognosis or pre-emptive 
transplant.
Overall, nephrologists (94.5%) believed that 
MDC-based clinics were superior to conventional 
clinics. Most of them (83%) also thought that this 
kind of clinic could be managed by nurses using 
algorithms, thus helping to reduce the burden on 
nephrologists. They were supportive of the value 
of MDC clinics for those with stable and slowly 
progressing CKD but reported that the clinics were 
not sufficiently funded.
Aspirational model of care
Fourteen papers describing aspirations for the care 
of patients with CKD were reviewed.159–172
Two broad categories of aspirations for care were 
described:
• optimal management of CKD patients
• integrated approach for CKD management.
Optimal management
Four papers proposed similar ranges of 
strategies of care for the management of early 
CKD patients that they hoped would lead to 
improved outcomes.160–163 The emphasis was on 
early detection of CKD and associated comorbid 
conditions. The proposals focused mainly on 
the need for delaying CKD progression, and 
preventing or treating complications by using 
timely intervention. Importantly, these papers 
identified the need for precise measures to stratify 
CKD patients into groups that may help to 
predict future risks. Patient education, to increase 
awareness of CKD and risk of comorbidities in 
CKD, was recommended as a part of optimal 
management. Moreover, two papers highlighted 
the importance of having co-ordinated care for the 
management of early CKD.162,164
Authors proposed that implementing the strategy 
of optimal management and early detection of the 
disease may help reduce hospitalisation, morbidity 
and mortality, and eventually help to reduce cost. 
For example, identifying comorbid conditions like 
anaemia and CVD at earlier states, and treating 
them, may reduce the risk of future morbidity and 
mortality. Controlling BP, proteinuria and other 
metabolic parameters may reduce the risk of CKD-
related comorbidities. Authors were proponents 
of the use of ACE Is and ARBs, identifying CKD 
at earlier stages and referring patients to the 
nephrologists to slow CKD progression. The use 
of existing data from patient database systems to 
develop an intervention programme to optimally 
managed CKD patients was suggested.160
Integrated approach for management
Seven papers proposed the advantages 
of collaborative approaches in CKD 
management.164,165,167–172 Involvement of 
multidisciplinary staff (GPs with specialist interest, 
specialist nurses, pharmacists, nutritionists, etc.) 
and co-operation between these staff may aid 
early referral and management. The key role 
of nurses was highlighted as: patient educators, 
care managers communicating between care 
providers and support staff, and following up 
patients to monitor their progression.166–168 Four 
of the papers suggested that patients should be 
managed and evaluated in primary care by skilled 
support staff, with only complex or severe cases 
referred to specialists or nephrologists in secondary 
care.166,168,171,172 Furthermore, they noted the 
importance of care plans being developed based 
on evidence-based practice guidelines. Recognition 
that CKD was a chronic and complex condition 
was found to be useful in supporting collaboration 
and education needs.164 The proponents of an 
integrated approach for management also hoped 
that it would contribute to reducing mortality and 
hospitalisation and delaying progression. Moreover, 
this co-operative care potentially provided a 
mechanism to deliver optimal management of 
CKD at early stages and thus increase quality of 
care and improve quality of life of patients while 
reducing cost.
Similar to the above proposals, A vision for the future 
of renal services, 2002126 also focused on prioritising 
early diagnosis and treatment of those with CKD 
and those who were at risk of developing CKD. 
The authors recommended the need for clinical 
networks as a model of future services provision. 
Details of the network focused on preparation for 
end-stage disease and those with progressive renal 
disease, but did note the need to integrate services 
across disciplines and to deliver a flexible and 
appropriate care for the individual patient’s needs. 
They also noted the need to tackle inequalities, 
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giving attention to the elderly, children, socially 
disadvantaged, ethnic minorities and those with 
comorbidity.126
Key themes from aspirational proposals
Thematic review of the aspiration studies identified 
the following key elements to care:
Strategy for early detection
Early identification of CKD and those who are 
at risk of CKD was seen as critical. Screening 
was discussed in the context of using eGFR and 
albuminuria in diabetes. Screening of higher 
risk group patients (> 65 years of age, any form 
of CVD, diabetes, a family history of CKD, 
hypertension) was noted and development of new 
screening strategies focused on the link between 
CKD and CVD.
Measures for defining at risk groups
Although CKD could be defined in terms of 
serum creatinine or urinary albumin levels, GFR 
estimation was proposed as the most precise 
measure to stratify CKD risk. High risk patients 
such as those with CVD, hypertension and diabetes 
were recognised. Urinary albumin was noted to be 
an important, and independent, risk factor.
Strategies for delaying progression
There was a focus of attention on development and 
implementation of strategies to delay progression. 
The need to determine individualised information 
about a patient’s probability of progression to renal 
end points was a priority. Identifying comorbid 
conditions, with timely intervention to prevent and 
manage these complications, was also considered 
crucial. Authors cited various examples of ‘effective 
drug therapy’: some antihypertensives agents (ACE 
Is or ARBs), antilipaemic agents (statins) to halt 
disease progression, and treating anaemia.
Co-ordinated care
The need for co-ordinated care tailored to the 
patients needs was recognised. Delivery was 
dichotomised between the need for nephrology 
specialist input versus primary care. Vision of 
shared care models utilising multidisciplinary 
skill sets needed high levels of co-ordination, but 
offered a potential way to reduce the burden on 
secondary care while ensuring high-quality patient 
care.
Patient education
It was highlighted that patient participation in 
his or her own care was essential for optimal 
management of chronic diseases. Increasing patient 
awareness of CKD and associated risk factors may 
help reduce the development of irreversible renal 
damages and other complications.
Discussion
Currently, specialist renal care is widely delivered 
through multidisciplinary teams in secondary 
care, and while attention is shifting towards how to 
care for the many people with evidence of CKD, 
the focus remains on the more intensive care 
needs of those with advanced CKD. Integration 
of specialist renal care with primary care was not a 
major feature in the UK, beyond that of referral; 
although at the time of the surveys there was 
evidence that some shared care practices were 
being developed. Since the last survey, CKD was 
introduced into primary care QOF targets and 
CKD care in the UK has been undergoing a period 
of substantial change. In this chapter we sought 
to explore the literature for evidence of other 
models for delivering care to people with CKD who 
did not rely solely on early referral to a specialist 
nephrologist. While a number of models of care 
were described in the literature, disappointingly, 
only one RCT evaluating the effectiveness of 
different care models was identified.145
Three principal models of care were reported:
1. Multidisciplinary clinics – very much developed 
along the lines of those for dialysis patients, but 
generally restricted to secondary care. Only two 
studies reported a primary care-based MDC 
where specialists and primary care practitioners 
worked together to deliver care to people 
with CKD.147,150 These adopted a secondary 
care-led approach, using primary care only 
as a vehicle to obtain routine monitoring and 
referral but with most decision-making driven 
by specialists. In some, the wider determinants 
of health were addressed through support 
from social workers facilitating access to care 
and financial services, and from a range of 
professionals providing health lifestyle advice.
2. Structured care delivered by individual 
specialties – a number of papers reported the 
often protocol driven utilisation of particular 
clinical specialists to deliver components 
of care for people with CKD. The roles of 
pharmacists, nurses, nutritionalists and other 
medical specialists (diabetologists) were all 
described.
3. Educational initiatives – either directed at 
health-care professionals or for the patients 
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and carers. Education was recognised as being 
key in underpinning the delivery of a service, 
although some of the MDCs reported little 
about the value of working together across 
specialties as a method for education of health-
care practitioners.
However, the division, while assisting in 
classification and description of the types of 
intervention, was somewhat artificial in practice 
with an overlap in approaches reported for the 
more comprehensive care packages. Nonetheless, 
a substantial number of the reports described 
services that appeared to adopt a single model 
operating in isolation.
Many of the MDC reports described the separation 
of CKD clinics from other renal services including, 
in some cases, from new referrals. Where reported, 
clinics offered high intensity of care but with low 
throughput of patients; a challenge when trying to 
deliver care for large numbers of patients.
While information technology (IT) systems would 
undoubtedly have supported many of the clinics 
described, the innovative use of IT and virtual 
follow-up through the review of clinical data by 
a specialist, remote from the patient, was also 
reported. The time taken to review these ‘virtual’ 
records was not described and, in the absence of an 
RCT and long-term follow-up, the potential safety 
and effectiveness of this approach could not be 
assessed. Others utilised multidisciplinary meetings 
to discuss patients’ care and management, 
remote from the patient. Again, the time taken to 
undertake this work was not described.
Regardless of the care model adopted or the 
attributes of the model, there was evidence of 
positive effects with regard to clinical markers and 
long-term outcomes from observational studies 
reliant on ‘before and after’ study designs. One 
cohort study comparing MDC to standard care 
did report benefit142 but the only RCT145 found no 
evidence of improvements in clinical parameters, 
long-term survival or renal progression; a lack of 
benefit despite substantial additional cost. In other 
clinical settings, however, intensive and aggressive 
risk factor management has been demonstrated to 
be of clinical benefit in RCTs. The Steno-2 study,174 
in people with diabetes and microalbuminuria, 
randomised people to intensive management of 
their diabetes and cardiovascular risk factors versus 
standard best practice. The clinical setting was 
the same, only the interventions differed between 
groups. Here, patients receiving intensive diabetes 
management had better cardiovascular (HR 0.47 
for CVD, 95% CI 0.24 to 0.73) and renal outcomes 
(HR 0.39 for nephropathy, 95% CI 0.17 to 0.87) 
after follow-up of 7.8 years.
So, despite universally promising results from 
observational data and evaluations, the only clinical 
trial has failed to demonstrate clinical benefit.
All of the models that provided some level of 
evaluation had methodological issues. Many of 
the studies were descriptive, relying on individual 
patient clinical findings at referral versus after 
care for a given period. If referral reflected the 
first recognition and proactive management of 
the person’s CKD, then improvements in various 
clinical parameters might be expected regardless 
of where or how that care was given. Where 
evaluations of a new service were conducted, most 
relied on evidence of change in care or clinical 
parameters compared with before entry into the 
care programme. Without a comparator group, it is 
difficult to interpret the changes observed in both 
these study designs. Regression to the mean may 
account for some of the changes observed. The 
effect of the model of care on health outcomes is 
difficult to assess.
Evaluations against a control group provided this 
comparison but, where made retrospectively, were 
vulnerable to bias and gave little detail of the 
care received by patients. Harris and colleagues145 
reported the only RCT of a nephrology case 
management intervention compared with standard 
care (general practice plus referral to specialist 
standard renal care as per normal) and, unlike the 
positive findings of other studies, they found no 
difference in the outcomes of patients receiving 
MDC care versus standard care. Despite being a 
reasonable quality RCT, with very similar groups 
at baseline, the two care models ran in the same 
hospital outpatient unit. Staff were independent 
but the opportunity for ‘contamination’ between 
the two groups was high. Indeed, the number of 
visits to the unit was similar in the intervention and 
standard care arms.
The review of aspirational literature identified a 
dichotomy in thinking about CKD management 
perhaps not truly reflected in the evaluation 
studies to date. Like the evaluation literature, 
there was a strong sense from many authors 
describing a vision for future services of the need 
for specialist nephrology input at the earliest 
opportunity in order to minimise the risk of renal 
disease progression. Others, however, described 
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an approach more consistent with chronic disease 
management and the recognition of the need 
for a collaborative approach across disciplines; 
utilising the skills to deliver enhanced care to 
large numbers of people with the intensity and 
skill mix tailored to suit the individual patient’s 
clinical requirements. Notably, this literature 
rarely identified the uncertainty regarding what 
interventions work, or the lack of good quality 
evaluations or trials. The authors consistently 
reiterated beliefs and assumptions.
In this chapter we have drawn together a body of 
literature describing a range of potential models 
of care for people with CKD, beyond that of early 
referral to nephrologists. We have noted a number 
of limitations. The diversity makes this literature 
difficult to identify when searching both in finding 
search terms sufficiently broad as to find the range 
of care models but also when seeking publications. 
We have restricted searches to published literature. 
Additional descriptive literature is likely to exist 
in grey literature sources and this will have been 
omitted here. We are, however, confident that 
any trials would have appeared in published 
form. Data extraction was undertaken by a single 
reviewer using a piloted template and checked by 
a second reviewer. The themes reported here were 
developed iteratively by one reviewer as the data 
were analysed and checked by a second reviewer.
Conclusions
A range of different models or components of 
care were reported in the literature and there was 
some evidence of an impact on surrogate end 
points such as BP control and renal progression. 
Authors reported aspects of care that fitted well 
within the chronic disease care model: the need 
for multidisciplinary teams; good communication 
between clinical staff involved in care and with 
patients; the role of self-care and education; 
and the utilisation of other allied health-care 
professionals to deliver aspects of care. However, 
the literature also identified the challenge of 
polarisation of attitudes towards care: specialist 
care delivered by early referral to specialists 
in kidney disease versus a shared care and 
collaboration approach based on increasing the 
skills of a wider pool of health-care professionals. 
While tackling CKD in the context of diabetes 
and diabetes services was discussed, we did not 
identify literature reporting on approaches to 
tackle CKD as part of a group of conditions that 
increase the risk of CVD. There was once again a 
striking lack of high-quality trials of effectiveness. 
The components of the models of care reported 
here provide a useful source of information about 
the feasibility of delivering aspects of care; pilots 
of potential models. The only controlled trial 
reported compared an MDC clinic with standard 
FIGURE 7 Pyramid model of population health management for long-term conditions. [Adapted from Department of Health (2004) 
Improving Chronic Disease Management.]177
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case management care and found little evidence 
of improvements in patient care.145 This perhaps 
reflects the fact that only a minority of patients 
have highly complex needs that gain substantial 
benefits from the very structured input of formal 
case management from an MDC (Figure 7). For 
many, a more straightforward care package may be 
optimal and, for most, education and supported 
self-care may be all that is required. Indeed, much 
of this care and education would be generic to a 
number of chronic conditions (diabetes, CVD and 
hypertension), and a combined approach that 
acknowledges this overlap could be trialled. Such 
an approach could then dovetail with screening 
programmes that seek to identify people at 
increased cardiovascular risk.175,176 The challenge, 
then, is to be able to identify who requires which 
level of care and to ensure that people can move 
between levels to access the most appropriate 
care for them at the appropriate time. The 
identification of the relatively small, but important, 
group of people with rapidly worsening kidney 
function, acute kidney injury and specific renal 
diagnoses that are both treatable and reversible will 
also be critical to the success of any intervention.
The literature described here could be viewed as 
feasibility studies, and any future trial of models 
for the management of CKD should draw on these 
approaches. It seems likely that a successful model 
of care will draw on a range of health-care skills 
and disciplines. High-quality RCTs are needed to 
assess the effectiveness of any such intervention.
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The aim of this chapter is to assess the existing evidence relating to the long-term cost-
effectiveness of early referral strategies for patients 
with markers of renal disease, and to develop a new 
economic model to assess the cost-effectiveness 
of early referral strategies from the perspective 
of the NHS. The chapter focuses on the cost-
effectiveness of interventions in individuals with 
non-diabetic CKD, as formal care pathways are 
already established for individuals with diabetes 
and diabetic nephropathy.
Review cost-effectiveness 
studies
Systematic searches of the literature revealed no 
studies that directly matched our inclusion criteria. 
Two studies were identified that assessed the cost-
effectiveness of screening for proteinuria178,179 
and one study assessed the cost-effectiveness of 
nephrology referral for patients with late stage 
4 CKD.180 The findings of these studies are 
summarised briefly below.
McLaughlin and colleagues180 developed a 
Markov model assessing the cost per life-year of 
nephrology referral for patients with a creatinine 
clearance rate of 20 ml/min (equivalent to late 
stage 4 CKD) compared with nephrology referral 
upon development of uraemia. The analysis 
was conducted from the perspective of the 
Canadian health-care provider, over a 5-year time 
horizon. Applying rates of renal function decline 
of 5.6 ml/min/year and 7.7 ml/min/year in the 
referral and control arms respectively (using data 
obtained from Canadian cohort studies), the model 
predicted that earlier referral would increase 
survival and life-years free of dialysis, and be cost 
saving from a health service provider’s perspective. 
This was based on an effect estimate obtained 
from a prospective study that showed education 
could increase dialysis free survival by an average 
of 4.6 months in patients with deteriorating renal 
function.181 The model took into consideration 
ACM and total costs of care, but it is unclear 
whether the model captured potential differences 
in costs associated with cardiovascular morbidity 
between the two groups.
Boulware and colleagues179 conducted a modelling 
study to assess the cost-effectiveness of screening 
for proteinuria using dipstick urinalysis in adults 
with neither hypertension nor diabetes, and in 
adults with hypertension. The authors developed a 
Markov model that tracked renal function decline 
in individuals with proteinuria identified through 
screening, compared with renal function decline 
in individuals with undetected proteinuria. Those 
identified through screening were assumed to 
be treated with ACE Is which slowed progression 
of renal insufficiency by 30% and reduced ACM 
by 23%; the RR reductions were taken from a 
systematic review of RCTs. The study concluded 
that screening for proteinuria would not be cost-
effective in individuals with neither hypertension 
nor diabetes, but would be cost-effective in 
individuals with hypertension [incremental cost-
effectiveness ratio (ICER): US$18,621 per quality-
adjusted life-year (QALY) (£11,232/QALY)]. 
However, the model did not appear to consider 
cost savings or utility gains associated with the 
prevention of cardiovascular morbidity.
Atthobari and colleagues178 subsequently conducted 
a cost-effectiveness analysis of screening for 
albuminuria that did take into consideration the 
effects of ACE Is on cardiovascular events. The 
economic evaluation was based on data from the 
Prevention of Renal and Vascular Endstage Disease 
Intervention Trial (PREVEND IT); a study that 
assessed the effect of fosinopril (an ACE I) on the 
incidence of cardiovascular events in individuals 
with albuminuria (> 15 mg/day), normal BP 
(< 160/100 mmHg) and normal cholesterol.182 
The study considered the costs of screening for 
albuminuria and treating identified cases with 
fosinopril, and the hospital costs associated with 
CVD events over a follow-up period of 46 months. 
Based on a non-significant risk reduction for CVD 
events associated with fosinopril (HR 0.87, 95% CI 
0.49 to 1.57), the authors estimated that screening 
for albuminuria would cost €16,700 (£14,671) 
per life-year gained. Using bootstrap resampling 
to assess uncertainty, the authors estimated a 59% 
chance of the ICER falling below a willingness-to-
pay threshold of €20,000 (£17,570) per life-year 
gained.
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In addition to the above studies assessing cost-
effectiveness of screening for proteinuria, a number 
of studies have assessed the cost-effectiveness of 
using ACE Is and ARBs in individuals with renal 
insufficiency. Most of these studies have been 
carried out for individuals with diabetes, and have 
found the use of these medications to be cost saving 
or highly cost-effective.183–187 However, a few studies 
have also looked at the cost-effectiveness of ACE Is 
in individuals with non-diabetic nephropathies and 
have reported similar findings.188,189 These studies 
demonstrate the potential for non-diabetic CKD 
management to be improved.
A report to Kidney Health Australia, identified 
through searches of grey literature, also suggests 
that improved treatment for individuals with 
hypertension, proteinuria, and or diabetes may 
offer a cost-effective option for preventing the 
incidence of CKD and ESRD.190 This study 
made use of Markov models to assess the cost-
effectiveness of various improved treatment and 
screening strategies for hypertension, proteinuria 
and diabetes. The authors concluded that intensive 
treatment for individuals with hypertension 
(without diabetes) would cost ~A$15,589 (£8247) 
per QALY gained, compared with standard 
management. They also suggest that screening 
for hypertension, proteinuria and diabetes 
would offer a cost-effective approach to reducing 
morbidity and mortality associated with CKD. 
These cost-effectiveness estimates were modelled 
using data from trials of individual clinical 
interventions (addition of ACE Is for diabetics, 
intensive glycaemic control for diabetics, intensive 
management for individuals with hypertension, 
and ACE Is for those with proteinuria) and do not 
explicitly imply the involvement of early referral to 
a nephrologist.
In addition to the above economic evaluations, a 
number of costs of illness studies were identified 
through our literature searches. These studies 
have been reviewed by Khan and Amedia.191 
Most were based on the retrospective analysis of 
insurance claims of individuals with CKD in the 
USA. A consistent finding was that health-care 
expenditures increase markedly through the stages 
of CKD to ESRD – mainly as a result of higher 
rates of hospitalisations due to comorbidities. The 
costs peak upon transition to ESRD requiring the 
initiation of RRT. This pattern of expenditure 
demonstrates the potential for early interventions 
that slow CKD progression and reduce the 
incidence of cardiovascular events.
Economic modelling
Model structure
A Markov cohort model was developed to represent 
the natural history of CKD using treeage pro 2008 
(Figure 8). Direct health service costs under current 
practice were then incorporated into the model. 
Following this, alternative early referral strategies 
were superimposed on top of the baseline model, 
and relative costs and consequences were assessed.
The states of the model are based on the stages of 
CKD as defined by the KDOQI,20 although stages 
1 and 2 were combined to form a single state 
(eGFR ≥ 60 ml/min/1.73 m2) with microalbuminuria 
or overt proteinuria used as the defining marker of 
kidney damage, and stage 3 was separated into two 
states: CKD 3a (eGFR 45–59 ml/min/1.73 m2) and 
CKD 3b (eGFR 30–44 ml/min/1.73 m2).
In addition to the core CKD states described 
above, further states were defined to keep track of 
comorbidities known to influence CKD progression 
and/or the incidence of cardiovascular events; 
ACR 30–299 mg/g, ACR ≥ 300 mg/g and prevalent 
CVD. States were also defined to keep track of 
cardiovascular mortality and mortality from other 
causes.
Cohort simulation was used to analyse the model, 
based on annual transition and event probabilities 
estimated from the literature. Within each cycle 
of the model, proportions could die from other 
causes, experience fatal cardiovascular events, 
experience non-fatal cardiovascular events and 
develop ACR 30–299 mg/g and ACR ≥ 300 mg/g. A 
representation of the model structure is presented 
in Figure 8. Details of the model cohort, transition 
probabilities, and incorporated costs are described 
below. In developing the natural history model 
we selected the most appropriate studies from 
the natural history review (see Chapter 3), where 
quality was deemed to be adequate and reporting 
allowed the relevant variables to be extracted.
Cohort details
The starting point for the analysis was taken as 
a cohort of individuals identified as having CKD 
in a primary care setting, but as yet unknown to 
nephrology services. People with diabetes were 
excluded from the analysis, as in the UK they 
already receive annual checks for kidney disease, 
have a structured care programme and are more 
likely to be on appropriate treatments than 
individuals with CKD without diabetes.
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FIGURE 8 Representation of the Markov model structure. As well as transiting down through the CKD stages, individuals can transit 
across the comorbidity states as they develop microalbuminuria, proteinuria and CVD. Individuals in all states can die from CVD or other 
causes in any cycle of the model. Not all of the possible transitions are marked on the diagram (individuals with stage 3b and stage 4 
CKD can also transit to microalbuminuria, proteinuria and CVD states).
As we wanted to model cardiovascular events and 
CKD progression according to patient history, i.e. 
levels of urine albumin/protein and CVD status, we 
attempted to identify demographic and CVD risk 
profile data for cohorts stratified by these variables.
In order to build up a picture of the demographic/
risk characteristics for the cohort strata of interest, 
we used a UK study reporting demographic 
information and cardiovascular risk factors for 
11,731 individuals with reduced eGFR, collected 
as part of routine practice from 17 primary 
care practices across Kent, Surrey and Greater 
Manchester (Table 25) in the UK.192 This study 
also reported proportions with diabetes and 
pre-existing CVD. In addition we assumed that 
32% of the cohort would have an ACR ≥ 30 mg/g, 
as reported for a US cohort identified through 
population screening,193 and that the mean 
cholesterol–high-density lipoprotein ratio would be 
5.1.194
We then stratified the original cohort by ACR 
level (< 30 mg/g; ≥ 30 mg/g), pre-existing CVD 
(yes; no) and diabetes status (yes; no) using 
adjustment factors estimated from a number of 
studies where individuals with CKD had been 
cross-classified by these variables (Table 26). For 
example, when stratifying the cohort by ACR level, 
the proportion of people with hypertension was 
calibrated to be 1.34 times higher in the 31.8% 
with an ACR ≥ 30 mg/g than in the 68.2% with an 
ACR < 30 mg/g.
Further to the adjustments outlined in Table 26, 
it was assumed that systolic BP would be 5 mmHg 
higher, and the total cholesterol/high density 
lipoprotein ratio 0.2 units higher in individuals 
with an ACR ≥ 30 mg/g, CVD or both.195,196 Finally, 
in removing people with diabetes from each of the 
strata, adjustments were made to reflect the fact 
that BMI tends to be higher in these individuals.197 
The estimated cohort profiles for the four strata of 
interest are presented in Table 27.
Transition probabilities
CVD risk estimation
Annual cardiovascular event risks for the different 
disease states were built up through a staged 
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TABLE 25 Demographics, cardiovascular risk factors, and comorbidities in a cohort with eGFR 15–59 ml/min/1.73m2
n = 11,731 Proportion
Demographics
Male 3949 0.337
Female 7782 0.663
Characteristics
Age (mean) years 72
BMI (mean) kg/m2 27.48
SBP (mean) mmHg 139.71
Comorbidities
Diabetes 1568 0.134
Hypertension 8839 0.753
Treated hypertension 5739 0.649
All CVD (IHD, PVD, HF, cerebrovascular disease) 3691 0.315
BMI, body mass index; CVD, cardiovascular disease; HF, heart failure; IHD, ischaemic heart disease; PVD, peripheral 
vascular disease; SBP, systolic blood pressure.
TABLE 26 Factors used to adjust cohort characteristics based on reported differences between subgroups defined by the 
presence/absence of comorbidities in people with eGFR 15–59 ml/min/1.73 m2
Comorbidity
With 
comorbidity
Without 
comorbidity RR ratio Source
ACR ≥ 30 mg/g
Hypertension (%) 78.3 58.3 1.343 Foster 2007195
Diabetes (%) 34.9 9.9 3.525 Foster 2007195
CVD (%) 38.6 16 2.413 Foster 2007195
% male 63.9 47.2 1.354 Foster 2007195
Prevalent CVD
Hypertension (%) 84.3 62.1 1.357 Weiner 2006196
Diabetes 24.2 13.9 1.741 Weiner 2006196
% male 49.9 33 1.512 Weiner 2006196
Diabetes
Mean systolic BP (mmHg) 146 144 1.014 Gerstein 2000198
Hypertension (%) 91.5 89.3 1.025 Lorber 2006197
Mean BMI 31.2 27.6 1.130 Lorber 2006197
ACR, albumin–creatinine ratio; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; RR, relative 
risk.
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TABLE 27 Estimated demographic and risk profiles for people with reduced eGFR stratified by albuminuria status and prevalent CVD
eGFR 15–59 ml/min/1.73 m2
ACR < 30 mg/g 
with no CVD
ACR < 30 mg/g 
with CVD
ACR ≥ 30 mg/g 
with no CVD
ACR ≥ 30 mg/g  
with CVD
Demographics
Male (%) 0.272 0.412 0.323 0.489
Female (%) 0.728 0.588 0.677 0.511
Age (mean) years 72 72 72 72
Risk characteristics
BMI (mean) kg/m2 27.0 27.0 27.0 27.0
SBP (mean) mmHg 137.4 142.4 142.4 142.4
Cholesterol–HDL ratio 5.0 5.2 5.2 5.2
Comorbidities (%)
Hypertension 62.9 85.5 81.5 100.
Treated hypertension 40.8 55.5 52.9 64.9
Annual CVD event risk from 
QRISK2
3.0 3.5 3.3 3.6
ACR, albumin–creatinine ratio; BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular 
filtration rate; HDL, high-density lipoprotein; SBP, systolic blood pressure.
approach. Annual base risks were first estimated 
for each cohort stratum using the demographic/
risk profiles in Table 27 and the QRISK2 (ClinRisk 
Ltd, University of Nottingham, UK) web-based risk 
calculator.199 This is based on a CVD risk algorithm 
which has been developed and validated for the 
general population of England and Wales.200 
Adjustments were made for gender and the 
proportion of people with hypertension within each 
stratum. These risk estimates reflect the average 
annual probabilities of cardiovascular events in 
cohorts with these risk profiles, without CKD or 
pre-existing CVD. Included in the definition of 
CVD events are coronary heart disease (angina 
and myocardial infarction), stroke and transient 
ischaemic attacks. Although there is likely to be a 
tendency for those with an ACR ≥ 30 mg/g or with 
CVD to be older than those with CKD alone, we 
assumed a constant age of 72 years across the strata 
when calculating base risks for incorporation in the 
model. This is because Markov models have to be 
analysed for cohorts of a single age. In addition, 
the effect of increasing age on cardiovascular 
events was incorporated in the model using an HR 
for increasing age (see below).
Following estimation of the base risks, we estimated 
annual probabilities of CVD events for each disease 
state by multiplying the base risks by RRs and/
or HRs for CVD events associated with reduced 
eGFR, ACR 30–299 mg/g, ACR ≥ 300 mg/g and 
pre-existing CVD (Table 28). The RRs associated 
with reduced eGFR, ACR 30–299 mg/g and 
ACR ≥ 300 mg/g were obtained from a study based 
on data from NHANES III.84 This study reported 
RRs for cardiovascular mortality by eGFR category 
(15–59 ml/min/1.73 m2, 60–89 ml/min/1.73 m2 and 
≥ 90 ml/min/1.73 m2) and ACR levels (< 30 mg/g, 
30–299 mg/g and ≥ 300 mg/g). We assume that the 
RRs for any CVD event (fatal and non-fatal) would 
be similar. The RRs were adjusted for all the factors 
in Table 27 used to generate the base risks.
To estimate the increased risk of cardiovascular 
events in people with pre-existing CVD, we used 
an adjusted HR associated with prevalent CVD 
based on data reported by Parikh and colleagues.194 
We estimated the HR inferred by existing CVD in 
people with CKD by dividing the HR associated 
with having CKD and CVD by the HR associated 
with having CKD without CVD.
In order to incorporate the increased probability 
of cardiovascular events with increasing age, we 
incorporated an HR for CVD events associated with 
a 10-year increase in age.196 The HR was adjusted 
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TABLE 28 Adjusted HRs and RRs used to estimate risks of cardiovascular events for each discrete morbidity state in the model
Morbidity/comorbidity HR or RR 95% CI Source
CKD 1 and 2 (ACR 30–299 mg/g) 2.19 1.45 to 3.29 Astor 200884
CKD 1 and 2 (ACR ≥ 300 mg/g) 3.40 0.99 to 8.28 Astor 200884
CKD 3–4 (ACR < 30 mg/g) 2.36 1.67 to 3.34 Astor 200884
CKD 3–4 (ACR 30–299 mg/g) 3.01 2.04 to 4.42 Astor 200884
CKD 3–4 (ACR ≥ 300 mg/g) 4.35 2.39 to 7.90 Astor 200884
Pre-existing CVD (HR) 1.38 Parikh 2008194
HR for 10-year increase in age 1.57 1.46 to 1.69 Weiner 2006196
ACR, albumin–creatinine ratio; CI, confidence interval; CKD, chronic kidney disease; CVD, cardiovascular disease; HR, 
hazard ratio; RR, relative risk.
TABLE 29 Annual CVD event risk by CKD stage and comorbidity 
CKD stage
Annual CVD event risks
CKD
CKD with 
ACR  
30–299 mg/g
CKD with 
ACR ≥ 300 mg/g
CKD 
with 
CVD
CKD with ACR 
30–299 mg/g 
and CVD
CKD with 
ACR ≥ 300 mg/g 
and CVD
Stage 1 and 2 0.073 0.113 0.109 0.169
Stage 3a 0.071 0.100 0.145 0.112 0.150 0.216
Stage 3b 0.071 0.100 0.145 0.112 0.150 0.216
Stage 4 0.071 0.100 0.145 0.112 0.150 0.216
ACR, albumin–creatinine ratio; CKD, chronic kidney disease; CVD, cardiovascular disease.
for pre-existing CVD and CKD and other classical 
risk factors.
When using HRs to estimate annual event 
probabilities, base risks were converted to average 
rates before being multiplied by HRs, and then 
converted back into risks (probabilities). The 
resultant annual CVD event risks for each disease 
state in the model are reported in Table 29.
The risk estimates reported in Table 29 represent 
approximations of the annual risk of experiencing 
any CVD event (fatal and non-fatal myocardial 
infarction, angina, fatal and non-fatal stroke, and 
transient ischaemic attacks). We assume that fixed 
proportions of people experiencing CVD events 
would die as a result within the year of the event. 
Proportions of 25% and 50% were selected for CVD 
events occurring in those with CKD stage 3a, and 
CKD stages 3b and 4 respectively in order that 
the model predicted cumulative cardiovascular 
mortality in line with the different CVD mortality 
rates observed for these subgroups in similar 
cohorts32,194,196 (see Model validation). Given the 
great uncertainty surrounding these assumptions, 
we subjected them to extensive sensitivity analysis. 
For purposes of costing, 33.5% of non-fatal events 
were assumed to be major (myocardial infarction or 
stroke) and 66.5% of non-fatal events were assumed 
to be non-major (angina, transient ischaemic 
attacks) – based loosely on numbers of non-fatal 
major and other CVD events reported in the Heart 
Protection Study.201 Again, these assumptions were 
subjected to sensitivity analysis.
Chronic kidney disease progression
In order to generate annual transition probabilities 
for CKD stage progression, we used a data set of 
all individuals with a recorded eGFR (calculated 
from recorded serum creatinine results) extracted 
from the Primary Care Clinical Informatics Unit 
(PCCIU) research database for another study.39 The 
PCCIU research database comprises patient data 
from 320 Scottish primary care practices (~1.8 
million patients). This represents 38% of Scottish 
practices and has been shown to be representative 
of the Scottish population. We simulated CKD 
progression over a 5-year period using reported 
rates of eGFR decline by level of urine albumin/
protein at baseline, and calculated the average 
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proportion of individuals that would be expected 
to transit annually from each CKD state to the next 
state. In the first instance we applied annual rates 
of eGFR decline of –2.5 ml/min/year for people 
with a normal ACR, –3.5 ml/min/year for people 
with microalbuminuria and –5.5 ml/min/year for 
people with proteinuria as reported in the MDRD 
study.202 However, application of the resultant CKD 
transition probabilities resulted in estimates of 
cumulative ESRD incidence significantly higher 
than the rates reported for general CKD cohorts in 
the literature. We therefore proportionally reduced 
these rates until they gave estimates of ESRD 
close to the cumulative 10-year incidence of ESRD 
observed in the study by Eriksen and Ingebretsen.96 
This study consisted mainly of individuals with 
early stage 3 disease (eGFR 45–59 ml/min/1.73 m2) 
and so probably underestimated the incidence 
of CKD in our cohort. The resultant transition 
probabilities are displayed in Table 30. We assumed 
that individuals in the cohort had established 
CKD and so, by definition, could not regress to 
less severe CKD states. It was also assumed that 
individuals could progress a maximum of one CKD 
stage per year.
Albumin–creatinine ratio
Individuals in the cohort were allowed to develop 
ACR 30–299 mg/g or ACR ≥ 300 mg/g over the 
course of the simulation. As we could find no 
evidence on the rate at which people with a low 
eGFR develop these complications, we used the 
rates reported for people with diabetes in the 
base-case analysis; 2% (95% CI 1.9 to 2.2) per year 
for development of ACR 30–299 mg/g, and 2.8% 
(95% CI 2.5 to 3.2) per year for development of 
ACR ≥ 300 mg/g from ACR 30–299 mg/g.203
Mortality from other cause
In each cycle of the model, individuals experience 
an age- and sex-adjusted probability of dying 
from causes other than CVD or ESRD. These 
probabilities were estimated by removing deaths 
due to CVD and renal disease from the data used 
to derive the interim life-tables published by the 
UK Office for National Statistics.204,205
Utilities
A recent review of the literature77 identified 
only one study reporting utility values (based on 
community preferences) for the full range of CKD 
TABLE 30 CKD state transition probabilities by level of urine albumin/protein
Reduced eGFR alone
CKD 1 and 2 CKD 3a CKD 3b CKD 4 CKD 5
CKD 1 and 2
CKD 3a 0 0.927 0.073 0 0
CKD 3b 0 0 0.952 0.048 0
CKD 4 0 0 0 0.966 0.034
Reduced eGFR with ACR 30–299 mg/g
CKD 1 and 2 CKD 3a CKD 3b CKD 4 CKD 5
CKD 1 and 2 0.930 0.070 0 0 0
CKD 3a 0 0.895 0.105 0 0
CKD 3b 0 0 0.931 0.069
CKD 4 0 0 0 0.950 0.050
Reduced eGFR with ACR ≥ 300 mg/g
CKD 1 and 2 CKD 3a CKD 3b CKD 4 CKD 5
CKD 1 and 2 0.880 0.120 0 0 0
CKD 3a 0 0.833 0.167 0 0
CKD 3b 0 0 0.882 0.118 0
CKD 4 0 0 0 0.911 0.089
ACR, albumin–creatinine ratio; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.
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states (stages 1 and 2 through to ESRD pre and 
post dialysis). This US study used HUI-3 to assign 
utility scores to 269 patients spread across the CKD 
stages.78 Unfortunately this study did not report 
utility scores by cohort strata (microalbuminuria, 
proteinuria and CVD), so we had to apply the 
same utility scores to CKD stages regardless of 
complication/comorbidity status. As a result our 
model may underestimate QALY gains attributable 
to the prevention of non-fatal CVD events.
Resource use and costs
Prior to assessing the incremental cost of early 
referral strategies, it was first important to establish 
the level of care that people with reduced eGFR, 
identifiable through primary care registers, 
currently receive in primary care. Following the 
development of standard resource use profiles, we 
estimated the incremental cost of implementing 
formal referral strategies, at various eGFR and 
ACR cut-offs, to an SCS described by Jones and 
colleagues147 and described in Models of care.
Patients referred to a specialist either received 
care from nephrology outpatient clinics, or if 
considered stable, were referred back to primary 
care where they received regular clinical reviews 
from their GP, which were then appraised remotely 
by nephrologists. This intervention was selected for 
the model as it was the best described intervention 
identified in Models of care which incorporates 
some element of ‘early referral’. There was also 
some evidence that can deliver a change in 
outcomes.
The baseline scenario against which all referral 
strategies are assessed is formal referral to, and 
hospital-based care under, a nephrologist upon 
transit to stage 5 CKD (referred to as standard 
practice from here on). All unit costs used in the 
analysis are presented in Table 31. Table 32 presents 
estimated resource use and total costs by CKD stage 
and comorbidity status, pre referral.
Table 33 shows estimated resource use and costs 
by CKD stage and comorbidity status, after 
implementation of the referral intervention. All 
costs are presented in 2006–7 prices.
Standard practice
In order to come up with estimates of annual 
resource use and costs of referral by stage 
of CKD and level of comorbidity (CVD and 
ACR > 30 mg/g), we used a combination of 
published data and assumptions based on expert 
opinion.
One of the main sources of current resource use 
data for unreferred CKD was the study by Stevens 
and colleagues,192 which reported hypertension 
rates and antihypertensive medication use by 
stage of CKD for a retrospective sample of 11,731 
patients with an eGFR below 60 ml/min/1.73 m2. 
The cohort was identified, using computerised 
records, from patients across 17 primary practices 
in England, who had a valid serum creatinine test 
between 1998 and 2003. The cohort was largely 
unknown to nephrology services.
Primary care resource use and medication costs 
were estimated by CKD stage for the four cohort 
strata described in Table 27. We based our costing, 
as far as possible, on resource use data reported by 
Stevens and colleagues.192 However, as this study 
relied on data collected between 1998 and 2003, 
we also attempted to update the initial costing to 
reflect possible increases in the use of resources 
for these individuals in recent years. The initial 
estimates were used in the base-case analysis.
Consultation costs
Stevens and colleagues192 reported the proportion 
of people by reduced eGFR categories (stage 
3a, stage 3b and stage 4 ml/min/1.73 m2) on 
hypertensive medication. We assumed all people 
on hypertensive medication192 would undergo on 
average four primary care consultations per year – 
the mean number of primary care visits reported 
for people with hypertension enrolled in an RCT 
of hypertension self-monitoring.206 Three of these 
visits were costed as consultations with a practice 
nurse, and one was costed as a consultation with a 
GP. For those people without hypertension, or with 
untreated hypertension, we assumed one routine 
visit to the GP per year, unless they had comorbid 
CVD, in which case we assumed four GP visits per 
year.
Medication costs
The following data, reported by Stevens and 
colleagues,192 were used to build up a picture 
of annual medication consumption and costs 
by CKD stage and comorbidity status: the 
proportion of people with hypertension receiving 
any hypertensive medication; the proportion of 
people on hypertensive medication receiving ACE 
Is or ARBs; the mean number of hypertensive 
medications prescribed per patient with treated 
hypertension; and the proportion of patients 
with comorbid CVD receiving ACE Is or ARBs, 
antiplatelet agents, and lipid lowering agents. 
We also assumed that the level of hypertensive 
medication use would be 10 percentage points 
higher in those with comorbid CVD. As Stevens 
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and colleagues192 did not report the proportion 
of people without CVD on statins and antiplatelet 
agents, we assumed that 50% of people without 
CVD receiving hypertensive treatment would also 
receive these medications (based on expert opinion 
of individuals within the research team).
For medication use under nephrology care, we 
assumed that 90% of all people with hypertension, 
an ACR > 30 mg/g or comorbid CVD would receive 
an ACE I.
The annual cost of being on different types 
of medication was estimated using unit prices 
from the British National Formulary, for a range 
of generic and non-generic drugs in each drug 
category (ACE Is/ARBs, other antihypertensive 
medications, statins, antiplatelet agents). The unit 
costs presented in Table 7 represent the average 
annual costs of being on any drug within each of 
the specific categories.
Total health service costs
The unit cost information in Table 31 was applied 
to the resource use information in Table 32 
(proportions using medications and mean numbers 
of consultation for the different subgroups) to 
derive total health service costs by CKD stage 
and comorbidity status (see Table 32). For CKD 
stages 1 and 2, we assumed the same level of 
resource use as for people with stage 3 CKD with 
an ACR > 30 mg/g. We assumed that upon transit 
to stage 5 CKD, prior to initiation of dialysis, 
individuals incur the average cost of those with 
stage 4 CKD under hospital nephrology care. For 
those with stage 5 CKD on dialysis, we applied 
published UK estimates of the annual cost of 
different modes of dialysis,207 weighted according to 
the proportions of people on these different modes 
as detailed in the Renal Registry Report (2008).7 
Data from the Aberdeen nephrology clinic suggest 
that 40% of surviving patients will commence 
dialysis within a year of transiting to stage 5. For 
subsequent years, we assumed the percentage of 
surviving patients on dialysis increased to 80%, with 
the remaining 20% managed conservatively. Costs 
associated with transplantation were not factored 
in as it was assumed that transplant rates would be 
low in the aging cohort considered in the model.
In attempting to update the health service costs 
under current practice, to reflect possible increases 
in certain types of recourse use, we increased 
the proportion of individuals on hypertensive 
medications, ACE Is and statins by 10%.
Early referral strategy
In estimating the costs of a formal referral strategy 
for people with reduced eGFR on GP registers, 
we followed the description of the SIMON 
programme, as reported by Jones and colleagues.147
In this shared primary and secondary care 
nephrology scheme, people with reduced eGFR 
were first referred to nephrologist for assessment. 
Those considered to be stable and uncomplicated 
were then managed under an SCS where they 
were monitored by nephrologists through clinical 
and biochemical reviews recorded in primary 
care. Those considered to be unstable and/
or complicated were managed under hospital 
outpatient care, but could be referred to shared 
care at a later date should their condition stabilise.
The scheme required an administrative system 
where patient records and reviews were stored 
on a central database. For those under shared 
care, administrators sent out blood and urine test 
forms every 6–12 months, depending on clinical 
condition, and asked that the patient attend their 
primary care practice to have the tests performed. 
The patient’s BP, weight, medications and 
urinalysis (ACR) results were recorded by practice 
nurses and then sent back to the administrative 
staff. Results were entered into the database and 
nephrologists reviewed the results via an electronic 
system, which used specialist software to chart 
trends in eGFR and other blood tests. If a patient’s 
renal function deteriorates significantly, or there 
is concern about BP control, the patient can be 
recalled for hospital care. Through this system, 
nephrologists can also advise on medication use.
We used the above description along with available 
unit cost data and several assumptions to estimate 
the average annual cost of implementing this 
system for cohorts of patients with varying levels of 
renal insufficiency and comorbidity.
Consultation costs
Upon referral to nephrology services, all patients 
incur the cost of an initial face-to-face consultation 
with a nephrologist (see Table 31). Then, by CKD 
stage and level of comorbidity, we assume that 
certain proportions of patients will be considered 
stable enough to be managed under shared 
care (see below). For these people, we assume 
an average time to enrolment in shared care of 
3.6 months, as reported by Jones and colleagues,147 
and assume that on average two follow-up 
nephrology outpatient visits are required during 
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TABLE 31 Unit costs used in the model
Average Lower Upper Source of uncertainty Source
Clinical inputs
Consultant-led face-to-
face outpatient (first 
visit)
£200.00 £101.00 £243.00 Quartiles NHS reference costs 
(2006–7)208
Consultant-led face-to-
face outpatient (follow-
up visits)
£114.68 £59.24 £129.73 Quartiles NHS reference costs 
(2006–7)208
GP consultation £30.00 £24.00 £34.00 With and without 
qualification and direct 
care staff costs
Unit costs of health and 
social care (2007)209
Practice nurse 
consultation
£8.00 Unit costs of health and 
social care (2007)209
Consultant result 
reviews (assume 10 
minutes per review)
£12.17 £5.17 £19.17 Lower limit assumes a 
registrar, upper assumes 
consultant carrying out 
reviews
Unit costs of health and 
social care (2007)209
Drug costs (per year on treatment)
ACE I or ARB £98.04 £49.59 £146.49 Lower limit (generic); 
upper limit (non-generic)
British National 
Formulary (2008)210
Other antihypertensive 
drug
£103.12 £58.32 £96.36 Lower limit (generic); 
upper limit (non-generic)
British National 
Formulary (2008)210
Statins £100.08 £17.04 £183.12 Lower limit (generic); 
upper limit (non-generic)
British National 
Formulary (2008)210
Antiplatelet agents 
(aspirin)
£3.36 British National 
Formulary (2008)210
Blood and urinalysis
ACR test £2.16 £1.04 £5.93 Range from survey of 
providers
NICE clinical guideline 
(2008)211
Blood tests (plasma/
serum creatinine)
£3.00 No uncertainty reported NHS reference costs 
(2007)208
Annual hospitalisation costs associated with CVD events
CVD death £3012.67 £2751.30 £3270.30 2.5th and 97.5th 
percentile of gamma 
distribution fitted using 
reported mean and 
standard error
Heart Protection Study 
Collaborative (2006)201
Major non-fatal CVD 
event (MI or stroke)
£8044.84 £7806.70 £8294.10 2.5th and 97.5th 
percentile of gamma 
distribution fitted using 
reported mean and 
standard error
Heart Protection Study 
Collaborative (2006)201
Other CVD event 
(angina or transient 
ischaemic attack)
£3944.85 £3810.00 £4091.50 2.5th and 97.5th 
percentile of gamma 
distribution fitted using 
reported mean and 
standard error
Heart Protection Study 
Collaborative (2006)201
History of CVD event 
(but no event current 
year)
£247.96 £211.40 £291.20 2.5th and 97.5th 
percentile of gamma 
distribution fitted using 
reported mean and 
standard error
Heart Protection Study 
Collaborative (2006)201
ACE I, angiotensin converting enzyme inhibitor; ACR, albumin–creatinine ratio; ARB, angiotensin receptor blocker; 
CVD, cardiovascular disease; MI, myocardial infarction.
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this period. Once patients are enrolled in the SCS, 
we assume that they incur the cost of one primary 
care review within the year.
Those who remain under hospital care from 
initial referral onward incur the cost of the initial 
consultation followed by the cost of three follow-up 
outpatient visits within the year of referral.
For consultation costs in subsequent years we 
assume a mean number of 1.5 primary care reviews 
per year for those managed under shared care, 
and four outpatient follow-up visits per year for 
those managed under hospital care. Those under 
hospital care are assumed to also require four 
visits to their GP each year. The cost of a shared 
care review was taken as the cost of a practice 
nurse consultation, the cost of an ACR and serum 
creatinine test, plus the cost for 10 minutes of a 
nephrologist’s time (consultant or registrar) to 
review results.
Unit costs for nephrology outpatient visits were 
taken from the Department of Health’s NHS 
reference costs (2006–7)208 and the unit cost for 
consultations with nurse practitioners and GPs 
were taken from the Unit costs of health and social care 
2007.209
In addition, we applied an annual cost per 
patient of £5.22 to cover administrative costs for 
the formal referral strategy, maintenance of the 
database, operation of the call–recall system, and 
purchasing and updating of any software required 
for reviewing results. This is based on a previous 
estimation carried out by the authors (GS and PM) 
of the administrative costs per patient of operating 
a systematic screening programme for diabetic 
retinopathy (unpublished data). It includes the 
cost of running a call–recall system, of storing 
and maintaining patient’s data electronically on a 
central server, and of purchasing specialist software 
to aid the grading process.
Proportions under shared care and 
hospital care
Assumptions were made regarding the proportions 
of people who would be managed under shared 
care and hospital care by CKD stage and level of 
comorbidity. We assumed that 50% of those with 
stage 3b or stage 4 CKD (ACR < 300 mg/g) would 
be managed under shared care, and that 100% of 
patients with an ACR > 300 mg/g would be retained 
for management under hospital care. For those 
with stage 3a CKD, we assumed that 75% of those 
with an ACR < 300 mg/g would be managed under 
shared care, and that 100% of patients with an 
ACR > 300 mg/g would be managed under hospital 
care.
Medication costs
We assumed that under the formal referral strategy, 
the proportion of people with hypertension on 
any hypertensive medication would increase by 10 
percentage points compared with standard practice 
(lower resource use scenario).
For those under hospital care after initial 
referral, we assumed that 90% of all people 
with hypertension, an ACR > 30 mg/g or 
comorbid CVD would receive an ACE I or ARB. 
For those under shared care, we inflated the 
proportions of individuals on ACE Is or ARBs 
in primary care (under current practice) using 
multipliers estimated from the study by Jones and 
colleagues;148 the proportion using ACE Is or ARBs 
increased by 58% for those managed under shared 
care after referral to the SIMON programme. We 
also applied proportional increases in the use of 
lipid lowering agents and aspirin, as reported for 
all patients enrolled in the SIMON programme, 
to estimate the levels of use of these medications 
under the formal referral strategy.
Total health service costs
Using the above assumptions, we estimated 
average annual costs of care by CKD stage and 
level of comorbidity, under a formal early referral 
programme (see Table 35). In addition, we assumed 
that people with stages 1 and 2 CKD would incur 
the same costs as those with stage 3a CKD with an 
ACR > 30 mg/g. For those with stage 5 CKD, prior 
to initiation of dialysis, we assumed the average 
annual cost across comorbidity groups in those with 
stage 4 CKD. The same assumptions were applied, 
as described above, for individuals on dialysis.
Additional hospital costs associated with 
CVD events
Costs associated with CVD events were taken from 
a published cost-effectiveness study which assessed 
patient level hospitalisation costs associated with 
major cardiovascular events (myocardial infarction, 
stroke), other CVD events (angina, transient 
ischaemic attacks, etc.) and CVD deaths.201 This 
study also reported hospitalisation costs in the 
years following CVD events, when no other CVD 
events occurred (see Table 7). These costs were 
applied in the model as transition costs. Given 
the high CVD mortality risk in people with ESRD 
(~0.125 per year), we assumed that 50% of these 
people would experience a CVD event each year; 
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TABLE 33 Estimated annual costs (£) of consultations and medications under a formal referral strategy, by CKD stage and level of 
comorbidity
CKD alone
ACR >  
30 mg/g
ACR >  
300 mg/g
CKD with 
CVD
CKD with 
ACR > 30 mg/g 
and CVD
CKD with 
ACR > 300 mg/g 
and CVD
CKD stages 1 
and 2
£376.56 £780.60 £583.96 £839.70
CKD stage 3a £344.37 £376.56 £780.60 £572.07 £583.96 £839.70
CKD stage 3b £475.15 £532.86 £796.10 £584.95 £599.02 £850.02
CKD stage 4 £492.00 £542.34 £804.61 £593.03 £608.48 £858.27
ACR, albumin–creatinine ratio; CKD, chronic kidney disease; CVD, cardiovascular disease.
with a CVD event fatality rate of 25%, this results 
in an annual risk of CVD mortality of 0.125. Those 
experiencing non-fatal CVD events incur the 
associated hospitalisation costs.
Effectiveness
In the absence of robust effectiveness evidence for 
the shared care strategy reported by Jones and 
colleagues,148 we applied a relative effect estimate 
obtained from a cohort study assessing the impact 
of nephrology referral on CKD progression and 
ACM, assuming that the shared care strategy might 
have a similar effect on CKD progression and 
CVD. Orlando and colleagues111 reported HRs 
associated with early referral for a composite end 
point of progression to the next stage of CKD or 
death. These HRs were reported for each CKD 
stage and were similar for CKD stages 3 and 4 
(0.80, 95% CI 0.61 to 0.90 and 0.75, 95% CI 0.45 
to 0.89 respectively). Given the lack of statistically 
significant difference between these estimates we 
assumed a constant HR of 0.8 associated with early 
referral across stages 3 and 4. Although Orlando 
and colleagues111 did not report the impact of early 
referral on CVD events separately, many of the 
deaths occurring in the cohort were due to CVD 
causes. We therefore applied the HR directly to the 
CKD transition probabilities and CVD event risks 
used in the natural history model. Given the large 
uncertainty surrounding the relative effectiveness 
of early referral, we varied this parameter 
substantially in the sensitivity analysis.
Cost-effectiveness analysis
In the first instance we assessed the incremental 
cost-effectiveness of early referral for everyone 
with an eGFR below 60 ml/min/1.73 m2 (CKD 
3a) compared with referral upon transit to stage 
5 CKD (from here on referred to as standard 
practice). Although this may no longer represent 
current practice in the UK, we decided to use 
this as the base comparator as it provides a useful 
reference point against which to compare all 
referral cut-offs incrementally. We then assessed 
the incremental cost-effectiveness of scenarios 
where referral occurs only for those with an eGFR 
below 45 ml/min/1.73 m2 (CKD 3b), or below 
30 ml/min/1.73 m2 (CKD 4). Under these scenarios 
we assumed that those above the thresholds 
would experience the same CVD event risks and 
transition probabilities as those under standard 
care, but that they would incur an eGFR and ACR 
monitoring cost; these individuals would have to be 
monitored in primary care in order to be picked up 
and appropriately referred upon falling below the 
thresholds. The cost of monitoring was taken as the 
cost of two consultations per year with a practice 
nurse for urinalysis and a plasma creatinine test. 
We also assumed that monitoring in primary care, 
under this referral strategy, would incur the same 
administrative costs as referral to the nephrology 
SCS (£5.22).
We then assessed the cost-effectiveness of referring 
only those people with ACRs over 30 mg/g or 
300 mg/g (microalbuminuria or proteinuria 
respectively). Finally, we assessed the cost-
effectiveness of referring anyone with stage 3b 
CKD and an ACR > 30 mg/g, and anyone with stage 
3b or an ACR > 300 mg/g. The latter strategy is 
similar to referral criteria recommended in recent 
clinical guidelines on the management of CKD.212 
The model was run over a 35-year time horizon 
using a discount rate of 3.5% for future costs and 
consequences. Discounting was applied to adjust 
for positive time preference: the observation that 
society prefers to receive benefits in the present 
and incur costs in the future. The discount rate 
currently recommended by the UK Treasury (http://
www.hm-treasury.gov.uk/) is 3.5%.
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The cohort was initially distributed across the CKD 
and comorbidity states (Table 34) according to 
proportions reported by Stevens and colleagues.192 
Within each CKD category we applied proportions 
with microalbuminuria and proteinuria as 
reported for the NHANES III cohort.193 Given 
that CVD prevalence is higher in those with 
microalbuminuria and proteinuria, we adjusted the 
proportions with CVD in the microalbuminuria/
proteinuria states accordingly.
Sensitivity analysis
Following the base-case analysis we explored the 
impact of varying uncertain model parameters 
and assumptions. The model was rerun for the 
following scenarios, most of which are biased 
against early referral:
• Annual rates of eGFR decline were doubled.
• The risk of ACR > 30 mg/g development was 
set to zero.
• CVD event risks were halved.
• The effect of nephrology referral on CVD 
events was set to zero.
• The effect of nephrology referral on eGFR 
decline (CKD progression) was set to zero.
• The effect of nephrology referral on CVD 
events and eGFR decline was simultaneously 
halved.
• The effects of nephrology referral on CVD 
events and eGFR decline were halved and 
constrained to last 5 years (the median length 
of follow-up in the study by Orlando and 
colleagues).111
• Costs for standard care were set at their upper 
limit.
• Costs of care under early nephrology referral 
were doubled.
• Costs associated with fatal and non-fatal CVD 
events were varied within the 95% confidence 
limits of their assigned distributions (see 
Probabilistic sensitivity analysis).
The cost of caring for people with ESRD was also 
subjected to sensitivity analysis. For the lower 
limit we applied the lowest dialysis cost estimates 
reported by Baboolal and colleagues207 and also 
assumed that only 70% of patients with ESRD 
would end up on dialysis, i.e. 30% would be 
managed conservatively. For the upper limit we 
applied high dialysis cost estimates207 and assumed 
that 60% of patients would commence dialysis 
within a year of transiting to ESRD, and that the 
proportion on dialysis would subsequently increase 
to 90%. In addition, we explored the impact of 
allowing for increasing cardiovascular event rates 
by CKD stage, and assessed the potential impact 
of allowing for non-linear rates of eGFR decline 
(by applying higher rates of eGFR decline for 
people with stage 4 CKD). Finally, we considered a 
scenario where individuals with an ACR ≥ 30 mg/g 
were considered separately from the main cohort.
Probabilistic sensitivity analysis
The impact of joint uncertainty across all model 
parameters was assessed using probabilistic 
sensitivity analysis. Monte Carlo simulation was 
employed whereby values were simultaneously 
selected for each parameter from an assigned 
distribution and the results recorded. The process 
was repeated 1000 times to give an estimate of the 
sampling distribution of cost and effect differences 
between the referral strategies. These results 
were then used to generate cost-effectiveness 
acceptability curves.
Gamma distributions were fitted to all cost 
parameters. As we had no information on the 
statistical precision of our CKD cost estimates 
(under standard practice), base-case costs were 
treated as means for these parameters and 
variances were selected so that our feasible high 
cost estimates fell below the 97.5th percentiles of 
the resultant distributions. For CKD costs under 
nephrology referral, distributions were centred 
TABLE 34 Initial distribution of cohort across the disease states
CKD 
alone
ACR >  
30 mg/g
ACR >  
300 mg/g
CKD with 
CVD
CKD with 
ACR > 30 mg/g and 
CVD
CKD with 
ACR > 300 mg/g and 
CVD
Stage 3a 0.447 0.070 0.023 0.112 0.066 0.022
Stage 3b 0.108 0.009 0.003 0.051 0.030 0.010
Stage 4 0.012 0.004 0.008 0.004 0.008 0.013
ACR, albumin–creatinine ratio; CKD, chronic kidney disease; CVD, cardiovascular disease.
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on our base-case estimates and assigned variances 
so that feasible high estimates fell within the 95% 
CIs of resultant distributions. The same principals 
were followed when assigning distributions to 
costs associated with ESRD. For costs associated 
with cardiovascular events, we applied gamma 
distributions using means and reported standard 
errors.201
For probabilities of CKD stage progression we 
assigned beta distributions. We centred these 
distributions on the base-case estimates and 
selected variances so that high estimates fell 
within the 97.5th percentiles of the resultant 
distributions. For probabilities of developing 
microalbuminuria and proteinuria, we assigned 
beta distributions using point estimates and CIs 
reported for individuals with diabetes.203 For RRs 
of CVD events conveyed by CKD, ACR > 30 mg/g, 
and ACR > 300 mg/g, we assigned log normal 
distributions using reported point estimates and 
CIs.84 The same approach was used to assign a 
log normal distribution to the HR associated with 
nephrology referral.111 For CVD event fatality rates, 
and the ratio of major to minor CVD events (used 
in the cost calculation), we reduced and increased 
point estimates by 50% and assigned uniform 
distributions.
Given the uncertainty underlying our effectiveness 
estimate, we also ran a probabilistic sensitivity 
analysis where the distribution for this parameter 
was centred on a 10% risk reduction (as opposed to 
a 20% risk reduction).
Model validation
The predicted survival curve for the CKD cohort 
(without early referral) was compared with the 
survival curve for an age- and sex-matched cohort 
of the UK general population (Figure 9). As 
anticipated, predicted life expectancy was lower 
for the CKD cohort than for the age- and sex-
matched general population. Our model predicts 
a reduction in life expectancy of 2.5 years, from 
13.45 years to 10.93 years.
Figure 10 shows the cumulative incidence of 
ESRD, cardiovascular mortality and other cause 
mortality predicted by the model using the base-
case parameter estimates and assumptions. Values 
reported in the literature for these outcomes in 
CKD cohorts vary widely. To give some examples, 
Menon and colleagues213 reported a 10-year 
cumulative incidence for ESRD of around 50% 
for those with a baseline eGFR between 24.5 and 
55.5 ml/min/1.73 m2 enrolled in the MDRD study. 
However, about 50% of individuals in this cohort 
had either polycystic or glomerular disease. Wakai 
and colleagues214 reported a 7-year cumulative 
incidence for ESRD of 23.3% in a Japanese cohort 
with immunoglobulin A nephropathy. On the 
other hand, Eriksen and Ingebretsen96 reported 
a cumulative 10-year incidence for ESRD of only 
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FIGURE 9 Predicted survival curve compared with the sex- and age-matched survival curve for the UK general population. CKD, 
chronic kidney disease.
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4% in a cohort of individuals with stage 3 CKD 
(identified through routine clinical measurements).
The corresponding 10-year cumulative incidence 
of ESRD predicted for the cohort modelled in 
the current analysis is 3.5%, indicating that our 
estimates are on the conservative side. We assessed 
the impact of increasing CKD progression rates 
through sensitivity analysis.
The 10-year cumulative incidence of cardiovascular 
mortality predicted by the model is 30% (Figure 10). 
Comparisons with estimates from published cohort 
studies are complicated by the fact that few studies 
have looked at long-term cardiovascular outcomes 
in CKD cohorts identified through case finding in 
general practice. Parikh and colleagues194 report 
a 10-year cumulative incidence for cardiovascular 
mortality of 16% and 21% for groups with stage 
3a and 3b CKD respectively with no pre-existing 
CVD. Hallan and colleagues,32 on the other hand, 
report higher 8-year cumulative incidence rates 
of approximately 20% and 40% for cohorts with 
stage 3a and 3b CKD respectively (including 
individuals with pre-existing CVD and diabetes). 
However, Weiner and colleagues196 report a lower 
10-year cumulative incidence of ~35% for a 
composite outcome of myocardial infarction, fatal 
coronary heart disease, ACM and non-fatal stroke. 
Although the cohort in this latter study consisted 
of individuals identified through screening, rather 
than individuals picked up as part of routine 
clinical practice, it raises the possibility that our 
model may be overestimating fatal and non-fatal 
CVD events. Given the variation in reported 
estimates, we subjected the CVD event risks and 
event fatality rates to extensive sensitivity analysis.
Results
The base-case results are presented in Table 35 and 
Figure 11. The axis of Figure 11 indicates that under 
baseline parameter estimates and assumptions, all 
strategies generate more QALYs than the practice 
of referral upon transit to CKD stage 5 (standard 
practice). Referral for everyone with an eGFR 
below 30 ml/min/1.73 m2 (CKD 4) had an ICER of 
£5923 compared with standard practice.
Referral for everyone with an eGFR below 
60 ml/min/1.73 m2 (CKD 3a) generated the most 
QALYs and, compared with referral for everyone 
at CKD 4, had an ICER of ~£3806 per QALY. 
Compared with referral for everyone at CKD 3b, 
referral at CKD 3a had an ICER of £3751 per 
QALY. The referral strategy based purely on the 
presence of proteinuria was dominated by the 
strategy of referral at stage 4. Compared with 
strategies of referral for those with ACR > 30 mg/g 
only, those with CKD 3b or ACR > 30 mg/g, or 
those with CKD 3b or ACR > 300 mg/g, referral at 
stage 3a had an ICER of ~£3440 per QALY, £3573 
per QALY and ~£3473 per QALY respectively. 
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FIGURE 10 Predicted cumulative incidence of end-stage renal disease (ESRD), cardiovascular mortality and mortality from other 
causes. CVD, cardiovascular disease.
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TABLE 35 Base-case cost-effectiveness results (per individual with CKD)
Strategya Total cost
Incremental 
cost
Effectiveness 
(QALYs)
Incremental 
effectiveness ICER
Standard practice £11,796 5.579
Refer at CKD 3a £13,487 £1691 5.992 0.413 £4091
Refer at CKD 3b £12,808 £1012 5.811 0.232 £4352
Refer at CKD 4 £12,129 £332 5.635 0.056 £5923
Refer ACR 30–299 mg/g £12,596 £800 5.733 0.154 £5194
Refer ACR ≥ 300 mg/g £12,308 £512 5.628 0.049 Dominated
Refer at CKD 3b or 
ACR ≥ 30 mg/g
£13,051 £1255 5.870 0.291 £4313
Refer at CKD 3b or 
ACR ≥ 300 mg/g
£12,915 £1118 5.827 0.248 £4508
ACR, albumin–creatinine ratio; CKD, chronic kidney disease; Dominated, the strategy is more costly and less effective 
than an alternative strategy; eGFR, estimated glomerular filtration rate; ICER, incremental cost-effectiveness ratio; 
QALY, quality-adjusted life-year.
a All strategies compared incrementally to standard practice.
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FIGURE 11 Base-case cost-effectiveness results. ACR, albumin–creatinine ratio; CKD, chronic kidney disease; QALYs, quality-adjusted 
life-years.
Thus CKD 3a is the preferred strategy from the 
base-case analysis.
The QALY gains associated with early referral are 
attributable to survival improvements (Figure 12) 
and a reduction progression, and in the cumulative 
incidence of ESRD (Figure 13). Compared with 
referral upon transit to stage 5 CKD, referral at 
CKD 3a is associated with an increase of 0.605 
discounted life-years (0.97 undiscounted life-years) 
and an 18% reduction in the cumulative incidence 
of ESRD.
Deterministic sensitivity analysis
The findings of various deterministic sensitivity 
analyses are presented in Table 36.
The model results were most sensitive to 
underlying rates of eGFR decline, the underlying 
risk of developing ACR > 30 mg/g, the effect of 
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FIGURE 12 Survival curves with and without early referral to nephrology services (referral for everyone with eGFR < 60 ml/min/1.73 m2). 
CKD, chronic kidney disease.
FIGURE 13 Cumulative incidence of ESRD with and without early referral to nephrology services (referral for everyone with 
eGFR < 60 ml/min/1.73 m2). CKD, chronic kidney disease.
referral on eGFR decline (CKD progression) and 
the costs of care under formal early nephrology 
referral. When we halved the rates of eGFR 
decline, the model predicted a cumulative 10-
year incidence of ESRD below that reported by 
Eriksen and Ingebretsen.96 However, early referral 
remained cost-effective under this specification, as 
it did under all other one-way sensitivity analyses 
presented in Table 36.
In addition to the scenarios presented in Table 36, 
halving and doubling CVD event fatality rates did 
not alter the overall findings, with referral at CKD 
3a (< 60 ml/min/1.73 m2) remaining the preferred 
strategy across all values.
When several parameters were simultaneously 
weighted against early nephrology referral, the 
ICER for referral at CKD 3a approached a value 
unlikely to be considered cost-effective (final row of 
Table 36).
In order to assess the potential implications of a 
non-linear pattern of eGFR decline, we modelled a 
scenario where the rate of eGFR decline increases 
at stage 4 compared with stages 3a and 3b. For 
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TABLE 36 Deterministic sensitivity analyses – referral for everyone with eGFR < 60 ml/min/1.73 m2 compared with standard practice 
(referral around time of developing ESRD)
Scenarios Incremental cost
Incremental 
effectiveness (QALYs) ICER
Refer CKD stage 3 (base case) £1691 0.413 £4091
Annual rates of eGFR decline doubled £388 0.437 £888
Risks for ACR > 30 mg/g development are zero £2031 0.322 £6314
CVD event risks halved £1659 0.337 £4923
No direct effect of referral on CVD events £1730 0.087 £19,885
Zero effect of referral on CKD progression £2631 0.230 £8218
Effect of referral on CKD progression and CVD 
events halved
£2118 0.199 £10,662
Effect of referral on CKD progression and CVD 
events halved and constrained to last 5 years
£2360 0.095 £24,908
High costs for standard practice £1430 0.413 £3460
Costs of care under nephrology referral doubled £6624 0.413 £16,027
Lower limit for CVD event costs £1708 0.413 £4132
Lower limits for ESRD costs £1830 0.413 £4428
Discount rate 6% £1449 0.308 £4704
10-year time horizon £1257 0.154 £8158
Costs under early nephrology referral doubled, 
effect sizes halved, base risk for ACR > 30 mg/g 
development halved
£6856 0.200 £34,323
ACR, albumin–creatinine ratio; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular 
filtration rate; ESRD, end-stage renal disease; ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life-
years.
this analysis we used the rates of decline reported 
in the MDRD study202 for individuals with stage 4 
CKD, while maintaining the lower rates of decline 
for those with 3a and 3b. This improved the cost-
effectiveness of all referral options. Compared with 
referral at stage 5, the ICERs for referral at stages 
4, 3b and 3a decreased to £3103, £2817 and £2954 
per QALY respectively. Compared with referral at 
stage 4, the ICER for referral at stage 3b was £2729 
per QALY, and compared with referral at stage 3b, 
the ICER for referral at stage 3a dropped to £3132 
per QALY.
Adjustment of cardiovascular events rates by CKD 
stage, to give a pattern of increasing cardiovascular 
mortality consistent with data reported by Go and 
colleagues,75 was found to have little impact on 
cost-effectiveness. Referral at stage 3a remained 
the most cost-effective strategy under this scenario, 
with an ICER of £4360 per QALY versus standard 
practice, and an ICER of £4011 and £4133 per 
QALY versus referral at stage 4 and stage 3b 
respectively.
Finally, we explored a scenario where individuals 
with an ACR ≥ 30 mg/g were considered separately. 
Although early referral in this group saves more 
QALYs on average, compared with the CKD 
cohort as a whole, average costs are also higher 
owing to the higher costs of managing this group 
under the early referral scheme. Under this 
scenario the ICERs for referral at stage 3a were 
£4009, £3951 and £4074 compared with standard 
practice, referral at stage 4 and referral at stage 3b 
respectively.
Probabilistic sensitivity analysis
Figure 14 plots the probability of each strategy 
being considered the most cost-effective option for 
different values of societal willingness to pay for 
an additional QALY, using optimistic assumptions 
about effectiveness of early referral.
Above a willingness-to-pay threshold of 
~£4100, referral for everyone with an 
eGFR < 60 ml/min/1.73 m2 (referral at CKD 3a) 
has the highest probability of being the most cost-
effective option.
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FIGURE 14 Cost-effectiveness acceptability curves for alternative referral strategies. ACR, albumin–creatinine ratio; CKD, chronic 
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FIGURE 15 Cost-effectiveness acceptability curves for alternative referral strategies when baseline CKD progression rates are centred 
on feasible low estimates. ACR, albumin–creatinine ratio; CKD, chronic kidney disease.
However, when the distribution for the effectiveness 
of early referral is centred on a 10% risk reduction 
(for CKD progression and cardiovascular events) 
and constrained to last 5 years, the acceptability 
curve indicates only a 55% chance of early referral 
(at stage 3a) being cost-effective at a willingness-to-
pay threshold of £30,000 per QALY (Figure 15).
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Discussion
This modelling exercise has attempted to assess 
the cost-effectiveness of referring individuals with 
markers of renal disease (based on various eGFR 
and ACR cut-offs) to a shared care nephrology 
programme. The baseline strategy against which 
the early referral strategies are compared is 
referral to nephrology upon transit to stage 5 CKD. 
Although this may not reflect current practice, it 
provides a useful baseline against which to compare 
the alternative referral cut-offs incrementally.
Results of the base-case analysis suggest early 
referral may offer an efficient use of scarce health 
service resources. All strategies produced more 
QALYs than standard practice (referral upon 
transit to stage 5 CKD). Referral for everyone with 
an eGFR below 30 ml/min/1.73 m2 (stage 4 CKD) 
produced 0.056 additional QALYs per patient at 
an additional cost to the NHS of £332 per patient 
(ICER: £5923 per QALY). Compared with referral 
upon transit to stage 4 CKD, referral at stage 3b 
increases the number of QALYs gained (0.176) 
for a increase in cost of £679 (ICER: ~£3857 
per QALY). Referral at stage 3a again increases 
the number of QALYs gained (0.181) compared 
with referral at stage 3b, with an ICER of £3751 
per QALY. Thus, under the base-case parameter 
values and assumptions, referral at stage 3a is the 
preferred option on grounds of cost-effectiveness.
Referral for everyone with stage 3b CKD, or 
ACR > 30 mg/g, is more effective and more costly 
than referral based on an eGFR < 45 ml/min alone, 
as these strategies reach individuals at stage 3a who 
have evidence of kidney damage. Compared with 
referral at CKD 3b, they have higher ICERs than 
referral for everyone with stage 3a CKD (£4119 
and £6625 per QALY versus £3751 per QALY 
respectively), due to the fact that they result in no 
reduction in progression or cardiovascular event 
rates for the large portion of the cohort with stage 
3a CKD alone. However, when the group with 
microalbuminuria or proteinuria is considered 
separately, the ICER for referral at stage 3a is 
slightly more favourable than the ICER for referral 
at stage 3a for the cohort as a whole (£4009 versus 
£4091 relative to standard practice respectively).
The superiority of earlier referral observed in the 
model is due to the fact that as patients progress 
to more severe disease states, they experience 
higher costs associated with CKD management 
and experience a higher risk of cardiovascular 
events and death. The costs incurred in preventing 
progression to more severe disease states are offset 
by the costs and life-years saved as a result. In 
particular, the earlier referral occurs, the lower the 
cumulative incidence of ESRD, which is associated 
with very high annual costs and mortality 
(~£27,000 per patient per year). Deterministic 
sensitivity analysis confirms this in revealing that 
the ICER is highly sensitive to changes in the 
baseline risk of CKD progression and the effect 
of referral on the risk of CKD progression and 
cardiovascular events. When we applied more 
conservative CKD progression rates, and reduced 
the effect of early referral on CKD progression and 
cardiovascular events, the ICER for early referral 
rose above £30,000 per QALY, the threshold 
applied by NICE to guide decisions on cost-
effectiveness.
A factor that was not formally considered in the 
current analysis is the possibility that CKD cohorts 
have a higher background risk of mortality from 
other causes. This was because no published 
data were identified indicating that CKD confers 
an increased risk for this outcome. However, 
unpublished data from a cohort study in Aberdeen, 
UK suggest that this may be the case (Dr Keith 
McCullough, University of Aberdeen, personal 
communication, 2009). To investigate the potential 
impact of such an effect, we multiplied other 
cause mortality by 2.36; the HR for CVD mortality 
associated with CKD. Under this scenario, the 
cost-effectiveness of early referral decreased 
only slightly, with the ICER for referral at stage 
3a increasing to £5167 compared with standard 
practice.
Affordability and feasibility
Although, our analysis suggests that early referral 
and improved management of individuals with 
CKD may represent a cost-effective use of health 
service resources, the affordability and feasibility 
of the intervention is questionable. To give an 
indication of the potential impact of moving from 
a strategy of referral to shared care at stage 4 
to referral at stage 3a, recent QOF data suggest 
that there are ~1.74 million adults registered in 
England and Scotland as having stage 3a CKD 
or worse under the QOF. Assuming 74% have 
stage 3a CKD and 21% have stage 3b CKD,202 
the net incremental cost of moving to a shared 
care strategy at stage 3a would be in the region 
of £1.02B over 3 years (discounted at 3.5%). 
The corresponding cost of moving to a strategy 
of shared care at stage 3b would be ~£375M. 
These estimates are based on the modelled net 
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incremental cost per patient of referral at stage 
3a or stage 3b versus referral at stage 4 (over a 
3-year time horizon) multiplied by 1.74 million. 
The unit costs for referral, upon which these 
estimates are based, may not reflect the true cost 
of scaling up nephrology services to the level 
required to meet the extra demand (increased 
numbers of nephrologists, increased clinic space 
and increased administrative costs). Assuming 
that referral at stage 4 is the current practice, 
and that existing nephrologists are working at 
capacity, movement to early referral at stage 3a 
might require somewhere in the region of 1300 
additional nephrologists, while movement to 
referral at stage 3b would require ~500 additional 
nephrologists across England and Scotland. These 
estimates are based on further assumptions that an 
individual nephrologist could manage ~1250 stage 
3a patients per year under an SCS (assuming 25% 
would require outpatient hospital treatment while 
the rest could be managed in primary care) or 800 
stage 3b patients per year (assuming 50% would 
require outpatient hospital treatment). As these 
numbers are unlikely to prove feasible, it is likely 
that alternative approaches to the management of 
individuals with CKD will have to be found.
Comparison with other studies
As outlined in the review section of this chapter, 
we were unable to identify any published studies 
specifically assessing the cost-effectiveness of early 
referral strategies (referral during stage 3a) for 
patients with markers of renal disease. However, 
our finding that referral at stage 4 CKD is highly 
cost-effective compared with referral upon transit 
to stage 5 CKD is consistent with the previously 
published modelling study by McLaughlin and 
colleagues.180 Our findings are also generally 
consistent with studies showing the use of ACE 
Is to be cost-effective in individuals with non-
diabetic nephropathies.188,189 Improved uptake and 
appropriate use of ACE Is is one of the mechanisms 
by which early referral may reduce progression 
and prevent cardiovascular mortality. Our findings 
are also consistent with the substantial body of 
evidence that shows early treatment of diabetic 
nephropathies with ACE Is or ARBs to be highly 
cost-effective, owing to their preventive effect on 
progression to ESRD.215,216
Strengths and weakness of the study
Owing to a lack of data on the natural history of 
CKD in individuals without diabetes, and a lack of 
evidence on the costs and effects of early referral, 
our model should be seen as an exploratory piece 
of research. Many assumptions had to be made 
regarding the transition of individuals through 
the CKD stages, the risk of cardiovascular events 
by stage, and the costs and effectiveness of early 
referral. In particular, more research is required 
to assess eGFR decline rates in individuals with 
early stage 3 CKD. In our base-case analysis, we 
estimated CKD transition rates by applying average 
rates of eGFR decline in line with rates reported 
in the literature for individuals with clinically 
established CKD to a cohort of individuals with an 
eGFR < 60 ml/min/1.73 m2 identified in primary 
care. Although these progression rates gave a 
predicted cumulative incidence of ESRD in line 
with that observed for a similar cohort,96 there 
is emerging evidence to suggest that a subset of 
patients identified with a low eGFR in primary care 
are relatively stable and do not in fact progress. 
Some may even regress to less severe stages of 
disease. Our analysis makes the assumption that 
everyone in the cohort has progressive renal 
insufficiency, and as a result may overestimate cost-
effectiveness of early referral individuals with stable 
eGFR who do not progress, and underestimate 
cost-effectiveness for individuals who have more 
progressive disease. More detailed investigation 
in primary care to identify those individuals who 
are progressive could potentially improve cost-
effectiveness and affordability of early referral 
strategies.
Another weakness of the study is that, due to 
lack of evidence, the modelling relies on an 
effectiveness estimate for early referral taken 
from the only prospective study looking at the 
impact of early referral on a cohort that included 
individuals without diabetes. Although this was 
one of the highest quality studies identified by 
the clinical effectiveness review (see Chapter 5), 
controlling for various patient characteristics and 
treatment factors expected to influence outcome 
(diabetes, proteinuria and hypertension), it may 
still be subject to bias. Moreover, the cohort was 
entirely male, 50% had diabetes and the vast 
majority had proteinuria (89%). Therefore, there is 
a question over whether the 20% reduction in CKD 
progression and cardiovascular mortality observed 
for early referral in this cohort can be achieved 
in mixed gender CKD cohorts without diabetes. 
Another factor that may limit the generalisability of 
the Orlando study111 is that the primary care arm 
may not reflect current primary care standards in 
the UK. Primary care management for people with 
CKD in the UK may have substantially improved as 
a result of the introduction of the QOF. Thus, the 
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relative effect achievable through early referral may 
be diminished. Sensitivity analysis demonstrates 
that cost-effectiveness is highly sensitive to the 
relative effect of early referral on CKD progression 
and/or cardiovascular event risks (see Table 36).
Potential for future research and further 
modelling
Although we attempted to use the best available 
evidence on the natural history of early CKD 
progression and the effectiveness of early referral, 
data in these areas are incomplete. There is clear 
need for prospective cohort studies to assess CKD 
progression and the incidence of cardiovascular 
events in individuals who have been identified as 
having an eGFR < 60 ml/min, with and without 
other complications/comorbidities such as 
microalbuminuria, proteinuria, diabetes and pre-
existing CVD. This is particularly pertinent for 
those with mild CKD who have been detected 
through opportunistic testing and who, in the 
past, would not have come to the attention of a 
renal physician. Once these data are available they 
will allow more accurate modelling of the cost-
effectiveness of referral based on different eGFR 
cut-offs and other comorbidities.
In addition, there is a clear need for prospective 
randomised studies to assess the effect of early 
referral or improved management strategies on 
the progression of CKD and the incidence of CVD 
events in the different subgroups of interest. The 
cost-effectiveness results reported here assume that 
early referral is associated with a 20% reduction 
in the risk of progression to the next stage or 
CVD mortality, regardless of CKD stage or level 
comorbidity. This was based on a reported HR 
associated with referral for individuals with CKD, 
which was adjusted for various comorbidities 
known to influence outcomes; but a question 
remains over the generalisability of these findings, 
particularly to cohorts with early stage 3 CKD.
No cardiovascular risk estimating equations were 
available at the time of writing, which incorporated 
eGFR, microalbuminuria or proteinuria as risk 
factors for cardiovascular events. As a result, we 
had to apply adjusted RR estimates for CVD events 
(associated with specific renal disease markers) to 
baseline risks for the cohort based on classical CVD 
risk factors. This staged approach will result in 
imprecision in the overall estimate of CVD event 
risk within each stage of the model. If in the future 
risk estimating equations that incorporate markers 
of renal disease become available, we will be able to 
update the model accordingly.
Reducing the risk of CKD progression and CVD 
in primary care also presents a feasible option for 
improving the management of individuals with 
markers of renal disease. This modelling study 
has focused on the potential cost-effectiveness of 
early referral to a specialist, but it is not the act of 
referral itself that reduces the risk of progression. 
A combination of factors such as obtaining better 
BP control, increasing appropriate use of ACE Is 
and other medications, and encouraging positive 
lifestyle changes are the likely mechanisms by 
which referral to a specialist affects the progression 
of disease. Appropriate use of these interventions 
may already be improving in primary care under 
the QOF, and it may be the case that further 
improvements can be achieved in a primary care 
setting without the need for referral. Furthermore, 
if the relative benefits of nephrology care were 
to be limited to improving the quality of life of 
patients within stage (through better management 
of anaemia for example), rather than preventing 
progression and prolonging life, then this would 
favour referral at later stages. Given the potentially 
prohibitive costs of implementing the SCS we have 
modelled here, it is pertinent that further research 
explores ways of improving management and 
outcomes for individuals with CKD in primary care.
Conclusions
Strategies to improve the management of 
people with CKD may offer an efficient use of 
health service resources. However, given the 
great uncertainty surrounding many parameter 
estimates, the effectiveness and cost-effectiveness 
of early referral needs to be demonstrated in 
prospective randomised studies. In addition, 
research is required to assess whether improved 
outcomes can be achieved for people with early 
stage renal disease through improved management 
in the primary care setting.
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Overview of findings
In the previous chapters we have presented the 
findings of a series of systematic reviews and the 
development of an economic model assessing 
aspects of the clinical effectiveness and cost-
effectiveness of early referral for CKD.
The review of the natural history of CKD identified 
evidence that reduced eGFR was a predictor for 
mortality, CVD, renal disease progression and 
ESRD. In cohorts of people with CKD, death was a 
common outcome regardless of whether the cohort 
was population or clinically based. The association 
between CKD and these outcomes was attenuated 
by taking into account comorbidities and age. 
Increasing stage of CKD was associated with 
higher levels of ACM, CVD and renal outcomes. A 
substantial increase in the risk of ACM and renal 
outcomes was noted when stage 3a was compared 
to stage 3b.
While RR estimates for ACM and renal outcomes 
increased with stage, the number of people in the 
affected category reduced. This should be borne in 
mind when considering where to target care. It may 
be possible to identify subgroups at higher risk of 
poor health outcomes but, because the prevalence 
of CKD falls steeply with eGFR, the absolute 
numbers of people experiencing a negative 
outcome will also fall.
The concept of ‘early referral’ implies a stage in 
an inevitable pathway. Though limited, there was 
some evidence that there may be a subgroup of 
people for whom the label of CKD does not result 
in progressive deterioration in kidney function 
or an increased risk of CVD. This subgroup was 
rarely considered in the literature and poorly 
characterised, but may account for more than 
50% of those with CKD defined by KDOQI. This 
group will have little to gain from referral and 
the potential for harm from investigation, anxiety 
and unnecessary treatment. At the current time, 
there is no good way to identify such individuals. 
Any models of care for CKD should, therefore, 
be evaluated in the context of an RCT to ensure 
the benefits sufficiently outweigh the harms for 
people with different stages of CKD. Indeed, even 
the evidence base around the effectiveness of 
pharmacological treatments (ACE I/ARB, statins) 
have largely considered CKD as a single group and 
have not considered the effect size for different 
stages of CKD.
Literature considering the effectiveness of 
early referral for CKD was limited and again 
there was heavy reliance on a study design that 
recruits people at the time of initiating RRT, with 
retrospective consideration of the care they have 
received. We found evidence that referral to a 
nephrology specialist more than 12 months prior 
to starting RRT (and even as early as more than 
72 months before RRT) may improve outcomes 
including long-term survival on RRT. This also 
supports the survival benefits being related to not 
only planning and preparation for RRT but also 
risk factor modification for causes of mortality (in 
particular CVD).
Only two studies provided information about the 
impact of referral on the pre-RRT phase of care 
(and thus also included people who did not survive 
to dialysis).111,120 Here there was some evidence 
that early referral (defined by degree of renal 
impairment) could be beneficial in terms of slowing 
progression and reducing mortality. A conclusion 
that must be treated with some caution for the 
following reasons: patients were not randomly 
allocated to the treatment groups; one study 
included only patients with diabetes and described 
a care setting likely to be substantially different 
from that in the UK; and very little information was 
available about what care was received. While little 
information was available about the care given, 
those in the early referral groups were more likely 
to be on ACE Is or ARBs. BP control was generally 
tighter in the referred group and some authors 
reported higher prescribing of statins.
The review of models of care for people with 
CKD found a dichotomy in the literature between 
early referral to specialist teams and approaches 
to shared care across a range of disciplines but 
including the primary care team. Three models 
of care were described: multidisciplinary clinics 
(including shared care across specialties and with 
primary care); structured care packages led by an 
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individual clinical specialty (such as renal nurses or 
pharmacists); and educative approaches to develop 
skills in both patients and professionals. Where 
evaluations were reported, there was evidence of 
the potential for well-designed services to provide 
benefit, with improvements in markers of disease 
and care. However, the reliance on self-reporting 
and descriptive or before-and-after designs by 
many authors did not allow robust assessment 
of effectiveness. Indeed, the only RCT (of MDC 
delivered as a case management programme versus 
standard care that combined primary care plus 
referral to a nephrologist in the usual way) found 
no statistically significant benefit but substantially 
higher cost.
We did not find any cost-effectiveness studies of 
early referral for CKD. One cost-effectiveness study 
of referral of patients with creatinine clearance 
rate of 20 ml/min (equivalent to advanced stage 
4 CKD) versus referral on the development of 
clinically significant uraemia (e.g. established 
ESRD) reported potential cost savings with the 
earlier referral approach. The model derived 
effect estimates of potential benefits from a 
prospective study of an education intervention that 
had demonstrated improvements in dialysis free 
survival. The model focused on renal outcomes.180
In the absence of high-quality RCT evidence of 
clinical effectiveness of early referral, we undertook 
an economic modelling exercise to assess the 
potential cost-effectiveness of referring individuals 
with markers for renal disease. This allowed us to 
determine what factors were driving the economic 
model and where uncertainty was having the 
greatest impact. We constructed a Markov model 
utilising the evidence from the review of the 
natural history of CKD and clinical effectiveness of 
early referral. Using individual patient creatinines 
from primary care to estimate GFR for our 
cohort, we applied reported eGFR decline rates 
to simulate how people with CKD might progress 
through CKD stages and the outcomes they might 
encounter. In order to consider the potential 
cost impact of an early referral strategy, we used 
the best described referral programme reported 
in the models of care review (a shared care 
programme described by Jones and colleagues)147 
as an example of how a service might operate. 
We compared this to referral to a nephrology 
service in stage 5 as a base case. We recognise that 
this may no longer reflect current practice in the 
UK but, as the review of models of care noted, 
UK practice was evolving rapidly and was not 
uniform across the country. We therefore felt that 
this provided a simple and transparent model 
against which to compare our hypothetical referral 
strategies. Moreover, this approach still allowed us 
to assess the incremental costs and consequences 
of sequentially increasing the eGFR referral cut-off 
up through the disease stages. The estimates of 
potential health benefits from such an intervention 
were obtained from a study using routine health-
care data to retrospectively compare early referral 
to a nephrology service with primary care only. All 
the referral strategies considered produced more 
QALYs than our standard care package. Referral 
at stage 3a was considered to be the best option 
with an ICER of £973 per QALY. Thus the base-
case modelling suggested that a package of early 
referral has the potential to offer a cost-effective 
use of resources. The model was found to be most 
sensitive to changes in the baseline risk of CKD 
progression (including the assumption that all 
patients have progressive diseases) and the effect of 
referral on risk of CKD progression.
Implications for health-care 
delivery
We have reported evidence of the potential 
for improvements in the care of people with 
CKD. While an early referral model, combining 
some form of shared care between primary 
and secondary care, has the potential to be 
cost-effective, it is unlikely that such a model is 
affordable or feasible. Key areas of uncertainty were 
identified around the natural history of people with 
CKD, in particular stage 1–3 CKD identified by the 
current ‘opportunistic screening’ approach, and 
whether subgroups can be identified where the risk 
of progression is low.
Indeed, the approaches already adopted in the UK 
to identify people with CKD have brought to the 
attention of the health-care system many people 
who would have previously gone unrecognised.217,218 
The majority of these people have stage 3 CKD. 
Such people are not those previously cared for by 
renal services. They would also not have made up 
a large component of people in clinical trials for 
treatments for CKD. As a result, the evidence for 
the optimal care of such people is unclear and this 
review further identifies the importance of well-
designed clinical trials of interventions that will 
address the care of people with CKD.
CVD was observed to be high among those with 
an eGFR < 60 ml/min/1.73 m2. At the current 
time CKD is not included as a high risk group 
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in the cardiovascular risk calculators widely 
used to determine a person’s need for CVD 
prevention. The National Screening Committee 
has been considering the place of vascular 
risk factor screening (including screening for 
CKD) for a number of years, and in England 
progress continues towards the introduction of 
an ‘NHS health check’ screening programme.175 
All 40–74 year olds not already known to have 
diabetes mellitus, CVD or CKD will be invited 
for a 5 yearly risk factor check. Anyone with a 
BP ≥ 140/90 mmHg will be assessed for CKD with a 
blood test to estimate GFR. This wider population 
screening will further identify people who would 
not previously have come to the attention of 
services. The potential health benefits and harms 
from early identification and intervention in such 
a group remain poorly understood. Population 
screening studies have been conducted to 
determine if people with previously unknown CKD 
can be identified effectively. Various combinations 
of age, comorbidity, microalbuminuria and eGFR 
criteria have been used. To date, we have found 
no evidence of evaluation of these screening 
approaches in combination with an intervention to 
assess the effectiveness in reducing morbidity and 
mortality in the screened population.175,219,220
The focus of this review was to consider the 
evidence of clinical effectiveness and cost-
effectiveness of ‘early referral’ to specialist services. 
The model of CKD services considered in the 
economics analysis relied heavily on specialist 
referral to secondary care but recognised that it 
was not feasible to do this in isolation from primary 
care. To implement a referral programme such 
as the SIMON model for all patients with CKD 
stage 3 or worse, even if it was possible to define 
a subgroup for whom progression was unlikely 
and referral therefore unnecessary, would require 
nephrology specialist capacity that is currently 
unavailable and unlikely to be affordable or 
feasible. Chapter 5 identified other options, all 
capable of delivering changes in clinical markers 
of improved control of risk factors that should 
be considered and evaluated in RCTs to identify 
the most clinically effective and cost-effective way 
forward.
The care of people with CKD in the UK is in a 
state of change. In recent years, attention has 
become more focused on the care of people 
with CKD, including the ‘early’ recognition and 
management of people with mild and moderate 
disease. The introduction of CKD to QOF has 
placed primary care at the centre of this process. 
The evidence from this review supports the 
adoption of approaches that seek to develop shared 
care between primary and secondary care, rather 
than focusing on early specialist referral. The 
economic modelling undertaken here suggests that 
interventions that can achieve the sort of health 
gains in reduction of progression, ESRD, CVD 
and mortality reported in the clinical effectiveness 
review have a good chance of being cost-effective 
and are, therefore, worthy of further evaluation.
Future research
A number of critical areas of uncertainty were 
highlighted in this review and economic analysis. 
Further research is, therefore required and the 
research priorities in order of need are summarised 
below.
1. Cohort study of the natural history of CKD 
stage 1–3. A number of cohort studies are 
underway in the UK focusing on different 
populations (the elderly; black and Indian-
Asians; laboratory detected CKD). The current 
natural history literature has identified that 
how a population was detected has important 
implications in terms of comorbidities and 
outcomes. The challenge, therefore, has been 
in applying the findings from the literature 
to what the natural history will be for people 
encountered in clinical practice.
In order to better understand the impact of 
the changing approaches to CKD detection 
we need to understand the natural history of 
CKD in relevant populations. People included 
in cohort studies should reflect the different 
approach being adopted to identify CKD 
in clinical practice: population screening; 
screening of high risk groups; laboratory-
detected CKD; and opportunistic detection as 
part of routine clinical care (e.g. addition to the 
QOF CKD register).
Cohorts might be constructed from existing 
clinical data (laboratory or QOF registers) 
and involve record linkage to provide long-
term follow-up or will require recruitment 
and follow-up of people with CKD. The 
introduction of screening programmes that 
include CKD should include an element of 
follow-up, particularly for those who were 
found to have evidence of kidney impairment.
Where possible such cohort studies should 
include measure of eGFR, creatinine, 
microalbuminuria and proteinuria as well 
as emerging prognostic markers. Details of 
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current care should be collected to allow 
a better understanding about where the 
opportunities are to optimise care. Measures 
of quality of life and the impact of diagnosis 
should be included along with the traditional 
outcomes of CVD morbidity and mortality, 
renal progression and ESRD.
Based on the event rates reported in the 
natural history literature, a cohort constructed 
from patients identified with CKD through 
opportunistic screening might anticipate 
observing 500 deaths for every 1000 patients 
followed up for 10 years with 40 people 
progressing to ESRD. General population 
screening will identify a ‘healthier’ population 
and mortality could be expected to be lower; 
250 per 1000 followed for 10 years with 10 
people progressing to ESRD.
2. Review of the clinical effectiveness and cost-
effectiveness of the main pharmacological 
interventions in people with CKD stage 1–3. 
Secondary research reviewing published studies 
of ACE Is/ARBs and statins reporting for this 
subgroup of CKD may be sufficient. A protocol 
has been published on Cochrane to this end 
but it is likely that most trials have not reported 
for these subgroups of CKD.221 Individual 
patient data meta-analysis from the key trials 
may provide sufficient data, but outcomes 
among such trial participants have been 
substantially different from population studies 
suggesting they are highly selected. RCTs of 
such interventions in patients with CKD stage 
1–3 may be required.
3. An RCT of models of care for people with 
CKD. Management of CKD is complex and 
the approach needs to be tailored to fit a 
patient’s needs. A population-based model of 
chronic disease management with intensive 
case management for those with complex 
needs, disease management for those with 
more straightforward CKD, and supported 
self-care for those with stable and mild CKD 
with few other risk factors for CVD could draw 
on aspects of many of the reports in Chapters 
4 and 5. An intervention should consider skill 
mix, education and support, communication, 
barriers to referral, sustainability and 
feasibility. RCTs will need to break down 
such a model to evaluate aspects of care, 
comparing how different levels of care are 
delivered and who delivers them: MDC teams, 
specialist nephrologist, specialist nurse, GP 
with special interest, GPs and practice nurses, 
etc. As a priority, shared care (with proactive 
involvement of primary care with delivery of 
more than simply a phlebotomy service) should 
be compared to standard specialist nephrology 
and primary care. Any trials should include 
prospective economic evaluations.
Conclusions
Despite substantial focus on the early identification 
and proactive management of CKD in the last 
few years, we have identified significant evidence 
gaps about how best to manage people with CKD. 
There was some evidence to suggest that the 
care of people with CKD could be improved and, 
because these people are at risk from both renal 
and cardiovascular outcomes, strategies to improve 
the management of people with CKD have the 
potential to offer an efficient use of health service 
resources. However, given the great uncertainty 
surrounding many parameter estimates, the 
effectiveness and cost-effectiveness of care 
strategies need to be demonstrated in prospective 
randomised studies prior to implementation. Given 
the numbers of people now being recognised as 
having markers of kidney impairment, there is 
an urgent need for further research to support 
service change. The natural history of CKD in this 
new population of people identified as having 
kidney impairment needs to be better understood. 
For many, CKD occurs as part of a complex 
comorbidity cluster, with hypertension, diabetes 
mellitus and CVD. In focusing on developing and 
evaluating approaches to provide care for people 
with CKD, it will be important to keep sight of 
opportunities to avoid developing silos of care and 
to balance with the need to identify those who have 
the most to gain from early specialist intervention.
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Searches for clinical 
effectiveness
Databases searched
MEDLINE (Ovid)
MEDLINE® In-Process & Other 
Non-Indexed Citations and Ovid 
MEDLINE® 1950 to present
1. Kidney Failure, Chronic/
2. exp “Referral and Consultation”/
3. 1 and 2
4. (renal or kidney or nephropath$or 
nephrolog$).tw.
5. referr$.tw.
6. (timing or timely or time or early or earlier or 
late or later).tw.
7. (referr$and (kidney or renal or 
nephrolog$)).m_titl.
8. 4 and 5 and 6
9. 3 or 7 or 8
10. limit 9 to (nglish language and yr=“1990 – 
2008”)
EMBASE (Ovid) 1988 to 2008 Week 05
1. Kidney Failure, Chronic/
2. (renal or kidney or nephropath$or 
nephrolog$).tw.
3. referr$.tw.
4. (timing or timely or time or early or earlier or 
late or later).tw.
5. (referr$and (kidney or renal or nephropath$or 
nephrolog$)).m_titl.
6. 2 and 3 and 4
7. exp patient referral/
8. 1 and 7
9. 2 and 3 and 4
10. 5 or 8 or 9
11. limit 10 to (English language and yr=  
“1990 – 2008”)
SCIENCE CITATION INDEX (SCI) 
searched on 4 February 2008
1. Topic=((renal or kidney or nephropath* or 
nephrolog*) and referr*)
2. Databases = SCI-EXPANDED; 
timespan = 1990–2008
3. #1 AND Language=(English) AND Document 
Type=(Meeting Abstract OR Meeting 
Summary OR Meeting-Abstract)
4. Databases = SCI-EXPANDED; 
timespan = 1990–2008
ISI Proceedings
1. Topic=((renal or kidney or nephropath* or 
nephrolog*) and referr*)
2. Timespan = All Years. Databases = STP
3. Refined by: Document Type=(PROCEEDINGS 
PAPER OR MEETING ABSTRACT) 
> Document Type=(PROCEEDINGS PAPER 
OR MEETING ABSTRACT)
British Nursing Index, British Nursing 
Index Archive, HMIC, CINAHL
1. (kidney or renal or nephrolog$or 
nephropath$).mp. and referr$.tw. [mp=ti, ab, 
hw, it, ot]
The National Research Register (NRR) 
archive up to October 2007
https://portal.nihr.ac.uk/Pages/NRRArchive.aspx
The UK Clinical Research Network
http://www.ukcrn.org.uk/index.html
COCHRANE LIBRARY
CDSR and CENTRAL
1. (referral to the paediatric):ti
2. (renal or kidney or nephropath* or 
nephrolog*) and (refer or referral):ti and (renal 
or kidney or nephropath* or nephrolog*) and 
(refer or referral):ab, from 1990 to 2008 in 
Cochrane Reviews and Clinical Trials
Additional searches for cost-
effectiveness
NHS EED searched on 26 March 2008
1. MeSH Diabetic Nephropathies EXPLODE 1 2
2. MeSH Kidney Diseases EXPLODE 1
3. MeSH Kidney Failure, Chronic EXPLODE 1 2
4. #1 or #2 or #3
5. MeSH Referral and Consultation EXPLODE 1
6. #4 and #5
7. renal OR kidney OR Nephrolog*:tw
8. refer*
9. timing OR timely OR time OR early OR earlier 
OR late OR later
Appendix 1  
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10. #7 and #8 and #9
11. refer*:ti
12. kidney OR ren
13. kidney OR renal OR Nephrolog*:ti
14. #11 and #12
15. #6 or #10 or #13
Searches for natural history
Databases searched
MEDLINE (Ovid) 1996 to March 2008
1. Exp *Kidney Failure, Chronic/
2. Exp *Natural History/
3. Exp Disease Progression/
4. renal or kidney or nephropath$or nephrolog$).
tw.
5. CKD.tw.
6. Natural course.tw.
7. Disease course.tw.
8. (Cohort or follow up or follow-up or 
longitudinal or prospective or screening or 
cross sectional or cross-sectional).tw.
9. (renal or kidney or nephropath$or 
nephrolog$).ti.
10. Exp Mass Screening/
11. Exp cohort studies/or exp cross-sectional 
studies/
12. Exp “review”/
13. Mass screen$.tw.
14. Review.ti.
15. Population-based stud$.tw.
16. 1 or 4 or 5 or 9
17. 2 or 3 or 6 or 7
18. 8 or 10 or 11 or 12 or 13 or 14 or 15
19. (Cohort or follow up or follow-up or 
longitudinal or prospective or screening or 
cross sectional or cross-sectional).ti.
20. Population-based stud$.ti.
21. 18 or 19 or 20
22. disease course or natural course).ti.
23. 17 or 22
24. 16 and 21 and 23
25. Limit 24 to (English language and humans and 
yr= “1998–2008”)
EMBASE (Ovid) 1996 to March 2008
Similar keywords as outlined in MEDLINE search 
were used with slight modification.
Searches for care model
Databases searched
MEDLINE (Ovid) 1950 to June 2008
1. exp *Kidney Failure, Chronic/
2. exp *Patient Care Management/
3. (renal or kidney or nephro$or ckd).ti
4. (manag$or service or care or practice or 
pathway).ti.
5. 1 and 2
6. 3 and 4
7. 5 or 6
8. limit 7 to (English language and yr=“2002 – 
2008”)
9. Animals/
10. 8 not 9
EMBASE (Ovid) 1996 to June 2008
Similar keywords as outlined in MEDLINE search 
were used with slight modification.
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Appendix 2  
Data extraction form
Clinical effectiveness
DATA EXTRACTION FORM (NICE guidelines manual)
Person extracting data: 
Date:
Bibliographic reference:
Ref ID
Authors
Title
Journal
Volume (issue)
Year
Pages
Reference type Abstract  Full publication
Country
Stated aim of study
Source of funding
Study type:
Study type
Prospective/retrospective
Number of patients:
Patient selection
How were patients identified
Inclusion criteria
Exclusion criteria
Number of patients started/completed
Give numbers and reasons (if reported) and 
indication if withdrawals were similar to those 
who completed study
Classification of CKD (e.g. KDOQI)
Number of patients at different stages of CKD
Appendix 2
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Patient characteristics at baseline
Data and indication if there were any significant differences observed
Definition of early/late referral (months)
Other definitions
Intervention
Initiation of referral
Intervention studied
Give as much detail as possible: setting, care, 
treatments, staffing, number and duration of visits, 
education
Comparison
Alternative treatment
Length of follow-up
Outcome measures
Primary outcomes
Secondary outcomes
Safety
Adverse effects
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Results
Renal Function
All-cause mortality
CVD mortality
Onset of RRT
Quality of life
Barriers to early referral
Hospitalisation
Emergency dialysis
Survival on dialysis
Costs
Treatments
Subgroups
Integrity/Fidelity of Intervention
Was the intervention implemented as planned?
Adherence
Exposure
Quality of delivery
Participant responsiveness
Programme differentiation
Subgroup variation
Additional comments:
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Appendix 3  
Excluded studies
Clinical effectiveness
TABLE 37 Studies excluded from the clinical effectiveness systematic review
Study Reason for exclusion
Anees 2007222 Cross-sectional survey
Arora 1999223 ER defined as < 12 months
Avorn 2002224 ER defined as < 12 months
Baker 2003225 Late referral
Barril 2002226 Not early CKD
Brown 2003227 Screening
Burton 1999228 Too little detail
Caskey 2003229 ER defined as < 12 months
Cass 2002230 ER defined as < 12 months
Chan 2007231 Review; ER defined as < 12 months
Chandna 1999232 Timing of referral not assessed
Curtis 2007233 Timing of referral not assessed
Dautlich 1999234 Referral patterns
Department of Health 20052 Not relevant to area
Dogan 2005235 ER defined as < 12 months
Ellis 1998236 ER defined as < 12 months
Fan 2002237 ER defined as < 12 months
Fox 2006238 Qualitative study of primary care practices and knowledge regarding CKD
Goransson 2001239 ER defined as < 12 months
Harris 1999240 ER defined as < 12 months
Hyder 2000241 Referral patterns
Innes 1992242 Not comparing ER with LR
Iseki 2002243 ER defined as < 12 months
Ismail 1998244 Review; non-systematic
Jones 2006147 Evaluating the effectiveness of a shared care scheme
Jones, 2006105 Natural history of CKD before and after first referral to nephrologist
Jungers 1993245 ER defined as < 12 months
Jungers 1993246 ER defined as < 12 months
Jungers 1997247 Abstract 1997
Jungers 2001121 ER defined as < 12 months
Kazmi 2002248 ER defined as < 12 months
Kazmi 2004249 ER defined as < 12 months
Klebe 2007250 Economics
Cost of implementing CKD guidelines
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Study Reason for exclusion
Komenda 2006169 Non-systematic review
Lhotta 2003251 ER defined as < 12 months
Lin 2003252 ER defined as < 12 months
Lin 2004253 ER defined as < 12 months
Locatelli 2002254 Non-systematic review
London 2003255 Predictors of suboptimum care
Lusenti 2006256 Specific RAS intervention
McLaughlin 2001180 Economic evaluation
Mendelssohn 1999257 Guidelines
Nakamura 200755 ER defined as < 12 months
Ohmit 2003258 Screening
Paris 2002259 Does not report mortality
Rao 2002260 Patterns of referral
Rasgon 2003261 Insufficient detail
Ratcliffe 1984262 1984
Ravani 2003263 ER defined as < 12 months
Roderick 1999264 Abstract 1999
Published in full reference ID 15
Roderick 2002265 Avoid ability of late referral
Roubicek 2000266 ER defined as < 12 months
Rutherford 1997267 ER defined as < 12 months
Schmidt 1998268 Economic evaluation
Schwenger 2006269 ER defined as < 12 months
Sesso 1996270 ER defined as < 12 months
Shin 2007271 ER defined as < 12 months
Stack 2003272 ER defined as < 12 months
Stoves 2001273 ER defined as < 12 months
Thanamayooran 2005151 Evaluation of a multidisciplinary clinic
Thomas 2007274 Guidelines
Tseng 200894 Not comparing early with late referral
Wavamunno 2005275 Non-systematic review
White 2002276 Evaluation of pre-dialysis clinic
Winkelmayer 2003277 ER defined as < 12 months
Wu 2003278 ER defined as < 12 months
AHRQ 2002279 Summary of research findings
AHRQ 2005280 Summary of research findings
AHRQ 2002281 Summary of research findings
AHRQ, Agency for Healthcare Research and Quality; CKD, chronic kidney disease; ER, early referral; LR, late referral; 
RAS, renal artery stenosis.
TABLE 37 Studies excluded from the clinical effectiveness systematic review (continued)
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Natural history
TABLE 38 Studies excluded from systematic review of natural history of CKD
Study Reason for exclusion
Adler 2003203 RCT, do not give outcomes by CKD group
Altman 1999282 Less than 100 patients
Boes 2006283 Mainly prediction study
Bruno 2003284 Study of incidence
Busch 2006285 RCT
Chandie 2006286 Does not include the cohort of CKD
Chauveau 2007287 Less than 100 patients
Chonchol 2007288 Does not separate out people with CKD from people without CKD
Chow 2003115 Cross-sectional study
Christensen 1999289 Less than 100 patients
Costacou 2007290 Less than 100 patients
Dale 200877 Reviews most of the studies including patients with ESRD
Damman 2007291 Cohort of patient with heart failure
Dean 2005292 Less than 2 years’ follow-up
Drummond 2002293 Does not separate out people with CKD from people without CKD
Earle 2001294 Less than 100 patients
Edwards 2005295 Does not identify those with or without CKD
El Kossi 2003296 Cohort of transplant not CKD
Fliser 2005297 Study of prediction only
Fliser 2007298 Duplicate cohort as above so only use one with relevant information
Fouque 200651 RCT
Fried 200150 Does not mention the difference of declining GFR
Fried 2004299 Presents the data by changing eGFR not by CKD
Hadjadj 2004300 Less than 100 patients
Hebert 2003301 Does not report the progression of CKD for whole cohort or relevant subgroup
Henry 2002302 Does not present data by CKD group
Hovind 2003303 Does not separate out people with or without CKD
Hovind 2001304 Does not split data by CKD
Hoy 2006305 Includes Australian Aborigines only
Hsu 2006306 Includes black people only
Imbasciati 2007307 Less than 100 patients
Iseki 2004308 Does not separate patients with or without CKD
Jacobsen 1999309 Does not separate patients with or without CKD
Jacobsen 2003310 Does not separate patient with or without CKD
Jafar 2001311 RCT and cohort defined only by protein
Jafar 200143 Duplicate of above study
Jafar 2003312 RCT and cohort defined by sex only
Jafar 2003313 Cohort defined by protein and blood pressure
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Study Reason for exclusion
Jovanovic 1999314 Less than 100 patients
Jude 2002315 Cohort presented by protein only, not by eGFR
Kasiske 1998316 Does not present change in renal function
Kim 2003317 Less than 100 patients
Kohli 2006318 Less than 100 patients
Kristjansson 2001319 Does not define by CKD group
Kronborg 2008320 Do not report data for CKD subgroup
Kshirsagar 200045 Study predicting risk not giving a rate of decline in GFR
Larsson 2005321 Does not define by CKD group
Leeder 2006322 Presented by haemoglobin subgroup
Lerma 2005323 Editorial
Locatelli 2000324 Comparison of two RCTs
Mann 2003325 Does not identify subgroups of CKD
Marcotte 2006326 Less than 100 patients
Massy 1999327 No relevant subgroups
McClellan 2004328 Cohort of patients with acute myocardial infarction
Menon 2008329 Includes patients who were initially restricted to protein diet in RCTs
Merkin 2005330 Cohort defined by socioeconomic status only
Middleton 2006331 Testing the value of different screening criteria
Morita 2006332 Follow-up < 2 years
Muhlhauser 2000333 Does not separate based on creatinine values
Neild 2004334 Cohort of people with reflux, specific renal diagnosis
Orth 2008335 Not a systematic review
Perlman 2003336 Does not include the cohort of CKD but those with ESRD
Ruggenenti 1998337 Cohort analysis of RCT
Rigalleau 2007338 Comment
Rottey 2000339 Less than 100 patients
Samuelsson 2000340 Letter
Sesso 2008341 Does not separate out by CKD group
Song 2005342 Less than 100 patients
Stam 2006343 Does not separate out by CKD group
Stojceva-Taneva 2001344 Less than 100 patients
Thomas 2006345 Less than 100 patients
Ueda 2003346 Less than 100 patients
Wang 2005347 Cross-sectional study
Wasse 2006348 Editorial
Wright 2002349 Less than 100 patients
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESRD; end-stage renal disease; GFR, 
glomerular filtration rate; RCT(s), randomised controlled trial(s).
TABLE 38 Studies excluded from systematic review of natural history of CKD (continued)
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Appendix 4  
Quality assessment
TABLE 39 Quality assessment of systematic reviews included in Chapter 3
Di 200768 Tonelli 200667
Internal validitya
The study addresses an appropriate 
and clearly focused question
Well covered Well covered
A description of the methodology used 
is included
Well covered Well covered
The literature search is sufficiently 
rigorous to identify all the relevant 
studies
Well covered Well covered
Study quality is assessed and taken into 
account
Not addressed Well covered
There are enough similarities 
between the studies selected to make 
combining them reasonable
Adequately addressed Adequately addressed
Overall assessment of the study
How well was the study done to 
minimise bias? Code ++, + or –
++ ++
If coded as + or – what is the likely 
direction in which bias might affect the 
study results?
NA NA
Description of the study
What types of study are included in 
the review?b
Cohort Cohort
How does this review help to answer 
your key question?
Summarise the main conclusion of the 
review and how it relates to the relevant 
key question. Comment on any particular 
strengths or weaknesses of the review
Study found that there is a moderate 
association between lower than 
average eGFR and CHD risk in general 
healthy population. Inclusion of 
participants from community with high 
response and follow-up rates were 
the main strength of this study. Study 
found less evidence for heterogeneity 
among studies and publication bias. 
Measurement bias was minimised by 
checking for serum creatinine assay 
within included studies; however, 
study failed to check for chronicity of 
CKD increasing the risk of inclusion of 
participants with acute renal failure
This study concluded that CKD 
(non-dialysis dependent) is associated 
with an increased risk for all-cause 
mortality or cardiovascular death and 
supports intervention in patients with 
CKD to prevent adverse outcomes. 
Overall, the study was of good quality. 
The study did not account for the 
chronicity (> 3 months) of CKD which 
may have reduced classification bias by 
reducing cases with acute renal failure
CHD, coronary heart disease; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; NA, not 
applicable.
a Well covered, adequately addressed, poorly addressed, not addressed, not reported or not applicable
b RCT, controlled clinical trial, cohort, case–control or other.
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Appendix 5  
Summarised result of Chapter 3
TABLE 40 Risk of all-cause mortality and cardiovascular mortality and morbidity for general CKD population (eGFR < 60 ml/
min/1.73 m2) unless stated
Study ID Measures Values (variance) Adjusted for what
Comparator/
reference 
group
ACM
HR or RR
Astor 200885 RR (95% CI) 1.77 (1.47 to 2.13) Age, sex, race/ethnicity, previous 
cardiovascular diseases, blood 
pressure, use of antihypertensive 
medication, diabetes, smoking, 
body mass index, physical activity, 
cholesterol and C-reactive protein
eGFR ≥ 90 ml/
min/1.73 m2
Eriksen 
200696,97
HR (95% CI) 
(stage 3 only)
1.25 (1.14 to 1.37) Sex and age For each eGFR 
decrease of 
10 ml/min/1.73 m2
Herzog 200492 HR CKD only 
(95% CI)
1.64 (1.58 to 1.70) Associated comorbidity Compared to 
those without 
CKD, CHF or 
anaemiaHR CKD + CHF + 
anaemia (95% CI)
3.63 (3.52 to 3.75) CKD defined based on ICD-9-CM 
and CPT codes
Irie 200681 RR (95% CI) M: 1.31 (1.12 to 1.52)
F: 1.39 (1.20 to 1.62)
Age, high blood pressure, smoking, 
alcohol, diabetes, cholesterol, body 
mass index, urinary protein
eGFR > 100 ml/
min/1.73 m2
Meisinger 
200676
HR (95% CI) M: 1.17 (0.97 to 1.41)
F: 1.12 (0.90 to 1.39)
Age and survey, history of diabetes, 
smoking, body mass index, alcohol, 
high blood pressure, physical 
activity, dyslipidaemia
eGFR ≥ 60 ml/
min/1.73 m2 
Tonelli 200668 RR (95% CI) 3.0 (2.18 to 4.11) (NB 
heterogeneity reported)
Pooled estimate therefore variable 
with each included study (range 
0.94–5.00)
eGFR ≥ 60 ml/
min/1.73 m2
FHS 1999a HR (95% CI) M: 1.31 (1.02 to 1.68
F: 1.08 (0.87 to 1.34)
Adjusted eGFR ≥ 60 ml/
min/1.73 m2
NHANES I 
2002a
HR (95% CI) 1.00 (0.76 to 1.32) Adjusted eGFR ≥ 60 ml/
min/1.73 m2
Shivonen 2004a HR (95% CI) 3.48 (1.95 to 6.21) Adjusted eGFR ≥60 ml/
min/1.73 m2
Weiner 200474 HR (95% CI) 1.36 (1.21 to 1.53) Age, sex, high blood pressure, 
diabetes, systolic blood pressure, 
body mass index, cholesterol, 
smoking, alcohol, left ventricular 
hypertrophy, high school 
graduation and race
eGFR ≥60 ml/
min/1.73 m2
SMR
Eriksen 
200696,97
Mortality rate 
ratio (95% CI) 
2.2 (2.1 to 2.4) Standardised for age and sex Tromsø general 
population
Evans 200598 SMR (95% CI) 8.3 (7.5 to 9.2) Standardised for age and sex Swedish 
population
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Study ID Measures Values (variance) Adjusted for what
Comparator/
reference 
group
John 2004104 SMR (95% CI) 1.53 (1.44 to 1.62) Standardised for age and sex Population 
of south-east 
England
Cardiovascular morbidity and mortality
HR or RR
Astor 200885 RR of CVD deaths 
(95% CI)
2.12 (1.65 to 2.73) Age, sex, race/ethnicity, previous 
cardiovascular diseases, blood 
pressure, use of antihypertensive 
medication, diabetes, smoking, 
body mass index, physical activity, 
cholesterol and C-reactive protein
eGFR ≥ 90 ml/
min/1.73m2
Irie 200681 RR of CVD deaths 
(95% CI)
M: 1.65 (1.25 to 2.18)
F: 1.81 (1.39 to 2.36)
Adjusted for age, high blood 
pressure, smoking, alcohol, 
diabetes, cholesterol, body mass 
index, urinary protein
eGFR>100 ml/
min/1.73 m2
Meisinger 
200676
HR for CVD 
deaths (95% CI)
M: 1.48 (1.15 to 1.92)
F: 1.60 (1.17 to 2.18)
Adjusted for age and survey, 
history of diabetes, smoking, 
body mass index, alcohol, high 
blood pressure, physical activity, 
dyslipidaemia
Without CKD
Meisinger 
200676
HR for incident MI 
(95% CI)
M: 1.51 (1.09 to 2.10)
F: 1.67 (1.07 to 2.61)
Adjusted for age and survey, 
history of diabetes, smoking, 
body mass index, alcohol, high 
blood pressure, physical activity, 
dyslipidaemia
Without CKD
Tonelli 200668 RR of CVD 
mortality (95% CI)
2.47 (1.42 to 4.30)
(heterogeneity 
reported)
Adjustment varies between the 
included studies 
eGFR ≥ 60 ml/
min/1.73 m2
Wannamethee 
200637
HR for CVD 
death (95% CI) 
eGFR < 60 ml/
min/1.73 m2: 1.49 (1.10 
to 2.03)
eGFR 60–69 ml/
min/1.73 m2: 1.27 (0.95 
to 1.68)
Adjusted for age, smoking, 
activity, alcohol, body mass index, 
cardiovascular diseases, diabetes, 
forced expiratory volume 1, 
albumin, systolic blood pressure, 
left ventricular hypertrophy, high 
blood pressure, high-density 
lipoprotein-cholesterol
eGFR > 70 ml/
min/1.73 m2
Weiner 200474 HR of MI/fatal 
CHD (95% CI)
1.09 (0.91 to 1.29) Age, sex, high blood pressure, 
diabetes, systolic blood pressure, 
body mass index, cholesterol, 
smoking, alcohol, left ventricular 
hypertrophy, high school 
graduation and race
eGFR ≥ 60 ml/
min/1.73 m2
Di 200769 RR for CHD  
(95% CI)
1.32 (1.19 to 1.68) Adjusted varies between the 
included studies
eGFR ≥ 60 ml/
min/1.73 m2
John 2004104 SMR for CVD 
mortality (95% CI)
1.14 (1.03 to 1.25) Standardised for age and sex Population 
of south-east 
England
ACM, all-cause mortality; CHD, coronary heart disease; CHF, congestive heart failure; CI, confidence interval; CKD, 
chronic kidney disease; CPT, physicians’ current procedural terminology; eGFR, estimated glomerular filtration rate; F, 
female; FHS, Framingham Heart Study; HR, hazard ratio; ICD-9-CM, International Classification of Diseases, Ninth Edition, 
Clinical Modification; M, male; MI, myocardial infarction; NHANES, National Health and Nutritional Examination Survey; 
RR, relative risk; SMR, standardised mortality rate.
a Study within Tonelli et al. 2006.68
TABLE 40 Risk of all-cause mortality and cardiovascular mortality and morbidity for general CKD population (eGFR < 60 ml/
min/1.73 m2) unless stated (continued)
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Appendix 6  
Summarised result (subgroups) of Chapter 3
TABLE 41 All-cause mortality/cardiovascular disease morbidity and mortality/renal outcomes for diabetes mellitus in CKD
Study ID Measures
Value (variance)
NotesTotal CKD CKD stages
ACM
Bruno 200779 HR of mortality 
(95% CI) 
1.92 (1.64 to 2.23) Stage 1: reference
Stage 2: 0.83 (0.58 to 1.17)
Stage 3a: 1.02 (0.70 to 1.49) 
Stage 3b: 1.10 (0.72 to 1.68) 
Stage 4: 4.12 (2.36 to 7.18)
HR adjusted for age and 
sex. Compared with 
eGFR ≥ 60 ml/min/1.73 m2
Bruno 200779 Mortality rate 
per 10,000 
person-years
953 Stage 1: 42.5
Stage 2: 49.5
Stage 3a: 85.8
Stage 3b: 108.8
Stage 4: 377.1
Compared to 487 with 
eGFR ≥ 60 ml/min/1.73 m2
Patel 200580 Mortality rate 
per 10,000 
person-years
eGFR > 60 no proteinuria: 470
eGFR > 60 + proteinuria: 580
Stage 3a: 810
Stage 3b: 1500
Stage 4: 2010
Stage 5: 2980
Cumulative mortality within follow-up period
Bruno 200779 Number of 
deaths
304/1539 (19.75%) Stage 1: 37/113 (32.7%)
Stage 2: 329/898 (36.6%)
Stage 3a: 217/400 (54.3%)
Stage 3b: 66/106 (62.3%)
Stage 4: 21/21 (100%)
10 years’ follow-up
Tarnow 200489 Number of 
deaths
51 (26%) 9 years’ follow-up 
Rossing 200488 Number of 
deaths
79 (35%) Median follow-up 6.5 
years 
Tseng 200894 Number of 
deaths
6934 (17.8%) Stage 3a: 3984/27,312 (14.6%)
Stage 3b: 1963/8760 (22.4%)
Stage 4: 987/2959(33.4%)
Median follow-up 19.3 
(range < 0.01 to 24) 
months
Tseng 200894 Number of 
dialysis-free 
deaths
6454 (16.5%) Stage 3a: 3854/27,312 (14.1%)
Stage 3b: 1810/8760 (20.7%)
Stage 4: 790/2959 (26.7%)
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Study ID Measures
Value (variance)
NotesTotal CKD CKD stages
continued
CVD morbidity/mortality
Bruno 200779 HR of CVD 
deaths (95% CI)
2.16 (1.74 to 2.68) Stage 1: reference
Stage 2: 0.77 (0.46 to 1.29)
Stage 3a: 0.96 (0.55 to 1.67)
Stage 3b: 1.19 (0.65 to 2.17)
Stage 4: 4.64 (2.15 to 10.01)
Adjusted for age and sex, 
compared with GFR ≥ 60: 
1
Bruno 200779 CVD deaths 
rate per 10,000 
person-years
507 Stage 1: 19.5
Stage 2: 22.9
Stage 3a: 43.8
Stage 3b: 64.3
Stage 4: 213.6
Compared to 225 with 
GFR≥60 
Cumulative cardiovascular mortality/events during follow-up
Bruno 200779 Number of CVD 
deaths 
162/1539 (10.5%) Stage 1: 17/113 (15%)
Stage 2: 152/898 (16.9%)
Stage 3a: 111/400 (27.8%)
Stage 3b: 39/106 (36.8%)
Stage 4: 12/21 (57.1%)
Mean follow-up 10 years
Tarnow 200489 CVD events (95% 
CI)
11% (8 to 14) 9 years’ follow-up
Rossing 200488 Number of 
deaths
55/227 (24.2%) Median follow-up 6.5 
years
Rossing 200488 Number of new 
CVD events
Range: 7–38 (3–
17%) 
Median follow-up 6.5 
years
Renal outcomes
Leehey 2005109 Mean rate of 
decline of GFR 
(range) ml/
min/1.73 m2/year
4.5 (–14 to 32)
Mulec 199887 Rate of decline 
in GFR (SD) ml/
min/1.73 m2/year
3.8 (3.7)
Hovind 200193 Mean rate of GFR 
decline (SD) ml/
min/1.73 m2/year
4.0 (0.2)  Median follow-up 6.7 
(range 3–14) years
Rossing 200488 Mean rate of 
decline of GFR 
(SD) ml/min/year
5.2 (4.1) Not standardised to body 
surface area
Hemmelgarn 
2006101
Rate of decline in 
eGFR (95% CI) 
ml/min/1.73 m2/
year
Stage 2: F: 1.6 (1.0 to 2.1);   
M: 2.1 (1.6 to 2.6)
Stage 3: F: 2.8 (2.3 to 3.3); M: 
3.6 (3.1 to 4.2)
Stage 4: F: 2.9 (2.2 to 3.7); M: 
3.2 (2.3 to 4.0)
Adjusted for age
TABLE 41 All-cause mortality/cardiovascular disease morbidity and mortality/renal outcomes for diabetes mellitus in CKD (continued)
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Study ID Measures
Value (variance)
NotesTotal CKD CKD stages
Patel 200580 Rate of 
progression to 
ESRD as events 
per 100 person-
years
eGFR > 60 no proteinuria: 0.0
eGFR > 60 + proteinuria: 0.2
Stage 3a: 0.3
Stage 3b: 1.7
Stage 4: 14.2
Stage 5: 0
Progression to ESRD is 
defined as a change to an 
estimated GFR less than 
15 ml/min/1.73 m2
Rate of any 
progression as 
events per 100 
person-years
eGFR > 60 no proteinuria: 3.2
eGFR > 60 + proteinuria: 7.8
Stage 3a: 10.5 
Stage 3b: 11.8
Stage 4: 15.1 
Stage 5: 0
Any progression of CKD 
is defined as a change to 
any disease group category 
with a lower GFR and/or 
presence of proteinuria 
with at least a 20 % 
decrease in estimated GFR 
(to avoid trivial changes in 
CKD classifications)
Orlando 
2007111
HR of 
progression (95% 
CI)
Stage 1 to 2: 1.32 (1.13 to 1.55)
Stage 2 to 3: 1.18 (0.97 to 1.43)
Stage 3 to 4: 1.13 (0.86 to 1.50)
Compared to non-
diabetics CKD
Rossing 200488 Proportion 
of doubling of 
baseline serum 
creatinine
63/227 (28%) Median follow-up 6.5 
years
Khatami 
2007108
Proportion 
progressed to 
CKD stages 4 
and 5 
8.6% 4 years’ follow-up, 
eGFR < 60 ml/min/1.73 m2 
at baseline
Jones 2006105 Proportion of 
progressors
64/314 (20.4%) ≤ –5 ml/min/year: 32/145 (22%)
> –5 to ≤ –1 ml/min/year: 
32/169 (19%)
Non-progressors 60/412 
(15%). Progression defined 
as ≤ –1 ml/min/year
Median follow-up 2.9 years
Rossing 200488 Number reaching 
ESRD within 
follow-up
15 (7%) Median follow-up 6.5 
years (range 3–17)
Tseng 200894 Number of 
dialysis during 
follow-up
841 (2.2%) Stage 3a: 203/27,312 (0.7%)
Stage 3b: 251/8760 (2.9%) 
Stage 4: 387/2959 (13.1%)
Median 19.3 months  
(1.6 years)
ACM, all-cause mortality; CI, confidence interval; CKD, chronic kidney disease, CVD, cardiovascular diseases; eGFR, 
estimated glomerular filtration rate; ESRD, end-stage renal disease; F, female; HR, hazard ratio; M, male; SD, standard 
deviation.
TABLE 41 All-cause mortality/cardiovascular disease morbidity and mortality/renal outcomes for diabetes mellitus in CKD (continued)
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TABLE 42 All-cause mortality/cardiovascular disease morbidity and mortality/renal outcomes for those with CKD and CVD or 
hypertension
Study ID Measures
Values (variances)
Comparator CommentsTotal CKD CKD stages
CKD with CVD
Levin 200184 Proportion of 
RRT
At 6 months: 
4/118 (3.4%)
At 12 months: 
6/92 (6.5%)
At 24 months: 
6/31 (19.4%)
No CVD
At 6 months: 
10/268 (3.7%)
At 12 months: 
7/218 (3.2%)
At 24 months: 
18/94 (19.1%)
Median follow-up 23 
months
Orlando 
2007111
HR for 
progression  
(95% CI)
Stage 1 to 2: 1.35 
(1.14 to 1.61)
Stage 2 to 3: 1.52 
(1.23 to 1.93)
Stage 3 to 4: 0.86 
(0.64 to 1.17)
Compared with 
no CVD
Tonelli 
200668
RR for ACM  
(95% CI)
1.71 (1.49 to 1.96) Compared with 
no CVD
Pooled from nine studies
Tonelli 
200668
RR for CVD 
mortality
1.8 (1.45 to 2.24) Compared with 
no CVD
Pooled from seven 
studies
Tseng 
200894 
(diabetic 
population 
at baseline)
HR for dialysis 
(95% CI)
1.25 (1.17 to 1.33) Adjusted for nephrology 
referrals, age, sex, race, 
poverty, index eGFR, 
life threatening disease, 
physical comorbid, 
mental morbidity, no of 
visits
HR for dialysis 
free death  
(95% CI)
1.30 (1.27 to 1.32)
HR for ACM  
(95% CI)
1.29 (1.27 to 1.32)
CKD with HBP
Orlando 
2007111
HR of CKD 
progression  
(95% CI)
Stage 1 to 2: 0.8 
(0.66 to 1.35)
Stage 2 to 3: 0.93 
(0.72 to 1.57)
Stage 3 to 4: 0.91 
(0.77 to 1.53)
Compared with 
no HBP
Tonelli 
200668
HR of ACM  
(95% CI)
2.15 (1.77 to 2.61) Compared with 
no HBP
Pooled from eight 
studies
Tonelli 
200668
HR of CVD 
mortality  
(95% CI)
2.35 (1.52 to 
3.64)
Compared with 
no HBP
Pooled from three 
studies
ACM, all-cause mortality; CI, confidence interval; CKD, chronic kidney disease, CVD, cardiovascular diseases; 
eGFR, estimated glomerular filtration rate; HBP, high blood pressure; HR, hazard ratio; RR, relative risk; RRT, renal 
replacement therapy.
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TABLE 43 Summarised result for different age groups in CKD
Study ID Measure Age groups Value (variance) Comments
ACM
Bruno 
200779
HR of ACM (95% CI) < 70 years 1.51 (1.07 to 2.13) eGFR < 60 vs ≥ 60, adjusted 
for age and sex (diabetics 
at baseline)≥ 70 years 1.09 (0.89 to 1.35)
Evans 200598 SMR for ACM (95% CI) < 69 years 20.6 (11 to 35.3) All population CKD stages 
4 and 5
Eriksen 
200696,97
Cumulative mortality 
of 10 years (95% CI)
< 69 years 0.17 (0.14 to 0.21) All population CKD stage 
3
70–79 years 0.49 (0.45 to 0.54)
> 79 years 0.84 (0.80 to 0.89)
Drey 200395 Number of deaths in 
median follow-up of 
5.5 years
< 50 years 17/70 (24.3%) Median survival time:
50–59 years: 55 months
> 80 years: 26 months
50–59 years 27/52 (51.9%)
60–69 years 92/159 (57.9%)
70–79 years 246/379 (64.9%)
> 80 years 354/410 (86.3%)
Eriksen 
200696,97
Mortality rate ratios 
(95% CI)
< 69 years 3.1 (2.5 to 3.9) All population CKD stage 
3
70–79 years 2.0 (1.8 to 2.3)
> 79 years 2.2 (2.0 to 2.3)
Cardiovascular morbidity and mortality
Bruno 
200779
HR of CVD mortality 
(95% CI)
< 70 years 1.46 (0.85 to 2.51) eGFR < 60 vs ≥ 60, adjusted 
for age and sex (diabetics 
at baseline)≥ 70 years 1.07 (0.80 to 1.42)
John 2004104 SMR for CVD 
mortality (95% CI)
< 60 years 10.8 (1.28 to 20.32) Compared to population 
of south-east England; 
standardised for age and 
sex≥ 80 years 0.96 (0.86 to 1.06)
ESRD
Eriksen 
200696,97
10 years’ cumulative 
incidence of ESRD 
(95% CI)
< 69 years 0.07 (0.05 to 0.11) All population CKD stage 
3
70–79 years 0.04 (0.02 to 0.07)
> 79 years 0.03 (0.01 to 0.05)
Cumulative incidence
Hsu 2003103 Incident of ESRD  
(4 years and 6 years)
Age 20–60 years Black people: 14,593; white 
people: 20,323
Fixed 1991–6 and 1994–9
Age 61–74 years Black people: 6714; white 
people: 18,693
Drey 200395 Incident of ESRD in 
follow-up
< 60 years 28 (21%) Mean 5.5 years
≥ 60 years 11 (1.5%)
continued
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Study ID Measure Age groups Value (variance) Comments
Eriksen 
200696,97
Incidence rate ratios of 
ESRD (95% CI)
< 69 years 36.6 (21.2 to 63.2) All population CKD stage 
3
70–79 years 3.1 (2.3 to 7.0)
> 79 years 3.7 (2.2 to 6.2)
Hsu 2003103 New ESRD cases 
(1996)/CRI prevalence 
(1991)
Age 20–60 years Black people: 0.099; white 
people: 0.017
Age 61–74 years Black people: 0.027; white 
people: 0.008
ACM, all-cause mortality; CI, confidence interval; CKD, chronic kidney disease, CRI; chronic renal insufficiency; CVD, 
cardiovascular diseases; ESRD, end-stage renal disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio; 
SD, standard deviation; SMR, standardised mortality rate.
TABLE 44 Summarised result for gender differences in CKD
Study ID Measures
Value (variances)
CommentsMale Female
ACM
Evans 200598 SMR of mortality (95% 
CI)
7.2 (6.3 to 8.1) 12.3 (10.3 to 14.5) Compared to general 
Swedish population
Eriksen 
200696,97
10 years’ cumulative 
mortality (95% CI)
0.61 (0.56 to 0.67) 0.47 (0.43 to 0.50)
Eriksen 
200696,97
Number of deaths 
during follow-up
383 (41%) 576 (27%) Median follow-up 3.6 
years
Drey 200395 Number of deaths 
during follow-up
448/646 (69.35%) 288/425 (67.76%) Mean 5.5 years
Eriksen 
200696,97
Mortality rate ratios 
(95% CI)
2.4 (2.2 to 2.7) 2.1 (1.9 to 2.3)
Renal outcomes
Eriksen 
200696,97
10 years’ cumulative 
incidence of ESRD (95% 
CI)
0.08 (0.05 to 0.11) 0.03 (0.02 to 0.04)
Eriksen 
200696,97
ESRD during follow-up Stage 5: 33 (4%)
RRT: 2 (0.2%)
Stage 5: 25 (1%)
RRT: 2 (0.1%)
Median follow-up 3.6 
years
Hsu 2003103 Incidence of ESRD (4 
and 6 years)
Black people: 10,555
White people: 22,001
Black people: 10,752
White people: 17,015
1991–6 and 1994–9
Eriksen 
200696,97
ESRD incidence rate 
ratios
6.5 (4.3 to 9.9) 4.3 (2.7 to 6.9)
Hsu 2003103 New ESRD cases(1996)/
CRI prevalence (1991)
Black people: 0.069
White people: 0.015
Black people: 0.044
White people: 0.008
Hovind 200193 Mean rate of GFR 
decline (SD) ml/
min/1.73 m2/year
4.1 (0.3) 4.0 (0.4) Median follow-up 6.7 
years
ACM, all-cause mortality; CI, confidence interval; CRI; chronic renal insufficiency; ESRD, end-stage renal disease; GFR, 
glomerular filtration rate; RRT renal replacement therapy; SD, standard deviation; SMR, standardised mortality rate.
TABLE 43 Summarised result for different age groups in CKD
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Background
As CKD progresses towards ESRD, the patient and 
clinical team need to prepare. Decisions about RRT 
modality, preparation for transplant if appropriate, 
establishment of vascular access for haemodialysis, 
nutritional preparation, management of anaemia, 
and fluid and electrolyte balance are all important 
aspects of preparations. During this time, patients 
and their carers need support and also the time to 
plan and prepare. The 12 months prior to dialysis 
have been described by some as a critical time, 
and yet very late referral to specialist renal services 
remains common place. Between 20% and 50% of 
referrals reportedly occur within 4 months of the 
need to start dialysis.54–56,350,351
In searching for literature about the effectiveness of 
early referral for CKD, we identified a substantial 
literature evidencing the implications of late 
referral and this is summarised here.
Chan and colleagues57 recently published a 
meta-analysis which compared the differences 
in mortality and duration of hospitalisation 
in CKD patients who were referred early to a 
nephrologist versus those who were referred late. 
They concluded that late referral of CKD patients 
significantly increased the risk of death (RR 1.99, 
95% CI 1.66 to 2.39).
Chan and colleagues’57 review focused on ACM and 
hospitalisation in dialysis patients in relation to 
the timing of referral to specialist nephrology care. 
In this appendix, we considered other outcomes, 
including cardiovascular mortality and morbidity 
and quality of life, and sought information about 
what criteria or factors triggered referral. We 
focused on studies reporting, as a minimum, 
mortality as an outcome and comparing referral 
less than 12 months before the initiation of RRT to 
earlier referral.
Results
Twenty-seven studies were identified from the 
literature search. Of these, 10 studies were 
excluded because they did not measure mortality, 
leaving 17 studies.
The studies reported findings from a wide range 
of countries: three studies from the UK,236,237,273 a 
further four from Europe,239,251,266,269 three from the 
USA,249,277,352 five from Asia,243,252,253,271,278 one from 
Australia/New Zealand230 and one from Brazil.270 All 
17 studies were available in full publication.
All 17 of the studies were retrospective, based on 
recruiting participants at the initiation of RRT.
The time interval used to define ‘late referral’ 
differed among the studies. Three studies237,243,270 
considered ‘late referral’ as being less than 
1 month between first contact with renal specialty 
and the commencement of dialysis. Seven 
studies230,236,239,271,273,277,352 defined ‘late referral’ 
as being less than 3 months between referral 
and starting dialysis. A definition of less than 
16 weeks/4 months was used in two studies,249,266 
while one study251 determined ‘late referral’ 
in relation to GFR. Patients with a GFR < 20 
ml/min/1.73 m² at first referral were grouped as 
‘late referral’. The remaining four studies252,253,269,278 
considered late referral as being referred less than 
6 months prior to commencing RRT.
Six of the 17 studies included in excess of 1000 
participants.230,243,249,273,277,352 The majority of the 
studies included smaller patient groups, where 
participant numbers ranged from 52 to 270. The 
number of study participants across all studies 
totalled 16,600. Only one study reported a measure 
of renal function at the time of referral.251 Four of 
the studies specified in their methods that people 
with acute renal failure were excluded.230,239,249,266 
Table 45 summarises the included studies.
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TABLE 45 Summary of included studies of late referral
Study ID Country
Definition 
of late 
referral
Total 
number 
starting 
dialysis Inclusion criteria
Total 
number 
of study 
participants
% late 
referrals
Avorn 
2002352
USA ≤ 90 days 17,884 Adequate records; ‘insured’ 
patients; first diagnosis of renal 
disease > 1 year prior to dialysis; 
> 30 days dialysis (exclusion: second 
dialysis not received but survived 
> 1 month or > 2 months between 
dialysis)
3014 34
Cass 2002230 Australia 
and New 
Zealand
< 3 months 5590 Patients with ESRD; started RRT in 
Australia (exclusion: ARF, death or 
transplantation within first year of 
dialysis)
4243 26.9
Ellis 1998236 UK < 12 weeks 198 Commencing RRT due to ESRD 198 32.3
Fan 2002237 UK < 30 days 211 Started HD for first time (exclusion: 
established on HD for > 30 days)
98 28
Goransson 
2001239
Norway < 3 months 242 Patients with renal failure/serum 
creatinine > normal for > 1 year 
(exclusion: ARF and entering RRT 
due to failing kidney graft)
242 81.7
Iseki 2002243 Japan < 28 days 1551 Exclusion: patients who died within 
first month of RRT; difficulty in 
confirming the first start day or 
serum creatinine level at first visit
1162 21.4
Kazmi 
2004249
USA ≥ 4 months 4024 ≥ 18 years old; completed 
questionnaire; survived first 60 
days dialysis (exclusion: ARF, 
pre-emptive or kidney transplant 
recipients, AIDS or cancer patients, 
returning to dialysis)
2195 34
Lhotta 
2003251
Austria GFR < 20 ml/
min/1.73 m2
NR Starting RRT 75 56
Lin 2003252 Taiwan < 6 months NR Type 2 diabetic receiving HD for at 
least 6 months (exclusion: switching 
between modalities)
115 54
Lin 2004253 Taiwan < 6 months NR RRT for at least 3 months 
(exclusion: switching modalities)
105 57
Roubicek 
2000266
France < 16 weeks 309 Dialysis for the first time, available 
medical records (exclusion: acute 
irreversible or rapidly progressing 
renal failure)
270 34
Schwenger 
2006269
Germany < 8 weeks 280 Initiating HD 254 47
Sesso 1996270 Brazil < 1 month 252 Exclusion: diabetic ESRD; diagnosis 
made > 1 and < 3 months before 
dialysis
184 57.6
Shin 2007271 Korea < 90 days 119 Receiving HD for 4-hour session 
three times/week (exclusion: those 
transferred from another dialysis 
programme, hypersensitivity to 
membrane, current infection, 
malignancy, liver disease, 
autoimmune disease, receiving 
drugs that affect immunity)
119 43.7
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Study ID Country
Definition 
of late 
referral
Total 
number 
starting 
dialysis Inclusion criteria
Total 
number 
of study 
participants
% late 
referrals
Stoves 
2008273
UK < 90 days 1260 (Exclusion: in receipt of transplant, 
transfer away from the unit)
1260 37.1
Winkelmayer 
2003277
USA < 90 days NR Diagnosis of renal disease > 1 year 
before first dialysis (exclusion: 
patients on single dialysis and 
survived > 1 month or limited 
dialysis treatment and survived > 2 
months)
3014 34
Wu 2003278 Taiwan < 6 months NR Type 2 diabetic nephropathy, new 
onset ESRD, on PD for more than 
3 months
52 69
ARF, acute renal failure; ESRD, end-stage renal disease; HD, haemodialysis; PD, peritoneal dialysis; NR, not reported; 
RRT, renal replacement therapy.
TABLE 45 Summary of included studies of late referral (continued)
Mortality
1-year mortality
Five studies reported the 1-year mortality rate after 
initiating RRT.236,237,243,271,277 Three studies reported 
the RR of death at 1 year, comparing late to early 
referral249,277,352 (Table 46). Two further studies 
reported mortality at 3 and 6 months and were 
included in the table for completeness.266,270
The 1-year ACM after initiation of RRT varied 
substantially between studies, ranging from 2.8%237 
to 27.5%236 in the early referral group. In late 
referral groups, 1-year mortality ranged from 
7.4%237 to 39.5%.236 Studies consistently reported 
higher mortality in the late referral group than 
in the early group at 1 year. This was also found 
at 6 months,270 but at 3 months a small study266 
reported no difference. The statistical significance 
of the differences was not reported by most 
authors.
Two studies provided data on the percentage of 
death attributable to CVD. At 3 months, CVD 
mortality accounted for 50% of deaths in the 
early referral group and 67% in the late referral 
group.266 At 6 months, 40% of deaths and 35% 
respectively were reported.270
Three studies reported risk of death associated 
with late as compared to early referral at 
1 year.249,277,352 Avorn and colleagues352 and Kazmi 
and colleagues249 found a statistically significant 
increase in risk among those referred late (37–42% 
greater risk than early referral) after adjustment for 
social demographics, insurance cover, comorbidity 
and aetiology of kidney disease. Winkelmayer and 
colleagues277 reported a non-significant difference 
[odds ratio (OR) 1.03, 95% CI 0.84 to 1.25] 
between the groups at 1 year after adjusting for 
social demographics and comorbidity.
5-year mortality
Mortality rates at 5 years after initial referral were 
reported in five studies.239,243,252,266,273 In the early 
referral groups, mortality ranged from 27.6%252 
to 51.5%239 at 5 years, and in the late referral 
groups this ranged from 36.1%266 to 83.3%.278 The 
5-year mortality rate was higher in the late referral 
group in all but two studies where there was little 
difference.243,266
Iseki243 reported no difference in risk of mortality 
with referral timing after adjustment (factors 
adjusted for were not reported) (HR 1.02, 95% 
CI 0.77 to 1.35). Roubicek and colleagues266 did 
not report details, but also found no statistically 
significant difference after adjustment. Lin and 
colleagues252 reported a lower RR of death in those 
referred early as compared to late (RR 0.45, 95% 
CI 0.25 to 0.81).
A further six studies reported follow-up for greater 
than 1 year (summarised in Table 47). The longest 
follow-up was reported by Shin and colleagues271 
at 6.7 years and 23% (early referral) versus 42% 
(late referral) died. Of the five studies where RR 
was estimated, only one reported no statistically 
significant difference in mortality comparing early 
and late referral.251 Schwenger and colleagues269 
calculated the RR of death in the late referral 
group at 1.7 years after initiation of dialysis. The 
RR of late referral for patients under the age 
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TABLE 46 Mortality at up to 1 year
Study ID
ER LR
Risk ratioa 
late vs 
early 
(95% CI) 
unadjusted
Risk ratioa 
late vs 
early 
(95% CI) 
adjusted Adjusted for% deaths
% of ER 
deaths 
due to 
CVD % deaths
% of LR 
deaths due 
to CVD
Avorn 2002352 NR NR NR NR NR RR 1.37 
(1.22 to 
1.52)
Age, race, 
socioeconomic 
status, 
presence of any 
renal diagnosis 
in year before 
dialysis
Ellis 1998236 27.5 NR 39.5 NR NR NR
Fan 2002237 2.8 NR 7.4 NR NR NR ‘No significant 
difference 
between ER 
and LR groups’
Iseki 2002243 10.9 NR 15.1 NR NR NR
Kazmi 2004249 NR NR NR NR HR 1.44 
(1.15 to 1.80)
HR 1.42 
(1.12 to 
1.80)
Social 
demographics, 
insurance 
cover, 
comorbidities, 
cause of kidney 
disease
Roubicek 
2000266
4.2  
(3 months)
50 4.2 67
Sesso 1996270 12.9  
(6 months)
40 29.2 35 HR 2.77 
(1.36 to 
5.55)
HR 2.05 
(0.93 to 
4.54)
Adjustment NR
Stoves 
2008273
13.0 NR 26.0 NR NR NR
Winkelmayer 
2003277
25.2 NR 32.2 NR HR 1.36 
(1.22 to 
1.51)
Age, gender, 
race, 
socioeconomic 
status, 
comorbidities
CI, confidence interval; CVD, cardiovascular disease; ER, early referral; HR, hazard ratio (reported for LR vs ER unless 
otherwise stated); LR, late referral; NS, not significant; NR, not reported; RR, risk ratio.
of 75 years was 2.32 (95% CI 1.48 to 3.64). For 
patients over 75 years, the RR was 1.8 (95% CI 
0.97 to 3.34). Lin and colleagues252 reported risk 
of death for patients receiving haemodialysis and 
peritoneal dialysis separately. The greatest impact 
from early referral on survival after dialysis was 
observed in the peritoneal dialysis group (RR 0.29, 
95% CI 0.07 to 0.48).
Death due to CVD was reported in four 
studies.252,266,271,273 CVD accounted for similar 
proportions of deaths in the early and late referral 
groups, with the exception of Shin and colleagues271 
who reported substantially lower proportion of 
deaths due to CVD in the early versus late referral 
groups (9% versus 30.8%; p = 0.04).
Specialist visits
Two studies provided a breakdown on the number 
of visits to a nephrology specialist by the early and 
late referral group.277,352 Avorn and colleagues352 
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reported 67.9% of the early referral group receive 
more than five specialist visits compared to 14.5% 
in the late referral group and also reported an 
increased RR of death at 1 year in those receiving 
fewer than five specialist visits prior to initiation on 
dialysis (RR 1.15, 95% CI 1.03 to 1.28). Again, a 
greater percentage of specialists visits was recorded 
in the early than in the late referral group in the 
study by Winkelmayer and colleagues.277 In the 
early group, 17.6% of participants received more 
than 10 specialist visits versus 11.2% in the late 
group.
The remainder of the studies failed to comment 
on specialist visits. Fan and colleagues237 was the 
only study that described pre-dialysis education 
by a nurse team. Both referral groups were noted 
to have had pre-dialysis education. None of the 
studies reported details of dietician input.
Preparing for dialysis
The choice of peritoneal dialysis was reported in 
two studies.237,253 Both reported that choice was 
available of both early and late referral, although 
Fan and colleagues237 noted that in the late 
referral group some participants were initiated 
on haemodialysis initially as an emergency. Final 
modality decisions were made at a later date.
The percentage of haemodialysis patients 
with functioning permanent vascular access at 
the initiation of dialysis was reported in three 
studies.239,266,270 Goransson and Bergrem239 
reported 43% of the early referral group versus 
0% in the late referral group had functioning 
permanent vascular access. Sesso and Belasco270 
and Roubicek and colleagues266 reported similarly 
low proportions with permanent access in the 
late referral group (53.1% versus 0%, early versus 
late and 70.7% versus 26.9%, early versus late, 
respectively).
Hospitalisation
There were more days spent in hospital, around 
the time of commencing RRT, in the late referral 
group than in the early group.236,239,251,266 Ellis and 
colleagues236 reported a median of 9.7 days of 
hospitalisation in the early group and a median of 
25 days in the late group (no p-value given). Lhotta 
and colleagues251 observed a mean initial hospital 
duration of 13 ± 12.5 days for early referral 
patients and 19.5 ± 14.1 days for late referral 
patients (p = 0.04). Length of initial hospitalisation 
reported by Roubicek and colleagues266 was 
20 ± 21.5 days for the early referral group 
compared to 33.3 ± 21.8 days for late referral 
patients (p < 0.001). Lastly, Goransson and 
Bergrem238 showed the duration of hospital stay 
around the commencement of dialysis to be more 
than four times longer for late referral patients 
than early referral patients – median of 31 (7–73) 
versus 7 (1–59) days (late versus early respectively). 
Again the difference between the groups was found 
to be statistically significant with p < 0.0001.
Treatments
Three studies reported on antihypertensive 
medication use among those referred late 
as compared to early.239,251,271 Goransson 
and Bergrem239 reported a median of two 
antihypertensive medications per person in both 
the late and early referral groups. Lhotta and 
colleagues251 also noticed no significant difference 
in ACE I use between referral groups (early 90.9% 
versus late 88.1%; p = 0.92). Shin and colleagues,271 
however, found substantial differences in 
antihypertensive medication use with higher 
prescribing in the early referral group (early versus 
late: ACE I 81% versus 11%; ARB 43% versus 
6%; β-blocker: 72% versus 15%; calcium channel 
blockers 42% versus 8%).
Goransson and Bergrem239 reported oral calcitrol 
was more likely to be prescribed to those referred 
early than late (89% versus 8%), but other authors 
found little difference.
Predialysis erythropoietin was prescribed more in 
those who were referred early.239,251
Quality of life
Quality of life was not reported by any of the 
studies.
Triggers for referral
None of the studies reported the triggers or criteria 
used to determine when to refer. None reported 
on the characteristics of the patients at the time of 
referral.
Barriers to early referral
None of our included studies of late referral 
reported data on barriers to referral. A 
supplementary search was undertaken to identify 
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barriers to referral. The findings are summarised 
thematically below.
A recent systematic review by Navaneethan and 
colleagues353 reviewed the evidence on patient 
and health system characteristics associated with 
late referral. The review included prospective and 
retrospective observational studies, and physician 
surveys in which adult patients were referred within 
6 months before initiation of dialysis, or referred 
to nephrologists in stage 5 CKD. The authors 
concluded that a combination of patient and health 
system characteristics were associated with late 
referral of patients with CKD. Overall, being older, 
belonging to a minority group, being uninsured, 
suffering from multiple comorbidities, and the lack 
of communication between primary care physicians 
and nephrologists contributed to late referral of 
patients with CKD. Factors associated with late 
referral identified from this review and from other 
studies are discussed below, categorised as follows: 
disease related, patient related, health-care system 
related and physician related.
Disease related
In some cases, late referral may be inevitable 
owing to the pathogenesis and mode of onset 
of the kidney disease, such as irreversible acute 
renal failure. De novo acute diseases may lead to 
referral that is unavoidably late and at the stage of 
irreversible kidney damage. On the other hand, 
some kidney diseases may progress so slowly 
that the development of symptoms goes almost 
unnoticed. Overall, such disease-related causes do 
not account for more than 15–20% of the presently 
observed late referral cases.354
Patient related
Age
The increasing age of patients was associated with 
late referral in several studies conducted in North 
America. Winkelmayer and colleagues355 showed 
that patients aged between 75 and 84 years were 
73% more likely to be referred late than 65- to 
74-year-olds (OR 1.73, 95% CI 1.44 to 2.08; 
p < 0.001). This association was more significant 
in patients over 85 years (OR 2.66, 95% CI 
1.87 to 3.79; p < 0.001). Ifudu and colleagues356 
concluded that even patients aged > 55 years 
were referred late (OR 4.7, 95% CI 1.37 to 16.0) 
when compared to patients aged < 55 years. 
Navaneethan and colleagues357 found that age 
> 75 years was significantly associated with late 
referral among patients in a community in New 
York in comparison to patients aged < 75 years 
(p = 0.03). A physician survey conducted in Canada 
concluded that primary care physicians are less 
likely to refer older patients to nephrologists than 
younger patients.358
In contrast, studies from France,246 Europe,359 
the UK360 and Ireland361 did not find any age 
differences in patients with CKD who were referred 
early compared to those who were referred late.
Gender
Winkelmayer and colleagues355 found that sex was 
not associated with late referral (OR 1.16, 95% 
CI 0.99, 1.37; p = 0.068). Several other studies 
reported no gender differences in the referral of 
patients with CKD including one from France246 
and one European.359
Race
Winkelmayer and colleagues355 identified a 
significant association between race other than 
black or white and late referral (OR 1.68, 95% CI 
1.21 to 2.32). Kinchen and colleagues123 and Ifudu 
and colleagues356 showed that black and Hispanic 
patients were referred late. In contrast, Steel and 
Ellis,360 from the UK, concluded that white people 
might be referred later to nephrologists than black 
people, although the results were non-significant 
(p = 0.08). Two studies from the USA223,357 and one 
from France246 did not identify any association 
between race and late referral of patients with 
CKD.
Social disadvantage
In an Australian study, the proportion of patients 
referred late varied between areas and was higher 
in areas of greater social disadvantage. Patients 
from densely populated areas with a predominantly 
indigenous population experienced more late 
referrals to nephrologists than other populations.362
A study from the USA363 reported that the homeless 
and unemployed were more likely to present as 
ultra late referral (< 1 month) (OR 6.0, p = 0.004) 
and concluded that poor socioeconomic status 
was a major contributor to delayed referral. There 
was no significant association, however, between 
education and referral pattern.363
In contrast, a study from Northern Ireland showed 
that less affluent populations are generally referred 
earlier to specialists than the more affluent.364
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Comorbidity
The presence of comorbid illness was associated 
with late referral in most studies. Kinchen and 
colleagues123 found that patients with higher 
index of coexistent disease score (combination of 
index of physical impairment and index of disease 
severity) were nearly twice as likely to be referred 
late than their counterparts with lower scores 
(OR 1.8, 95% CI 1.16 to 2.84). Similar results were 
seen in two European studies.124,358 Wauters and 
colleagues359 concluded that the presence of an 
active cancer would delay the referral of patients 
with CKD to nephrologists. In a Scottish study, 
Khan and colleagues124 allocated CKD patients to 
low, intermediate, and high risk groups based on 
their age and the presence of other comorbidities 
(heart disease, diabetes and pulmonary disease). 
The presence of these coexisting illness resulted in 
late referral. A physician survey by Mendelssohn 
and colleagues358 identified that the presence of 
comorbidity would result in late or non-referral 
by physicians. Navaneethan and colleagues357 
determined that patients referred late had a higher 
Charlson Comorbidity Index (calculated with 
17 comorbidities) than patients referred earlier 
(OR 1.17, 95% CI 1.04 to 1.32, p = 0.009).
In contrast, Winkelmayer and colleagues355 
determined that the presence of hypertension 
(OR 0.47, 95% CI 0.40 to 0.56), malignancy 
(OR 0.73, 95% CI 0.59 to 0.91), coronary artery 
disease (OR 0.69, 95% CI 0.58 to 0.82) and 
diabetes (OR 0.82, 95% CI 0.69 to 0.97) resulted 
in earlier referral to nephrologists than for 
patients with no comorbidities. Patients with CKD 
and other coexisting illness may have their renal 
function monitored more frequently as part of 
routine chemistry panels. Early referral may reflect 
enhanced physician awareness of the relationship 
between these diseases and CKD progression, or 
increased physician attentiveness to management 
of patients with CKD, because of an increased 
frequency of patient–physician interaction. These 
seemingly contradictory results could be attributed 
to geographic variations, type of patients included 
and provider misconceptions about the outcome of 
patients with multiple comorbidities on dialysis.353
Other studies have not demonstrated an 
association between the presence of comorbidity 
and late referral.223,361
Aetiology of renal disease
Patients with non-diabetic kidney disease were 
1.4 times (95% CI 1.15 to 5.26) more likely to be 
referred later to nephrologists than patients with 
diabetic kidney disease.357 Patients with congenital 
kidney disease were referred earlier than patients 
with hypertensive renal disease. Patients with 
rapidly progressing kidney disease were referred 
earlier than patients who had gradual worsening of 
renal function (OR 7.1, 95% CI 2.9 to 16.7).246
Patient non-compliance
Patient compliance with appointments was 
identified as a major issue in two studies and 
accounted for ~40% of late referrals. Jungers 
and colleagues246 and Sprangers and colleagues365 
reported that 42% of late referrals could be 
attributed to patient non-compliance. Patients may 
be reluctant to visit a nephrologist because of lack 
of disease awareness and/or understanding, denial, 
fear of the unknown, fear of loss of independence 
and economic difficulties.365
Health-care system related
Type and location of referral and dialysis 
centre
In a survey of a cohort of incident dialysis 
patients in three European regions, Wauters and 
colleagues359 identified that late referral was more 
frequent in large city centres than in the private or 
regional structures (OR 7.3, 95% CI 1.8 to 30).
The distance to the centre might also be a reason 
for late referral, but in one study concerning a 
rural population in the USA,268 the distance to 
the dialysis centre was not a determining factor. 
In contrast, for patients of lower socioeconomic 
classes, an Australian study showed a correlation 
between higher rates of late referrals and the 
distance to dialysis centres.366 In Northern Ireland, 
Kee and colleagues364 also reported that increasing 
distance to the nearest renal centre was associated 
with later referral.
Physician factors
Winkelmayer and colleagues355 found that hospital 
physicians (not renal specialists), rather than GPs, 
were more likely to refer patients with CKD later 
to nephrologists. A finding repeated in several 
studies.54,359
In a study by Boulware and colleagues,367 
hypothetical clinical vignettes were used to assess 
physician evaluation of the severity of CKD, 
recommendations for referral, and awareness 
of current guideline recommendations. The 
participants were randomly selected from a 
nationally representative sample of physicians 
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(family medicine and internal medicine physicians) 
and nephrologists. Compared to the nephrologists, 
both physician groups were worse at identifying 
patients with stage 3 (GFR 30–59 ml/min/1.73 m2) 
or stage 4 (GFR 15–29 ml/min/1.73 m2) CKD. 
Physicians were less likely to recommend referral 
for the patient scenarios and requested input from 
the referring nephrologist at a less frequent rate 
than recommended. Physicians were less likely 
than nephrologists to be aware of existing practice 
guidelines, and awareness of the guidelines did 
increase the likelihood of referral by the primary 
care physician.367
In a study from Ireland,361 which also used 
clinical scenarios to evaluate referral behaviour, 
it was demonstrated that fewer than half of the 
patients were referred after the first encounter, 
whereas nearly all patients were referred as the 
renal function worsened and the patients became 
symptomatic. As the scenarios increased in 
complexity, the likelihood of referral decreased.361
Mendelssohn and colleagues358 concluded that 
‘rationing by physicians about the need for dialysis’ 
was a major factor in late referral. This non-referral 
was influenced by age and coexisting disease, 
and physicians evaluated the distance of dialysis 
centres and overcrowding of the nearest dialysis 
centres before referring a patient with CKD.358 
Similar rationing by physicians was not, however, 
demonstrated in a survey conducted in England.368 
Specialists (other than nephrologists) were likely 
to recommend referral for patients with CKD later 
than primary care physicians.368
In a survey of referring physicians, Campbell369 
documented the reasons for late referral. These 
included perception by the referring physicians 
of being evaluated negatively by nephrologists 
in 43% of cases, lack of communication or faulty 
communication between primary care physicians 
and nephrologists (37%), and lack of specific 
referral criteria for patients with ESRD (31%). 
It was also reported that more than 90% of 
referring primary care physicians felt that they 
had inadequate training regarding timing or 
indications for referral of patients with CKD.369
Discussion
We identified a substantial number of reports about 
the impact of late referral on outcomes after the 
initiation of dialysis. All studies recruited patients 
to their study at the time of initiation of dialysis. 
Thus all these studies focus on reporting outcomes 
among those who survive to dialysis. Those dying 
prior to dialysis were excluded. Notably, ACM on 
dialysis was high, though variable across studies. 
Variability between studies may be explained by 
differences in baseline characteristics, the health 
care received and the small size of some of the 
studies.
At 1 year, mortality was consistently higher in the 
late versus early referral group regardless of the 
definition of early referral. At longer follow-up, 
the majority of studies reported higher mortality 
in the late referral group but Iseki (Japan)243 
and Roubicek and colleagues (France)266 found 
little difference. While absolute differences in 
mortality were observed, the relative difference, 
once adjusted for comorbidities, was less. In 
those reaching dialysis, CVD accounted for a 
substantial proportion of deaths. Other outcomes 
were less well reported but there was evidence that 
late referral impacted on the number of clinic 
appointments with specialists, access to choice 
about dialysis modality and preparation for dialysis 
with permanent vascular access established before 
dialysis started. In addition, there was evidence 
of an increased requirement for hospitalisation 
around the start of dialysis in those referred late to 
specialist services.
None of the studies reported eGFR at the time of 
referral, so the definition relied on a retrospective 
consideration of time prior to dialysis. One study 
defined ‘late referral’ as referral once the eGFR 
was < 20 ml/min. Here, authors reported mortality 
to be higher in the late referral group in the first 
year of dialysis. The difference was, however, 
accounted for by difference in comorbidity and 
age. The difference in care received was also 
poorly described. It was, therefore, difficult to 
determine whether timing of referral was mainly a 
surrogate for severity at the time referred, degree 
of comorbidity or the care delivered. The triggers 
for referral were not reported and data on barriers 
to early referral were not collected. Very late 
presentation to nephrology services can occur as 
a result of an acute and aggressive deterioration 
in renal function. The studies were generally poor 
at explicitly excluding people with an acute renal 
event from their analysis.
A review of additional literature seeking to identify 
potential barriers to early referral found a range 
of potential patient, health-care system and 
physician related factors described. Reporting of 
the variability of the importance of different factors 
suggested that individual health-care systems would 
have to consider local issues when designing or 
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modifying services to optimise referral timing. 
Good communication between primary care and 
hospital physicians, and nephrology specialists 
was important in ensuring timely and appropriate 
referral.
Conclusions
The impact of late referral on predialysis survival 
and outcomes has not been studied. There was 
evidence that late referral impacts negatively on 
survival on dialysis particularly in the first year. 
The implications for care delivery and preparation 
for RRT were significant but the impact on patient 
quality of life was not reported. Many potential 
barriers to earlier referral have been described 
in the literature and by health-care system and 
local setting as well as by patient- and physician-
related factors. Communication between aspects 
of the health-care system was important to ensure 
appropriate referral.
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